WO2007149451A2 - Cycloalkanopyrrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors - Google Patents
Cycloalkanopyrrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors Download PDFInfo
- Publication number
- WO2007149451A2 WO2007149451A2 PCT/US2007/014300 US2007014300W WO2007149451A2 WO 2007149451 A2 WO2007149451 A2 WO 2007149451A2 US 2007014300 W US2007014300 W US 2007014300W WO 2007149451 A2 WO2007149451 A2 WO 2007149451A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituted
- compound
- substituent
- group
- independently
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title description 24
- 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 title description 2
- 101100540419 Danio rerio kdrl gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 295
- 230000000694 effects Effects 0.000 claims abstract description 30
- 101001005602 Homo sapiens Mitogen-activated protein kinase kinase kinase 11 Proteins 0.000 claims abstract description 26
- 102100025207 Mitogen-activated protein kinase kinase kinase 11 Human genes 0.000 claims abstract description 26
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 claims abstract description 25
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims abstract description 25
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 24
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 22
- 201000011510 cancer Diseases 0.000 claims abstract description 18
- 230000004770 neurodegeneration Effects 0.000 claims abstract description 9
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 9
- 230000004054 inflammatory process Effects 0.000 claims abstract description 8
- 206010061218 Inflammation Diseases 0.000 claims abstract description 7
- 125000001424 substituent group Chemical group 0.000 claims description 324
- 125000000217 alkyl group Chemical group 0.000 claims description 290
- 125000001072 heteroaryl group Chemical group 0.000 claims description 228
- 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 184
- 125000003118 aryl group Chemical group 0.000 claims description 174
- 229910052739 hydrogen Inorganic materials 0.000 claims description 133
- 239000001257 hydrogen Substances 0.000 claims description 130
- 150000001413 amino acids Chemical class 0.000 claims description 123
- -1 carbonyloxy, sulfonyl Chemical group 0.000 claims description 120
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 98
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 claims description 85
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 claims description 85
- 125000004429 atom Chemical group 0.000 claims description 85
- 101710179684 Poly [ADP-ribose] polymerase Proteins 0.000 claims description 84
- 238000000034 method Methods 0.000 claims description 84
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims description 80
- 125000001589 carboacyl group Chemical group 0.000 claims description 74
- 125000003107 substituted aryl group Chemical group 0.000 claims description 58
- 125000003545 alkoxy group Chemical group 0.000 claims description 49
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 46
- 125000003282 alkyl amino group Chemical group 0.000 claims description 45
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 44
- 125000005346 substituted cycloalkyl group Chemical group 0.000 claims description 41
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 39
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 38
- 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 37
- 125000004391 aryl sulfonyl group Chemical group 0.000 claims description 37
- 125000004432 carbon atom Chemical group C* 0.000 claims description 37
- 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 36
- 125000003368 amide group Chemical group 0.000 claims description 35
- 125000005129 aryl carbonyl group Chemical group 0.000 claims description 35
- 125000005161 aryl oxy carbonyl group Chemical group 0.000 claims description 35
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 claims description 35
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 34
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 33
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 29
- 125000004466 alkoxycarbonylamino group Chemical group 0.000 claims description 28
- 230000015572 biosynthetic process Effects 0.000 claims description 28
- 125000005907 alkyl ester group Chemical group 0.000 claims description 27
- 150000007860 aryl ester derivatives Chemical class 0.000 claims description 27
- 125000004104 aryloxy group Chemical group 0.000 claims description 27
- 125000005162 aryl oxy carbonyl amino group Chemical group 0.000 claims description 26
- ODBUVFPEAXCCMH-UHFFFAOYSA-N hydroxysulfanyl azanylidynemethanesulfonate Chemical compound OSOS(=O)(=O)C#N ODBUVFPEAXCCMH-UHFFFAOYSA-N 0.000 claims description 26
- 241000124008 Mammalia Species 0.000 claims description 25
- JCXJVPUVTGWSNB-UHFFFAOYSA-N Nitrogen dioxide Chemical compound O=[N]=O JCXJVPUVTGWSNB-UHFFFAOYSA-N 0.000 claims description 20
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 19
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims description 18
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 14
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 14
- 230000002401 inhibitory effect Effects 0.000 claims description 14
- 201000006474 Brain Ischemia Diseases 0.000 claims description 9
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 9
- 206010008118 cerebral infarction Diseases 0.000 claims description 9
- 208000031225 myocardial ischemia Diseases 0.000 claims description 9
- 208000018737 Parkinson disease Diseases 0.000 claims description 8
- 210000003169 central nervous system Anatomy 0.000 claims description 8
- 208000024827 Alzheimer disease Diseases 0.000 claims description 7
- 208000035475 disorder Diseases 0.000 claims description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 7
- ILVXOBCQQYKLDS-UHFFFAOYSA-N pyridine N-oxide Chemical compound [O-][N+]1=CC=CC=C1 ILVXOBCQQYKLDS-UHFFFAOYSA-N 0.000 claims description 7
- 208000001738 Nervous System Trauma Diseases 0.000 claims description 6
- 210000004204 blood vessel Anatomy 0.000 claims description 6
- 230000001413 cellular effect Effects 0.000 claims description 6
- 206010012601 diabetes mellitus Diseases 0.000 claims description 6
- 230000002062 proliferating effect Effects 0.000 claims description 6
- 125000000714 pyrimidinyl group Chemical group 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 230000000472 traumatic effect Effects 0.000 claims description 6
- 206010014824 Endotoxic shock Diseases 0.000 claims description 5
- 208000023105 Huntington disease Diseases 0.000 claims description 5
- 201000004681 Psoriasis Diseases 0.000 claims description 5
- 206010040070 Septic Shock Diseases 0.000 claims description 5
- 125000004076 pyridyl group Chemical group 0.000 claims description 5
- 206010012689 Diabetic retinopathy Diseases 0.000 claims description 4
- 201000009273 Endometriosis Diseases 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 230000015556 catabolic process Effects 0.000 claims description 4
- 238000006731 degradation reaction Methods 0.000 claims description 4
- 208000002780 macular degeneration Diseases 0.000 claims description 4
- 230000001537 neural effect Effects 0.000 claims description 4
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 4
- 208000011580 syndromic disease Diseases 0.000 claims description 4
- 125000001475 halogen functional group Chemical group 0.000 claims 10
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 238000011282 treatment Methods 0.000 abstract description 21
- 201000010099 disease Diseases 0.000 abstract description 17
- 208000028867 ischemia Diseases 0.000 abstract description 10
- 230000002255 enzymatic effect Effects 0.000 abstract description 4
- 101000735456 Homo sapiens Protein mono-ADP-ribosyltransferase PARP3 Proteins 0.000 abstract 1
- 102100034935 Protein mono-ADP-ribosyltransferase PARP3 Human genes 0.000 abstract 1
- 238000002360 preparation method Methods 0.000 description 180
- 239000000203 mixture Substances 0.000 description 166
- 239000007787 solid Substances 0.000 description 151
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 145
- 229910001868 water Inorganic materials 0.000 description 128
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 124
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 124
- 229940024606 amino acid Drugs 0.000 description 121
- 235000001014 amino acid Nutrition 0.000 description 121
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 111
- 150000002431 hydrogen Chemical class 0.000 description 108
- 238000005160 1H NMR spectroscopy Methods 0.000 description 93
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 79
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 74
- 239000000047 product Substances 0.000 description 62
- 239000000243 solution Substances 0.000 description 57
- 238000005481 NMR spectroscopy Methods 0.000 description 53
- 239000002244 precipitate Substances 0.000 description 52
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 49
- 125000002619 bicyclic group Chemical group 0.000 description 48
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 43
- 229910052760 oxygen Inorganic materials 0.000 description 43
- 238000006243 chemical reaction Methods 0.000 description 41
- 125000005843 halogen group Chemical group 0.000 description 41
- 239000002904 solvent Substances 0.000 description 35
- 235000019439 ethyl acetate Nutrition 0.000 description 31
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 30
- 229910052717 sulfur Inorganic materials 0.000 description 28
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 27
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 26
- 238000001816 cooling Methods 0.000 description 25
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 24
- 239000012661 PARP inhibitor Substances 0.000 description 24
- 108091000080 Phosphotransferase Proteins 0.000 description 24
- 229940121906 Poly ADP ribose polymerase inhibitor Drugs 0.000 description 24
- 239000005864 Sulphur Substances 0.000 description 24
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 24
- 102000020233 phosphotransferase Human genes 0.000 description 24
- NXQGTFAFSMVQJC-UHFFFAOYSA-N (diaminomethylideneamino) carbamimidate Chemical compound NC(=N)NOC(N)=N NXQGTFAFSMVQJC-UHFFFAOYSA-N 0.000 description 23
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 23
- 238000003786 synthesis reaction Methods 0.000 description 22
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 21
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 21
- 230000005764 inhibitory process Effects 0.000 description 19
- 239000011541 reaction mixture Substances 0.000 description 19
- RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 18
- 125000002950 monocyclic group Chemical group 0.000 description 18
- 239000002243 precursor Substances 0.000 description 18
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 17
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 17
- 238000001914 filtration Methods 0.000 description 17
- 239000000543 intermediate Substances 0.000 description 17
- 239000007858 starting material Substances 0.000 description 17
- 238000003756 stirring Methods 0.000 description 17
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 16
- 241000699670 Mus sp. Species 0.000 description 16
- 230000004913 activation Effects 0.000 description 16
- 239000000706 filtrate Substances 0.000 description 16
- 150000003949 imides Chemical class 0.000 description 16
- 238000002390 rotary evaporation Methods 0.000 description 16
- 239000011734 sodium Substances 0.000 description 16
- 239000000725 suspension Substances 0.000 description 16
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 15
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical class [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 229910000104 sodium hydride Inorganic materials 0.000 description 15
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 13
- 239000000741 silica gel Substances 0.000 description 13
- 229910002027 silica gel Inorganic materials 0.000 description 13
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- 229910052757 nitrogen Inorganic materials 0.000 description 12
- 239000003921 oil Substances 0.000 description 12
- 235000019198 oils Nutrition 0.000 description 12
- 230000002829 reductive effect Effects 0.000 description 12
- 102000004190 Enzymes Human genes 0.000 description 11
- 108090000790 Enzymes Proteins 0.000 description 11
- 108010055717 JNK Mitogen-Activated Protein Kinases Proteins 0.000 description 11
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 11
- 239000012317 TBTU Substances 0.000 description 11
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 11
- 238000003556 assay Methods 0.000 description 11
- 239000000470 constituent Substances 0.000 description 11
- 230000037361 pathway Effects 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 11
- 238000010992 reflux Methods 0.000 description 11
- SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 10
- BAWFJGJZGIEFAR-NNYOXOHSSA-O NAD(+) Chemical compound NC(=O)C1=CC=C[N+]([C@H]2[C@@H]([C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OC[C@@H]3[C@H]([C@@H](O)[C@@H](O3)N3C4=NC=NC(N)=C4N=C3)O)O2)O)=C1 BAWFJGJZGIEFAR-NNYOXOHSSA-O 0.000 description 10
- 238000006352 cycloaddition reaction Methods 0.000 description 10
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 10
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 9
- MCTWTZJPVLRJOU-UHFFFAOYSA-N 1-methyl-1H-imidazole Chemical compound CN1C=CN=C1 MCTWTZJPVLRJOU-UHFFFAOYSA-N 0.000 description 9
- UJOBWOGCFQCDNV-UHFFFAOYSA-N 9H-carbazole Chemical compound C1=CC=C2C3=CC=CC=C3NC2=C1 UJOBWOGCFQCDNV-UHFFFAOYSA-N 0.000 description 9
- 238000005698 Diels-Alder reaction Methods 0.000 description 9
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 9
- 238000004587 chromatography analysis Methods 0.000 description 9
- 239000007789 gas Substances 0.000 description 9
- 150000002460 imidazoles Chemical class 0.000 description 9
- 239000002002 slurry Substances 0.000 description 9
- 239000012312 sodium hydride Substances 0.000 description 9
- PXBFMLJZNCDSMP-UHFFFAOYSA-N 2-Aminobenzamide Chemical compound NC(=O)C1=CC=CC=C1N PXBFMLJZNCDSMP-UHFFFAOYSA-N 0.000 description 8
- 102100025184 Mitogen-activated protein kinase kinase kinase 13 Human genes 0.000 description 8
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 8
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 8
- 239000012043 crude product Substances 0.000 description 8
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 8
- 235000018102 proteins Nutrition 0.000 description 8
- 102000004169 proteins and genes Human genes 0.000 description 8
- 238000005406 washing Methods 0.000 description 8
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 7
- 101001005609 Homo sapiens Mitogen-activated protein kinase kinase kinase 13 Proteins 0.000 description 7
- 206010061216 Infarction Diseases 0.000 description 7
- 102000019145 JUN kinase activity proteins Human genes 0.000 description 7
- 241000700159 Rattus Species 0.000 description 7
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000005755 formation reaction Methods 0.000 description 7
- 239000005457 ice water Substances 0.000 description 7
- 230000007574 infarction Effects 0.000 description 7
- 150000003951 lactams Chemical class 0.000 description 7
- 239000012044 organic layer Substances 0.000 description 7
- 229920006395 saturated elastomer Polymers 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- PEEHTFAAVSWFBL-UHFFFAOYSA-N Maleimide Chemical compound O=C1NC(=O)C=C1 PEEHTFAAVSWFBL-UHFFFAOYSA-N 0.000 description 6
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 6
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 6
- 239000007868 Raney catalyst Substances 0.000 description 6
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 6
- 229910000564 Raney nickel Inorganic materials 0.000 description 6
- 208000006011 Stroke Diseases 0.000 description 6
- WVFGMLNDFFCHKN-UHFFFAOYSA-N [2-(cyclopenten-1-yl)pyrrol-1-yl]-tri(propan-2-yl)silane Chemical compound CC(C)[Si](C(C)C)(C(C)C)N1C=CC=C1C1=CCCC1 WVFGMLNDFFCHKN-UHFFFAOYSA-N 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 6
- 239000012267 brine Substances 0.000 description 6
- 230000030833 cell death Effects 0.000 description 6
- 239000000460 chlorine Substances 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 6
- 238000001035 drying Methods 0.000 description 6
- 238000001704 evaporation Methods 0.000 description 6
- 230000008020 evaporation Effects 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- 229940043355 kinase inhibitor Drugs 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000001301 oxygen Substances 0.000 description 6
- 230000026731 phosphorylation Effects 0.000 description 6
- 238000006366 phosphorylation reaction Methods 0.000 description 6
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 6
- 230000009467 reduction Effects 0.000 description 6
- 230000010410 reperfusion Effects 0.000 description 6
- 230000004044 response Effects 0.000 description 6
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 6
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 description 6
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 6
- SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical group C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 description 5
- 108020004414 DNA Proteins 0.000 description 5
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 5
- 108010033040 Histones Proteins 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 102000001253 Protein Kinase Human genes 0.000 description 5
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 5
- 229960000583 acetic acid Drugs 0.000 description 5
- QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 5
- 125000003710 aryl alkyl group Chemical group 0.000 description 5
- 229910002092 carbon dioxide Inorganic materials 0.000 description 5
- 239000003054 catalyst Substances 0.000 description 5
- 230000002068 genetic effect Effects 0.000 description 5
- 125000000623 heterocyclic group Chemical group 0.000 description 5
- PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 5
- RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 5
- 208000027866 inflammatory disease Diseases 0.000 description 5
- 239000010410 layer Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 108060006633 protein kinase Proteins 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 239000000758 substrate Substances 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical class [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- 102100023274 Dual specificity mitogen-activated protein kinase kinase 4 Human genes 0.000 description 4
- 102100023332 Dual specificity mitogen-activated protein kinase kinase 7 Human genes 0.000 description 4
- 101001115395 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 4 Proteins 0.000 description 4
- 101000624594 Homo sapiens Dual specificity mitogen-activated protein kinase kinase 7 Proteins 0.000 description 4
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 4
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- PCLIMKBDDGJMGD-UHFFFAOYSA-N N-bromosuccinimide Chemical compound BrN1C(=O)CCC1=O PCLIMKBDDGJMGD-UHFFFAOYSA-N 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 description 4
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 4
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 4
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 4
- 235000011054 acetic acid Nutrition 0.000 description 4
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 4
- 125000003277 amino group Chemical group 0.000 description 4
- 230000002238 attenuated effect Effects 0.000 description 4
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 4
- 230000033228 biological regulation Effects 0.000 description 4
- 230000017531 blood circulation Effects 0.000 description 4
- 210000004556 brain Anatomy 0.000 description 4
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 4
- 229910052794 bromium Inorganic materials 0.000 description 4
- 230000004663 cell proliferation Effects 0.000 description 4
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 125000004177 diethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 4
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 238000010438 heat treatment Methods 0.000 description 4
- XLYOFNOQVPJJNP-ZSJDYOACSA-N heavy water Substances [2H]O[2H] XLYOFNOQVPJJNP-ZSJDYOACSA-N 0.000 description 4
- 125000005842 heteroatom Chemical group 0.000 description 4
- FFUAGWLWBBFQJT-UHFFFAOYSA-N hexamethyldisilazane Chemical compound C[Si](C)(C)N[Si](C)(C)C FFUAGWLWBBFQJT-UHFFFAOYSA-N 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 125000004356 hydroxy functional group Chemical group O* 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 208000014674 injury Diseases 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 150000002576 ketones Chemical class 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- CTSLXHKWHWQRSH-UHFFFAOYSA-N oxalyl chloride Chemical compound ClC(=O)C(Cl)=O CTSLXHKWHWQRSH-UHFFFAOYSA-N 0.000 description 4
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 4
- CMFNMSMUKZHDEY-UHFFFAOYSA-N peroxynitrous acid Chemical compound OON=O CMFNMSMUKZHDEY-UHFFFAOYSA-N 0.000 description 4
- 230000005731 poly ADP ribosylation Effects 0.000 description 4
- 238000012746 preparative thin layer chromatography Methods 0.000 description 4
- 230000004224 protection Effects 0.000 description 4
- 230000019491 signal transduction Effects 0.000 description 4
- ZSJLQEPLLKMAKR-GKHCUFPYSA-N streptozocin Chemical compound O=NN(C)C(=O)N[C@H]1[C@@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O ZSJLQEPLLKMAKR-GKHCUFPYSA-N 0.000 description 4
- 229960001052 streptozocin Drugs 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- 229910052720 vanadium Inorganic materials 0.000 description 4
- GIANIJCPTPUNBA-QMMMGPOBSA-N (2s)-3-(4-hydroxyphenyl)-2-nitramidopropanoic acid Chemical compound [O-][N+](=O)N[C@H](C(=O)O)CC1=CC=C(O)C=C1 GIANIJCPTPUNBA-QMMMGPOBSA-N 0.000 description 3
- FTWCWEWGJWDPDG-UHFFFAOYSA-N 2-(cyclopenten-1-yl)-1h-pyrrole Chemical compound C1CCC=C1C1=CC=CN1 FTWCWEWGJWDPDG-UHFFFAOYSA-N 0.000 description 3
- LSSICPJTIPBTDD-UHFFFAOYSA-N 2-ethenyl-1h-indole Chemical class C1=CC=C2NC(C=C)=CC2=C1 LSSICPJTIPBTDD-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 3
- 230000033616 DNA repair Effects 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 3
- 229910004373 HOAc Inorganic materials 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 3
- 102000043136 MAP kinase family Human genes 0.000 description 3
- 108091054455 MAP kinase family Proteins 0.000 description 3
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 3
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 3
- 102100038243 Mitogen-activated protein kinase kinase kinase 10 Human genes 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 101150101566 Parp gene Proteins 0.000 description 3
- 108091026813 Poly(ADPribose) Proteins 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 description 3
- 230000001154 acute effect Effects 0.000 description 3
- 229910021529 ammonia Inorganic materials 0.000 description 3
- 239000000538 analytical sample Substances 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 230000006907 apoptotic process Effects 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- 230000005779 cell damage Effects 0.000 description 3
- 229910052801 chlorine Inorganic materials 0.000 description 3
- 230000001684 chronic effect Effects 0.000 description 3
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 3
- 230000001054 cortical effect Effects 0.000 description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000012217 deletion Methods 0.000 description 3
- 230000037430 deletion Effects 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- VHILMKFSCRWWIJ-UHFFFAOYSA-N dimethyl acetylenedicarboxylate Chemical compound COC(=O)C#CC(=O)OC VHILMKFSCRWWIJ-UHFFFAOYSA-N 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 229910052736 halogen Inorganic materials 0.000 description 3
- 150000002367 halogens Chemical class 0.000 description 3
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 3
- 230000008595 infiltration Effects 0.000 description 3
- 238000001764 infiltration Methods 0.000 description 3
- 230000000977 initiatory effect Effects 0.000 description 3
- 238000001990 intravenous administration Methods 0.000 description 3
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 description 3
- 239000012452 mother liquor Substances 0.000 description 3
- 230000000926 neurological effect Effects 0.000 description 3
- 230000000324 neuroprotective effect Effects 0.000 description 3
- 102000002574 p38 Mitogen-Activated Protein Kinases Human genes 0.000 description 3
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000035939 shock Effects 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000009529 traumatic brain injury Effects 0.000 description 3
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 description 2
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 2
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 2
- FALRKNHUBBKYCC-UHFFFAOYSA-N 2-(chloromethyl)pyridine-3-carbonitrile Chemical compound ClCC1=NC=CC=C1C#N FALRKNHUBBKYCC-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 2
- MZNSQRLUUXWLSB-UHFFFAOYSA-N 2-ethenyl-1h-pyrrole Chemical class C=CC1=CC=CN1 MZNSQRLUUXWLSB-UHFFFAOYSA-N 0.000 description 2
- CEPBVJYGKONNDA-UHFFFAOYSA-N 3,9-dihydrocarbazol-2-one Chemical compound C1=CC=C2NC3=CC(=O)CC=C3C2=C1 CEPBVJYGKONNDA-UHFFFAOYSA-N 0.000 description 2
- ZFZQMPTTXPUWGI-UHFFFAOYSA-N 3-(cyclopenten-1-yl)-1h-pyrrole Chemical compound C1CCC=C1C1=CNC=C1 ZFZQMPTTXPUWGI-UHFFFAOYSA-N 0.000 description 2
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 description 2
- GSCPDZHWVNUUFI-UHFFFAOYSA-N 3-aminobenzamide Chemical compound NC(=O)C1=CC=CC(N)=C1 GSCPDZHWVNUUFI-UHFFFAOYSA-N 0.000 description 2
- 125000005917 3-methylpentyl group Chemical group 0.000 description 2
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 2
- YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 239000005711 Benzoic acid Substances 0.000 description 2
- 208000020084 Bone disease Diseases 0.000 description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-N Butyric acid Chemical compound CCCC(O)=O FERIUCNNQQJTOY-UHFFFAOYSA-N 0.000 description 2
- 108091007914 CDKs Proteins 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 102000003903 Cyclin-dependent kinases Human genes 0.000 description 2
- 108090000266 Cyclin-dependent kinases Proteins 0.000 description 2
- 108090000695 Cytokines Proteins 0.000 description 2
- 102000004127 Cytokines Human genes 0.000 description 2
- 229910052693 Europium Inorganic materials 0.000 description 2
- 102000001267 GSK3 Human genes 0.000 description 2
- 108060006662 GSK3 Proteins 0.000 description 2
- DHCLVCXQIBBOPH-UHFFFAOYSA-N Glycerol 2-phosphate Chemical compound OCC(CO)OP(O)(O)=O DHCLVCXQIBBOPH-UHFFFAOYSA-N 0.000 description 2
- 239000007995 HEPES buffer Substances 0.000 description 2
- 102000006947 Histones Human genes 0.000 description 2
- 101000958409 Homo sapiens Mitogen-activated protein kinase kinase kinase 10 Proteins 0.000 description 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 2
- 239000005909 Kieselgur Substances 0.000 description 2
- 102000001291 MAP Kinase Kinase Kinase Human genes 0.000 description 2
- 108060006687 MAP kinase kinase kinase Proteins 0.000 description 2
- 229910021380 Manganese Chloride Inorganic materials 0.000 description 2
- GLFNIEUTAYBVOC-UHFFFAOYSA-L Manganese chloride Chemical compound Cl[Mn]Cl GLFNIEUTAYBVOC-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 102100028199 Mitogen-activated protein kinase kinase kinase kinase 1 Human genes 0.000 description 2
- 101710144519 Mitogen-activated protein kinase kinase kinase kinase 1 Proteins 0.000 description 2
- 102100028192 Mitogen-activated protein kinase kinase kinase kinase 2 Human genes 0.000 description 2
- 101710144533 Mitogen-activated protein kinase kinase kinase kinase 2 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000047918 Myelin Basic Human genes 0.000 description 2
- 101710107068 Myelin basic protein Proteins 0.000 description 2
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 2
- JRNVZBWKYDBUCA-UHFFFAOYSA-N N-chlorosuccinimide Chemical compound ClN1C(=O)CCC1=O JRNVZBWKYDBUCA-UHFFFAOYSA-N 0.000 description 2
- 206010029350 Neurotoxicity Diseases 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 208000001132 Osteoporosis Diseases 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 102000001708 Protein Isoforms Human genes 0.000 description 2
- 108010029485 Protein Isoforms Proteins 0.000 description 2
- 108060006706 SRC Proteins 0.000 description 2
- 102000001332 SRC Human genes 0.000 description 2
- 208000020339 Spinal injury Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 206010044221 Toxic encephalopathy Diseases 0.000 description 2
- 108091008605 VEGF receptors Proteins 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- ZKHQWZAMYRWXGA-KNYAHOBESA-N [[(2r,3s,4r,5r)-5-(6-aminopurin-9-yl)-3,4-dihydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl] dihydroxyphosphoryl hydrogen phosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(=O)OP(O)(=O)O[32P](O)(O)=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KNYAHOBESA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 239000012190 activator Substances 0.000 description 2
- 125000002252 acyl group Chemical group 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 230000033115 angiogenesis Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 2
- 235000010233 benzoic acid Nutrition 0.000 description 2
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000001569 carbon dioxide Substances 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000010261 cell growth Effects 0.000 description 2
- 230000002490 cerebral effect Effects 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- KQIADDMXRMTWHZ-UHFFFAOYSA-N chloro-tri(propan-2-yl)silane Chemical compound CC(C)[Si](Cl)(C(C)C)C(C)C KQIADDMXRMTWHZ-UHFFFAOYSA-N 0.000 description 2
- 235000015165 citric acid Nutrition 0.000 description 2
- 206010009887 colitis Diseases 0.000 description 2
- 239000012230 colorless oil Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 150000001916 cyano esters Chemical class 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 150000001993 dienes Chemical class 0.000 description 2
- IEPRKVQEAMIZSS-AATRIKPKSA-N diethyl fumarate Chemical compound CCOC(=O)\C=C\C(=O)OCC IEPRKVQEAMIZSS-AATRIKPKSA-N 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 125000005982 diphenylmethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- 210000005064 dopaminergic neuron Anatomy 0.000 description 2
- 230000009977 dual effect Effects 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- ZKQFHRVKCYFVCN-UHFFFAOYSA-N ethoxyethane;hexane Chemical compound CCOCC.CCCCCC ZKQFHRVKCYFVCN-UHFFFAOYSA-N 0.000 description 2
- RZCCPZHODWAFPU-UHFFFAOYSA-N ethyl 4-cyano-1,2,3,4,5,10-hexahydrocyclopenta[a]carbazole-5-carboxylate Chemical compound N1C2=CC=CC=C2C2=C1C(CCC1)=C1C(C#N)C2C(=O)OCC RZCCPZHODWAFPU-UHFFFAOYSA-N 0.000 description 2
- PQJJJMRNHATNKG-UHFFFAOYSA-N ethyl bromoacetate Chemical compound CCOC(=O)CBr PQJJJMRNHATNKG-UHFFFAOYSA-N 0.000 description 2
- OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000284 extract Substances 0.000 description 2
- 238000003818 flash chromatography Methods 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 239000001530 fumaric acid Substances 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- 230000014509 gene expression Effects 0.000 description 2
- VANNPISTIUFMLH-UHFFFAOYSA-N glutaric anhydride Chemical compound O=C1CCCC(=O)O1 VANNPISTIUFMLH-UHFFFAOYSA-N 0.000 description 2
- 230000007062 hydrolysis Effects 0.000 description 2
- 238000006460 hydrolysis reaction Methods 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000001041 indolyl group Chemical group 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000012669 liquid formulation Substances 0.000 description 2
- UBJFKNSINUCEAL-UHFFFAOYSA-N lithium;2-methylpropane Chemical compound [Li+].C[C-](C)C UBJFKNSINUCEAL-UHFFFAOYSA-N 0.000 description 2
- 229910001629 magnesium chloride Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 239000011976 maleic acid Substances 0.000 description 2
- FPYJFEHAWHCUMM-UHFFFAOYSA-N maleic anhydride Chemical compound O=C1OC(=O)C=C1 FPYJFEHAWHCUMM-UHFFFAOYSA-N 0.000 description 2
- 230000003211 malignant effect Effects 0.000 description 2
- 239000011565 manganese chloride Substances 0.000 description 2
- OJURWUUOVGOHJZ-UHFFFAOYSA-N methyl 2-[(2-acetyloxyphenyl)methyl-[2-[(2-acetyloxyphenyl)methyl-(2-methoxy-2-oxoethyl)amino]ethyl]amino]acetate Chemical compound C=1C=CC=C(OC(C)=O)C=1CN(CC(=O)OC)CCN(CC(=O)OC)CC1=CC=CC=C1OC(C)=O OJURWUUOVGOHJZ-UHFFFAOYSA-N 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 230000006540 mitochondrial respiration Effects 0.000 description 2
- 239000000178 monomer Substances 0.000 description 2
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 230000004112 neuroprotection Effects 0.000 description 2
- 230000007135 neurotoxicity Effects 0.000 description 2
- 231100000228 neurotoxicity Toxicity 0.000 description 2
- 210000000440 neutrophil Anatomy 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 229910000069 nitrogen hydride Inorganic materials 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000012038 nucleophile Substances 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 239000007800 oxidant agent Substances 0.000 description 2
- 125000004430 oxygen atom Chemical group O* 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000000286 phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 2
- XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 208000008423 pleurisy Diseases 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000003389 potentiating effect Effects 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 230000000770 proinflammatory effect Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- LVTJOONKWUXEFR-FZRMHRINSA-N protoneodioscin Natural products O(C[C@@H](CC[C@]1(O)[C@H](C)[C@@H]2[C@]3(C)[C@H]([C@H]4[C@@H]([C@]5(C)C(=CC4)C[C@@H](O[C@@H]4[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@@H](O)[C@H](O[C@H]6[C@@H](O)[C@@H](O)[C@@H](O)[C@H](C)O6)[C@H](CO)O4)CC5)CC3)C[C@@H]2O1)C)[C@H]1[C@H](O)[C@H](O)[C@H](O)[C@@H](CO)O1 LVTJOONKWUXEFR-FZRMHRINSA-N 0.000 description 2
- 208000037803 restenosis Diseases 0.000 description 2
- 125000006413 ring segment Chemical group 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
- 239000012265 solid product Substances 0.000 description 2
- 238000000935 solvent evaporation Methods 0.000 description 2
- 208000020431 spinal cord injury Diseases 0.000 description 2
- 230000035882 stress Effects 0.000 description 2
- 210000003523 substantia nigra Anatomy 0.000 description 2
- 229940014800 succinic anhydride Drugs 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000000967 suction filtration Methods 0.000 description 2
- 239000011593 sulfur Substances 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- YUKQRDCYNOVPGJ-UHFFFAOYSA-N thioacetamide Chemical compound CC(N)=S YUKQRDCYNOVPGJ-UHFFFAOYSA-N 0.000 description 2
- DLFVBJFMPXGRIB-UHFFFAOYSA-N thioacetamide Natural products CC(N)=O DLFVBJFMPXGRIB-UHFFFAOYSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000012546 transfer Methods 0.000 description 2
- 230000008736 traumatic injury Effects 0.000 description 2
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 2
- ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 2
- 239000003656 tris buffered saline Substances 0.000 description 2
- 238000001665 trituration Methods 0.000 description 2
- 125000002221 trityl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1C([*])(C1=C(C(=C(C(=C1[H])[H])[H])[H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 2
- VCGRFBXVSFAGGA-UHFFFAOYSA-N (1,1-dioxo-1,4-thiazinan-4-yl)-[6-[[3-(4-fluorophenyl)-5-methyl-1,2-oxazol-4-yl]methoxy]pyridin-3-yl]methanone Chemical compound CC=1ON=C(C=2C=CC(F)=CC=2)C=1COC(N=C1)=CC=C1C(=O)N1CCS(=O)(=O)CC1 VCGRFBXVSFAGGA-UHFFFAOYSA-N 0.000 description 1
- FANCTJAFZSYTIS-IQUVVAJASA-N (1r,3s,5z)-5-[(2e)-2-[(1r,3as,7ar)-7a-methyl-1-[(2r)-4-(phenylsulfonimidoyl)butan-2-yl]-2,3,3a,5,6,7-hexahydro-1h-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol Chemical compound C([C@@H](C)[C@@H]1[C@]2(CCCC(/[C@@H]2CC1)=C\C=C\1C([C@@H](O)C[C@H](O)C/1)=C)C)CS(=N)(=O)C1=CC=CC=C1 FANCTJAFZSYTIS-IQUVVAJASA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- SHAHPWSYJFYMRX-GDLCADMTSA-N (2S)-2-(4-{[(1R,2S)-2-hydroxycyclopentyl]methyl}phenyl)propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1C[C@@H]1[C@@H](O)CCC1 SHAHPWSYJFYMRX-GDLCADMTSA-N 0.000 description 1
- QMGHHBHPDDAGGO-IIWOMYBWSA-N (2S,4R)-1-[(2S)-2-[[2-[3-[4-[3-[4-[[5-bromo-4-[3-[cyclobutanecarbonyl(methyl)amino]propylamino]pyrimidin-2-yl]amino]phenoxy]propoxy]butoxy]propoxy]acetyl]amino]-3,3-dimethylbutanoyl]-4-hydroxy-N-[[4-(4-methyl-1,3-thiazol-5-yl)phenyl]methyl]pyrrolidine-2-carboxamide Chemical compound CN(CCCNC1=NC(NC2=CC=C(OCCCOCCCCOCCCOCC(=O)N[C@H](C(=O)N3C[C@H](O)C[C@H]3C(=O)NCC3=CC=C(C=C3)C3=C(C)N=CS3)C(C)(C)C)C=C2)=NC=C1Br)C(=O)C1CCC1 QMGHHBHPDDAGGO-IIWOMYBWSA-N 0.000 description 1
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
- KRIWIRSMQRQYJG-DLBZAZTESA-N (2s,3s)-3-[[7-(benzylamino)-3-propan-2-ylpyrazolo[1,5-a]pyrimidin-5-yl]amino]butane-1,2,4-triol Chemical compound C=1C(N[C@@H](CO)[C@H](O)CO)=NC2=C(C(C)C)C=NN2C=1NCC1=CC=CC=C1 KRIWIRSMQRQYJG-DLBZAZTESA-N 0.000 description 1
- LPNRUMVKXCLEBE-JXVRESAISA-L (3r)-4-[[(e)-2-[5-ethyl-4-(4-fluorophenyl)-6-phenyl-2-propan-2-ylpyridin-3-yl]ethenyl]-oxidophosphoryl]-3-hydroxybutanoate Chemical compound CCC1=C(C=2C=CC=CC=2)N=C(C(C)C)C(\C=C\P([O-])(=O)C[C@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 LPNRUMVKXCLEBE-JXVRESAISA-L 0.000 description 1
- MAYZWDRUFKUGGP-VIFPVBQESA-N (3s)-1-[5-tert-butyl-3-[(1-methyltetrazol-5-yl)methyl]triazolo[4,5-d]pyrimidin-7-yl]pyrrolidin-3-ol Chemical compound CN1N=NN=C1CN1C2=NC(C(C)(C)C)=NC(N3C[C@@H](O)CC3)=C2N=N1 MAYZWDRUFKUGGP-VIFPVBQESA-N 0.000 description 1
- RTTUBUXMNUJHRR-DXRVJIQQSA-N (3s)-4-[[(e)-2-[1-(4-fluorophenyl)-3-propan-2-ylindol-2-yl]ethenyl]-hydroxyphosphoryl]-3-hydroxybutanoic acid Chemical compound C12=CC=CC=C2C(C(C)C)=C(\C=C\P(O)(=O)C[C@@H](O)CC(O)=O)N1C1=CC=C(F)C=C1 RTTUBUXMNUJHRR-DXRVJIQQSA-N 0.000 description 1
- AOSODOHQJJPEAM-VUVZNRFTSA-N (3s)-4-[[(e)-2-[3'-(4-fluorophenyl)spiro[cyclopentane-1,1'-indene]-2'-yl]ethenyl]-hydroxyphosphoryl]-3-hydroxybutanoic acid Chemical compound OC(=O)C[C@H](O)CP(O)(=O)\C=C\C1=C(C=2C=CC(F)=CC=2)C2=CC=CC=C2C11CCCC1 AOSODOHQJJPEAM-VUVZNRFTSA-N 0.000 description 1
- WHQUHTXULUACFD-KRWDZBQOSA-N (3s)-4-[[2-(4-fluoro-3-methylphenyl)-4-methyl-6-propan-2-ylphenyl]methoxy-hydroxyphosphoryl]-3-hydroxybutanoic acid Chemical compound CC(C)C1=CC(C)=CC(C=2C=C(C)C(F)=CC=2)=C1COP(O)(=O)C[C@@H](O)CC(O)=O WHQUHTXULUACFD-KRWDZBQOSA-N 0.000 description 1
- FOLCUFKJHSQMEL-BIXPGCQOSA-N (4-butylcyclohexyl) N-[(2S)-4-methyl-1-oxo-1-[[(2S)-1-oxo-3-[(3S)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]pentan-2-yl]carbamate Chemical compound CCCCC1CCC(CC1)OC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@@H]2CCNC2=O)C=O FOLCUFKJHSQMEL-BIXPGCQOSA-N 0.000 description 1
- VPMIAOSOTOODMY-KJAPKAAFSA-N (4r)-6-[(e)-2-[6-tert-butyl-4-(4-fluorophenyl)-2-propan-2-ylpyridin-3-yl]ethenyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1/C=C/C=1C(C(C)C)=NC(C(C)(C)C)=CC=1C1=CC=C(F)C=C1 VPMIAOSOTOODMY-KJAPKAAFSA-N 0.000 description 1
- PNHBRYIAJCYNDA-VQCQRNETSA-N (4r)-6-[2-[2-ethyl-4-(4-fluorophenyl)-6-phenylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1CCC=1C(CC)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 PNHBRYIAJCYNDA-VQCQRNETSA-N 0.000 description 1
- QVBVQHTXLPNXEY-ZMFCMNQTSA-N (4r)-6-[2-[4-(4-fluorophenyl)-6-phenyl-2-propan-2-ylpyridin-3-yl]ethyl]-4-hydroxyoxan-2-one Chemical compound C([C@H](O)C1)C(=O)OC1CCC=1C(C(C)C)=NC(C=2C=CC=CC=2)=CC=1C1=CC=C(F)C=C1 QVBVQHTXLPNXEY-ZMFCMNQTSA-N 0.000 description 1
- VIMMECPCYZXUCI-MIMFYIINSA-N (4s,6r)-6-[(1e)-4,4-bis(4-fluorophenyl)-3-(1-methyltetrazol-5-yl)buta-1,3-dienyl]-4-hydroxyoxan-2-one Chemical compound CN1N=NN=C1C(\C=C\[C@@H]1OC(=O)C[C@@H](O)C1)=C(C=1C=CC(F)=CC=1)C1=CC=C(F)C=C1 VIMMECPCYZXUCI-MIMFYIINSA-N 0.000 description 1
- MNIPVWXWSPXERA-IDNZQHFXSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-(11-phenoxyundecanoyloxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@@H]([C@@H](OC(=O)CCCCCCCCCCOC=3C=CC=CC=3)C(O1)(C(O)=O)C(O)(C(O2)C(O)=O)C(O)=O)O)C1=CC=CC=C1 MNIPVWXWSPXERA-IDNZQHFXSA-N 0.000 description 1
- QBTROWHSMGZXCV-RQURQNPSSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-(11-phenoxyundecoxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@@H]([C@@H](OCCCCCCCCCCCOC=3C=CC=CC=3)C(O1)(C(O)=O)C(O)(C(O2)C(O)=O)C(O)=O)O)C1=CC=CC=C1 QBTROWHSMGZXCV-RQURQNPSSA-N 0.000 description 1
- QOLHWXNSCZGWHK-BWBORTOCSA-N (6r,7r)-1-[(4s,5r)-4-acetyloxy-5-methyl-3-methylidene-6-phenylhexyl]-4,7-dihydroxy-6-(11-phenoxyundecylcarbamoyloxy)-2,8-dioxabicyclo[3.2.1]octane-3,4,5-tricarboxylic acid Chemical compound C([C@@H](C)[C@H](OC(C)=O)C(=C)CCC12[C@@H]([C@@H](OC(=O)NCCCCCCCCCCCOC=3C=CC=CC=3)C(O1)(C(O)=O)C(O)(C(O2)C(O)=O)C(O)=O)O)C1=CC=CC=C1 QOLHWXNSCZGWHK-BWBORTOCSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- LVHOHZHTZXRVRJ-CMDGGOBGSA-N (e)-3-(3-methoxyphenyl)-n-(3,4,5-trimethoxyphenyl)prop-2-enamide Chemical compound COC1=CC=CC(\C=C\C(=O)NC=2C=C(OC)C(OC)=C(OC)C=2)=C1 LVHOHZHTZXRVRJ-CMDGGOBGSA-N 0.000 description 1
- QRDAPCMJAOQZSU-KQQUZDAGSA-N (e)-3-[4-[(e)-3-(3-fluorophenyl)-3-oxoprop-1-enyl]-1-methylpyrrol-2-yl]-n-hydroxyprop-2-enamide Chemical compound C1=C(\C=C\C(=O)NO)N(C)C=C1\C=C\C(=O)C1=CC=CC(F)=C1 QRDAPCMJAOQZSU-KQQUZDAGSA-N 0.000 description 1
- MOWXJLUYGFNTAL-DEOSSOPVSA-N (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxypyridazin-3-yl)methanol Chemical compound N1=NC(OC)=CC=C1[C@@H](O)C1=CC(C=2C3=CC=C(C=C3N=CN=2)N2CCOCC2)=C(F)C=C1Cl MOWXJLUYGFNTAL-DEOSSOPVSA-N 0.000 description 1
- 125000004514 1,2,4-thiadiazolyl group Chemical group 0.000 description 1
- CEDRGDFENMZKCQ-UHFFFAOYSA-N 1,2-oxazole-5-carbothioamide Chemical compound NC(=S)C1=CC=NO1 CEDRGDFENMZKCQ-UHFFFAOYSA-N 0.000 description 1
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 1
- APWRZPQBPCAXFP-UHFFFAOYSA-N 1-(1-oxo-2H-isoquinolin-5-yl)-5-(trifluoromethyl)-N-[2-(trifluoromethyl)pyridin-4-yl]pyrazole-4-carboxamide Chemical compound O=C1NC=CC2=C(C=CC=C12)N1N=CC(=C1C(F)(F)F)C(=O)NC1=CC(=NC=C1)C(F)(F)F APWRZPQBPCAXFP-UHFFFAOYSA-N 0.000 description 1
- SRLMDYIOEAPKNW-UHFFFAOYSA-N 1-(5-methoxy-1h-indol-2-yl)cyclopentan-1-ol Chemical compound C=1C2=CC(OC)=CC=C2NC=1C1(O)CCCC1 SRLMDYIOEAPKNW-UHFFFAOYSA-N 0.000 description 1
- KOFSFYBXUYHNJL-UHFFFAOYSA-N 1-(cyclopenten-1-yl)pyrrolidine Chemical compound C1CCCN1C1=CCCC1 KOFSFYBXUYHNJL-UHFFFAOYSA-N 0.000 description 1
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 1
- KQZLRWGGWXJPOS-NLFPWZOASA-N 1-[(1R)-1-(2,4-dichlorophenyl)ethyl]-6-[(4S,5R)-4-[(2S)-2-(hydroxymethyl)pyrrolidin-1-yl]-5-methylcyclohexen-1-yl]pyrazolo[3,4-b]pyrazine-3-carbonitrile Chemical compound ClC1=C(C=CC(=C1)Cl)[C@@H](C)N1N=C(C=2C1=NC(=CN=2)C1=CC[C@@H]([C@@H](C1)C)N1[C@@H](CCC1)CO)C#N KQZLRWGGWXJPOS-NLFPWZOASA-N 0.000 description 1
- ABDDQTDRAHXHOC-QMMMGPOBSA-N 1-[(7s)-5,7-dihydro-4h-thieno[2,3-c]pyran-7-yl]-n-methylmethanamine Chemical compound CNC[C@@H]1OCCC2=C1SC=C2 ABDDQTDRAHXHOC-QMMMGPOBSA-N 0.000 description 1
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 description 1
- QJPHKSCFCYKOGH-UHFFFAOYSA-N 1-[5-(2-ethoxyethoxy)-1h-indol-2-yl]cyclopentan-1-ol Chemical compound C=1C2=CC(OCCOCC)=CC=C2NC=1C1(O)CCCC1 QJPHKSCFCYKOGH-UHFFFAOYSA-N 0.000 description 1
- OTLFQTIXTWLWCY-UHFFFAOYSA-N 1-[5-(2-morpholin-4-ylethoxy)-1h-indol-2-yl]cyclopentan-1-ol Chemical compound C=1C2=CC(OCCN3CCOCC3)=CC=C2NC=1C1(O)CCCC1 OTLFQTIXTWLWCY-UHFFFAOYSA-N 0.000 description 1
- ORCAEWOLULGJOE-UHFFFAOYSA-N 1-[5-[2-(diethylamino)ethoxy]-1h-indol-2-yl]cyclopentan-1-ol Chemical compound C=1C2=CC(OCCN(CC)CC)=CC=C2NC=1C1(O)CCCC1 ORCAEWOLULGJOE-UHFFFAOYSA-N 0.000 description 1
- GODKPLPABYSZOS-UHFFFAOYSA-N 1-[5-tri(propan-2-yl)silyloxy-1h-indol-2-yl]cyclopentan-1-ol Chemical compound C=1C2=CC(O[Si](C(C)C)(C(C)C)C(C)C)=CC=C2NC=1C1(O)CCCC1 GODKPLPABYSZOS-UHFFFAOYSA-N 0.000 description 1
- BOOYHBPHFVNWNH-OAHLLOKOSA-N 1-tert-butyl-6-[[(1R)-1-(4-chlorophenyl)ethyl]amino]-5-[(4-fluorophenyl)methyl]pyrazolo[3,4-d]pyrimidin-4-one Chemical compound C[C@H](C1=CC=C(C=C1)Cl)NC2=NC3=C(C=NN3C(C)(C)C)C(=O)N2CC4=CC=C(C=C4)F BOOYHBPHFVNWNH-OAHLLOKOSA-N 0.000 description 1
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 description 1
- XKLNOVWDVMWTOB-UHFFFAOYSA-N 2,3,4,9-tetrahydro-1h-carbazole Chemical compound N1C2=CC=CC=C2C2=C1CCCC2 XKLNOVWDVMWTOB-UHFFFAOYSA-N 0.000 description 1
- NHJVRSWLHSJWIN-UHFFFAOYSA-N 2,4,6-trinitrobenzenesulfonic acid Chemical compound OS(=O)(=O)C1=C([N+]([O-])=O)C=C([N+]([O-])=O)C=C1[N+]([O-])=O NHJVRSWLHSJWIN-UHFFFAOYSA-N 0.000 description 1
- BAPCIDIRHDGBDG-UHFFFAOYSA-N 2-(2,3-dihydrofuran-4-yl)-1h-indole Chemical compound O1CCC(C=2NC3=CC=CC=C3C=2)=C1 BAPCIDIRHDGBDG-UHFFFAOYSA-N 0.000 description 1
- NJWIMFZLESWFIM-UHFFFAOYSA-N 2-(chloromethyl)pyridine Chemical compound ClCC1=CC=CC=N1 NJWIMFZLESWFIM-UHFFFAOYSA-N 0.000 description 1
- VLSFGJIHVUCHHB-UHFFFAOYSA-N 2-(cyclohexen-1-yl)-1-methylindole Chemical compound C=1C2=CC=CC=C2N(C)C=1C1=CCCCC1 VLSFGJIHVUCHHB-UHFFFAOYSA-N 0.000 description 1
- KJKXOZREZXQOQE-UHFFFAOYSA-N 2-(cyclohexen-1-yl)-1h-indole Chemical compound C1CCCC(C=2NC3=CC=CC=C3C=2)=C1 KJKXOZREZXQOQE-UHFFFAOYSA-N 0.000 description 1
- DAFHKPCWHUMOSF-UHFFFAOYSA-N 2-(cyclopenten-1-yl)-1h-indole Chemical compound C1CCC=C1C1=CC2=CC=CC=C2N1 DAFHKPCWHUMOSF-UHFFFAOYSA-N 0.000 description 1
- XSDHUNJXGTUPDB-UHFFFAOYSA-N 2-(cyclopenten-1-yl)-1h-pyrrolo[2,3-b]pyridine Chemical compound C1CCC=C1C1=CC2=CC=CN=C2N1 XSDHUNJXGTUPDB-UHFFFAOYSA-N 0.000 description 1
- KHAUBPIFYZCGGD-UHFFFAOYSA-N 2-(furan-3-yl)-1h-indole Chemical compound O1C=CC(C=2NC3=CC=CC=C3C=2)=C1 KHAUBPIFYZCGGD-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- VRPJIFMKZZEXLR-UHFFFAOYSA-N 2-[(2-methylpropan-2-yl)oxycarbonylamino]acetic acid Chemical compound CC(C)(C)OC(=O)NCC(O)=O VRPJIFMKZZEXLR-UHFFFAOYSA-N 0.000 description 1
- AKBHYCHPWZPGAH-UHFFFAOYSA-N 2-[3-[(3-chloro-4-methylphenyl)methoxy]azetidine-1-carbonyl]-7-oxa-5-azaspiro[3.4]octan-6-one Chemical compound CC1=C(Cl)C=C(COC2CN(C2)C(=O)C2CC3(C2)COC(=O)N3)C=C1 AKBHYCHPWZPGAH-UHFFFAOYSA-N 0.000 description 1
- JWHYSEDOYMYMNM-QGZVFWFLSA-N 2-[4-[(2r)-2-ethoxy-3-[4-(trifluoromethyl)phenoxy]propyl]sulfanyl-2-methylphenoxy]acetic acid Chemical compound C([C@@H](OCC)CSC=1C=C(C)C(OCC(O)=O)=CC=1)OC1=CC=C(C(F)(F)F)C=C1 JWHYSEDOYMYMNM-QGZVFWFLSA-N 0.000 description 1
- QLVGHFBUSGYCCG-UHFFFAOYSA-N 2-amino-n-(1-cyano-2-phenylethyl)acetamide Chemical compound NCC(=O)NC(C#N)CC1=CC=CC=C1 QLVGHFBUSGYCCG-UHFFFAOYSA-N 0.000 description 1
- VCPILRQMBVXXID-UHFFFAOYSA-N 2-benzyl-4-bromobutanenitrile Chemical compound BrCCC(C#N)CC1=CC=CC=C1 VCPILRQMBVXXID-UHFFFAOYSA-N 0.000 description 1
- LSTRKXWIZZZYAS-UHFFFAOYSA-N 2-bromoacetyl bromide Chemical compound BrCC(Br)=O LSTRKXWIZZZYAS-UHFFFAOYSA-N 0.000 description 1
- FWOHDAGPWDEWIB-UHFFFAOYSA-N 2-bromoethoxymethylbenzene Chemical compound BrCCOCC1=CC=CC=C1 FWOHDAGPWDEWIB-UHFFFAOYSA-N 0.000 description 1
- UOSUPIGXOGUDDA-UHFFFAOYSA-N 2-but-2-en-2-yl-1h-indole Chemical compound C1=CC=C2NC(C(C)=CC)=CC2=C1 UOSUPIGXOGUDDA-UHFFFAOYSA-N 0.000 description 1
- HVFZVIHIJNLIED-UHFFFAOYSA-N 2-ethenyl-1-benzofuran Chemical class C1=CC=C2OC(C=C)=CC2=C1 HVFZVIHIJNLIED-UHFFFAOYSA-N 0.000 description 1
- UEPFNQXGOLWTAD-UHFFFAOYSA-N 2-ethenyl-1-benzothiophene Chemical class C1=CC=C2SC(C=C)=CC2=C1 UEPFNQXGOLWTAD-UHFFFAOYSA-N 0.000 description 1
- GJTFYLXUKPLSNX-UHFFFAOYSA-N 2-hept-3-en-3-yl-1h-indole Chemical compound C1=CC=C2NC(C(CC)=CCCC)=CC2=C1 GJTFYLXUKPLSNX-UHFFFAOYSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
- SWXPAPNPQXSLMV-UHFFFAOYSA-N 2-methylsulfonylethanethioamide Chemical compound CS(=O)(=O)CC(N)=S SWXPAPNPQXSLMV-UHFFFAOYSA-N 0.000 description 1
- WLJVXDMOQOGPHL-PPJXEINESA-N 2-phenylacetic acid Chemical compound O[14C](=O)CC1=CC=CC=C1 WLJVXDMOQOGPHL-PPJXEINESA-N 0.000 description 1
- 125000004485 2-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])([H])C1([H])* 0.000 description 1
- MNLXPMODUGFBAA-UHFFFAOYSA-N 2-tert-butylsulfonylethanethioamide Chemical compound CC(C)(C)S(=O)(=O)CC(N)=S MNLXPMODUGFBAA-UHFFFAOYSA-N 0.000 description 1
- HCDMJFOHIXMBOV-UHFFFAOYSA-N 3-(2,6-difluoro-3,5-dimethoxyphenyl)-1-ethyl-8-(morpholin-4-ylmethyl)-4,7-dihydropyrrolo[4,5]pyrido[1,2-d]pyrimidin-2-one Chemical compound C=1C2=C3N(CC)C(=O)N(C=4C(=C(OC)C=C(OC)C=4F)F)CC3=CN=C2NC=1CN1CCOCC1 HCDMJFOHIXMBOV-UHFFFAOYSA-N 0.000 description 1
- BYHQTRFJOGIQAO-GOSISDBHSA-N 3-(4-bromophenyl)-8-[(2R)-2-hydroxypropyl]-1-[(3-methoxyphenyl)methyl]-1,3,8-triazaspiro[4.5]decan-2-one Chemical compound C[C@H](CN1CCC2(CC1)CN(C(=O)N2CC3=CC(=CC=C3)OC)C4=CC=C(C=C4)Br)O BYHQTRFJOGIQAO-GOSISDBHSA-N 0.000 description 1
- WCFJUSRQHZPVKY-UHFFFAOYSA-N 3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NCCC(O)=O WCFJUSRQHZPVKY-UHFFFAOYSA-N 0.000 description 1
- WNEODWDFDXWOLU-QHCPKHFHSA-N 3-[3-(hydroxymethyl)-4-[1-methyl-5-[[5-[(2s)-2-methyl-4-(oxetan-3-yl)piperazin-1-yl]pyridin-2-yl]amino]-6-oxopyridin-3-yl]pyridin-2-yl]-7,7-dimethyl-1,2,6,8-tetrahydrocyclopenta[3,4]pyrrolo[3,5-b]pyrazin-4-one Chemical compound C([C@@H](N(CC1)C=2C=NC(NC=3C(N(C)C=C(C=3)C=3C(=C(N4C(C5=CC=6CC(C)(C)CC=6N5CC4)=O)N=CC=3)CO)=O)=CC=2)C)N1C1COC1 WNEODWDFDXWOLU-QHCPKHFHSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- QGMROEZDWJTIDW-UHFFFAOYSA-N 3-bromopropoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCCBr QGMROEZDWJTIDW-UHFFFAOYSA-N 0.000 description 1
- ISULZYQDGYXDFW-UHFFFAOYSA-N 3-methylbutanoyl chloride Chemical compound CC(C)CC(Cl)=O ISULZYQDGYXDFW-UHFFFAOYSA-N 0.000 description 1
- BGEDGKFPSNKTOV-UHFFFAOYSA-N 3-methylsulfonylpropoxymethylbenzene Chemical compound CS(=O)(=O)CCCOCC1=CC=CC=C1 BGEDGKFPSNKTOV-UHFFFAOYSA-N 0.000 description 1
- 125000004575 3-pyrrolidinyl group Chemical group [H]N1C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- LIDUGWDLSDKCLM-CSKARUKUSA-N 4-[[3-[[[(e)-6,6-dimethylhept-2-en-4-ynyl]-ethylamino]methyl]phenoxy]methyl-dimethylsilyl]benzonitrile Chemical compound CC(C)(C)C#C/C=C/CN(CC)CC1=CC=CC(OC[Si](C)(C)C=2C=CC(=CC=2)C#N)=C1 LIDUGWDLSDKCLM-CSKARUKUSA-N 0.000 description 1
- RSUDLACLOAKYCN-UHFFFAOYSA-N 4-amino-2-[(2-methylpropan-2-yl)oxycarbonyl]butanoic acid Chemical compound CC(C)(C)OC(=O)C(C(O)=O)CCN RSUDLACLOAKYCN-UHFFFAOYSA-N 0.000 description 1
- KVCQTKNUUQOELD-UHFFFAOYSA-N 4-amino-n-[1-(3-chloro-2-fluoroanilino)-6-methylisoquinolin-5-yl]thieno[3,2-d]pyrimidine-7-carboxamide Chemical compound N=1C=CC2=C(NC(=O)C=3C4=NC=NC(N)=C4SC=3)C(C)=CC=C2C=1NC1=CC=CC(Cl)=C1F KVCQTKNUUQOELD-UHFFFAOYSA-N 0.000 description 1
- NCXCIXKCYIILLT-UHFFFAOYSA-N 4-ethenyl-1,3-thiazole Chemical class C=CC1=CSC=N1 NCXCIXKCYIILLT-UHFFFAOYSA-N 0.000 description 1
- MCXLQFOCWZMFHV-UHFFFAOYSA-N 4-ethenyl-2h-triazole Chemical class C=CC1=CNN=N1 MCXLQFOCWZMFHV-UHFFFAOYSA-N 0.000 description 1
- JDRMYOQETPMYQX-UHFFFAOYSA-M 4-methoxy-4-oxobutanoate Chemical compound COC(=O)CCC([O-])=O JDRMYOQETPMYQX-UHFFFAOYSA-M 0.000 description 1
- NSPMIYGKQJPBQR-UHFFFAOYSA-N 4H-1,2,4-triazole Chemical compound C=1N=CNN=1 NSPMIYGKQJPBQR-UHFFFAOYSA-N 0.000 description 1
- RLJHWDXXBPSWDT-UHFFFAOYSA-N 5,7,8,9,10,11-hexahydrocyclopent[a]pyrrolo[3,4-c]carbazole-5(6h)-one Chemical compound C1CCCC2=C1NC1=C3CC(=O)C=C3C3=CN=CC3=C12 RLJHWDXXBPSWDT-UHFFFAOYSA-N 0.000 description 1
- IRPVABHDSJVBNZ-RTHVDDQRSA-N 5-[1-(cyclopropylmethyl)-5-[(1R,5S)-3-(oxetan-3-yl)-3-azabicyclo[3.1.0]hexan-6-yl]pyrazol-3-yl]-3-(trifluoromethyl)pyridin-2-amine Chemical compound C1=C(C(F)(F)F)C(N)=NC=C1C1=NN(CC2CC2)C(C2[C@@H]3CN(C[C@@H]32)C2COC2)=C1 IRPVABHDSJVBNZ-RTHVDDQRSA-N 0.000 description 1
- MHQZDNQHLGFBRN-UHFFFAOYSA-N 5-ethenyl-1h-imidazole Chemical class C=CC1=CNC=N1 MHQZDNQHLGFBRN-UHFFFAOYSA-N 0.000 description 1
- ODFFPRGJZRXNHZ-UHFFFAOYSA-N 5-fluoroindole Chemical compound FC1=CC=C2NC=CC2=C1 ODFFPRGJZRXNHZ-UHFFFAOYSA-N 0.000 description 1
- KCBWAFJCKVKYHO-UHFFFAOYSA-N 6-(4-cyclopropyl-6-methoxypyrimidin-5-yl)-1-[[4-[1-propan-2-yl-4-(trifluoromethyl)imidazol-2-yl]phenyl]methyl]pyrazolo[3,4-d]pyrimidine Chemical compound C1(CC1)C1=NC=NC(=C1C1=NC=C2C(=N1)N(N=C2)CC1=CC=C(C=C1)C=1N(C=C(N=1)C(F)(F)F)C(C)C)OC KCBWAFJCKVKYHO-UHFFFAOYSA-N 0.000 description 1
- CYJRNFFLTBEQSQ-UHFFFAOYSA-N 8-(3-methyl-1-benzothiophen-5-yl)-N-(4-methylsulfonylpyridin-3-yl)quinoxalin-6-amine Chemical compound CS(=O)(=O)C1=C(C=NC=C1)NC=1C=C2N=CC=NC2=C(C=1)C=1C=CC2=C(C(=CS2)C)C=1 CYJRNFFLTBEQSQ-UHFFFAOYSA-N 0.000 description 1
- PZASAAIJIFDWSB-CKPDSHCKSA-N 8-[(1S)-1-[8-(trifluoromethyl)-7-[4-(trifluoromethyl)cyclohexyl]oxynaphthalen-2-yl]ethyl]-8-azabicyclo[3.2.1]octane-3-carboxylic acid Chemical compound FC(F)(F)C=1C2=CC([C@@H](N3C4CCC3CC(C4)C(O)=O)C)=CC=C2C=CC=1OC1CCC(C(F)(F)F)CC1 PZASAAIJIFDWSB-CKPDSHCKSA-N 0.000 description 1
- PWJFNRJRHXWEPT-UHFFFAOYSA-N ADP ribose Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)C=O)C(O)C1O PWJFNRJRHXWEPT-UHFFFAOYSA-N 0.000 description 1
- 230000005730 ADP ribosylation Effects 0.000 description 1
- NLHHRLWOUZZQLW-UHFFFAOYSA-N Acrylonitrile Chemical compound C=CC#N NLHHRLWOUZZQLW-UHFFFAOYSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000219495 Betulaceae Species 0.000 description 1
- REDUQXCPUSNJOL-UHFFFAOYSA-N C(C1=CC=CC=C1)NC(CN(C(C1=CC=C(C=C1)C(C)C)=O)CC1=CC=C(C=C1)C(NO)=O)=O Chemical compound C(C1=CC=CC=C1)NC(CN(C(C1=CC=C(C=C1)C(C)C)=O)CC1=CC=C(C=C1)C(NO)=O)=O REDUQXCPUSNJOL-UHFFFAOYSA-N 0.000 description 1
- 102000017420 CD3 protein, epsilon/gamma/delta subunit Human genes 0.000 description 1
- 101150006084 CHKB gene Proteins 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 206010008089 Cerebral artery occlusion Diseases 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 208000000094 Chronic Pain Diseases 0.000 description 1
- CYSWUSAYJNCAKA-FYJFLYSWSA-N ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O Chemical compound ClC1=C(C=CC=2N=C(SC=21)OCC)OC1=CC=C(C=N1)/C=C/[C@H](C)NC(C)=O CYSWUSAYJNCAKA-FYJFLYSWSA-N 0.000 description 1
- QBXVXKRWOVBUDB-GRKNLSHJSA-N ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C Chemical compound ClC=1C(=CC(=C(CN2[C@H](C[C@H](C2)O)C(=O)O)C1)OCC1=CC(=CC=C1)C#N)OCC1=C(C(=CC=C1)C1=CC2=C(OCCO2)C=C1)C QBXVXKRWOVBUDB-GRKNLSHJSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 229940126650 Compound 3f Drugs 0.000 description 1
- 229940126559 Compound 4e Drugs 0.000 description 1
- 229940125761 Compound 6g Drugs 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 102100023033 Cyclic AMP-dependent transcription factor ATF-2 Human genes 0.000 description 1
- 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 1
- 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 1
- 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 1
- 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 1
- 102000053602 DNA Human genes 0.000 description 1
- 102000011724 DNA Repair Enzymes Human genes 0.000 description 1
- 108010076525 DNA Repair Enzymes Proteins 0.000 description 1
- 230000007035 DNA breakage Effects 0.000 description 1
- 230000005778 DNA damage Effects 0.000 description 1
- 231100000277 DNA damage Toxicity 0.000 description 1
- 230000004543 DNA replication Effects 0.000 description 1
- 231100001074 DNA strand break Toxicity 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010048554 Endothelial dysfunction Diseases 0.000 description 1
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 1
- 208000009386 Experimental Arthritis Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- KGPGFQWBCSZGEL-ZDUSSCGKSA-N GSK690693 Chemical compound C=12N(CC)C(C=3C(=NON=3)N)=NC2=C(C#CC(C)(C)O)N=CC=1OC[C@H]1CCCNC1 KGPGFQWBCSZGEL-ZDUSSCGKSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 108010009202 Growth Factor Receptors Proteins 0.000 description 1
- 102000009465 Growth Factor Receptors Human genes 0.000 description 1
- 208000032456 Hemorrhagic Shock Diseases 0.000 description 1
- 101000974934 Homo sapiens Cyclic AMP-dependent transcription factor ATF-2 Proteins 0.000 description 1
- 101000997829 Homo sapiens Glial cell line-derived neurotrophic factor Proteins 0.000 description 1
- 101000628949 Homo sapiens Mitogen-activated protein kinase 10 Proteins 0.000 description 1
- 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 description 1
- 101001050288 Homo sapiens Transcription factor Jun Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 101000668058 Infectious salmon anemia virus (isolate Atlantic salmon/Norway/810/9/99) RNA-directed RNA polymerase catalytic subunit Proteins 0.000 description 1
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 1
- 238000000023 Kugelrohr distillation Methods 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102000003960 Ligases Human genes 0.000 description 1
- 108090000364 Ligases Proteins 0.000 description 1
- 108010002481 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Proteins 0.000 description 1
- 102000036243 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Human genes 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 239000012359 Methanesulfonyl chloride Substances 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 102100026931 Mitogen-activated protein kinase 10 Human genes 0.000 description 1
- 206010061297 Mucosal erosion Diseases 0.000 description 1
- 101100237799 Mus musculus Mlkl gene Proteins 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- HOKKHZGPKSLGJE-GSVOUGTGSA-N N-Methyl-D-aspartic acid Chemical compound CN[C@@H](C(O)=O)CC(O)=O HOKKHZGPKSLGJE-GSVOUGTGSA-N 0.000 description 1
- AYCPARAPKDAOEN-LJQANCHMSA-N N-[(1S)-2-(dimethylamino)-1-phenylethyl]-6,6-dimethyl-3-[(2-methyl-4-thieno[3,2-d]pyrimidinyl)amino]-1,4-dihydropyrrolo[3,4-c]pyrazole-5-carboxamide Chemical compound C1([C@H](NC(=O)N2C(C=3NN=C(NC=4C=5SC=CC=5N=C(C)N=4)C=3C2)(C)C)CN(C)C)=CC=CC=C1 AYCPARAPKDAOEN-LJQANCHMSA-N 0.000 description 1
- XJTWGMHOQKGBDO-GOSISDBHSA-N N-[(3-Fluorophenyl)methyl]-1-[(1r)-1-Naphthalen-1-Ylethyl]piperidine-4-Carboxamide Chemical compound C1CN([C@H](C)C=2C3=CC=CC=C3C=CC=2)CCC1C(=O)NCC1=CC=CC(F)=C1 XJTWGMHOQKGBDO-GOSISDBHSA-N 0.000 description 1
- IPCRBOOJBPETMF-UHFFFAOYSA-N N-acetylthiourea Chemical compound CC(=O)NC(N)=S IPCRBOOJBPETMF-UHFFFAOYSA-N 0.000 description 1
- OPFJDXRVMFKJJO-ZHHKINOHSA-N N-{[3-(2-benzamido-4-methyl-1,3-thiazol-5-yl)-pyrazol-5-yl]carbonyl}-G-dR-G-dD-dD-dD-NH2 Chemical compound S1C(C=2NN=C(C=2)C(=O)NCC(=O)N[C@H](CCCN=C(N)N)C(=O)NCC(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC(O)=O)C(N)=O)=C(C)N=C1NC(=O)C1=CC=CC=C1 OPFJDXRVMFKJJO-ZHHKINOHSA-N 0.000 description 1
- 229910020889 NaBH3 Inorganic materials 0.000 description 1
- 206010028851 Necrosis Diseases 0.000 description 1
- 101710138657 Neurotoxin Proteins 0.000 description 1
- IDRGFNPZDVBSSE-UHFFFAOYSA-N OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F Chemical compound OCCN1CCN(CC1)c1ccc(Nc2ncc3cccc(-c4cccc(NC(=O)C=C)c4)c3n2)c(F)c1F IDRGFNPZDVBSSE-UHFFFAOYSA-N 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 235000019502 Orange oil Nutrition 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 229910019213 POCl3 Inorganic materials 0.000 description 1
- 102000004422 Phospholipase C gamma Human genes 0.000 description 1
- 108010056751 Phospholipase C gamma Proteins 0.000 description 1
- 102000012338 Poly(ADP-ribose) Polymerases Human genes 0.000 description 1
- 108010061844 Poly(ADP-ribose) Polymerases Proteins 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108090000315 Protein Kinase C Proteins 0.000 description 1
- 102000003923 Protein Kinase C Human genes 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 108091005682 Receptor kinases Proteins 0.000 description 1
- 229940125907 SJ995973 Drugs 0.000 description 1
- 108010077895 Sarcosine Proteins 0.000 description 1
- 101710184528 Scaffolding protein Proteins 0.000 description 1
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 1
- 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- 206010049771 Shock haemorrhagic Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- OUUQCZGPVNCOIJ-UHFFFAOYSA-M Superoxide Chemical compound [O-][O] OUUQCZGPVNCOIJ-UHFFFAOYSA-M 0.000 description 1
- 239000006180 TBST buffer Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- YGZWVPBHYABGLT-KJEVXHAQSA-N Thr-Pro-Tyr Chemical group C[C@@H](O)[C@H](N)C(=O)N1CCC[C@H]1C(=O)N[C@H](C(O)=O)CC1=CC=C(O)C=C1 YGZWVPBHYABGLT-KJEVXHAQSA-N 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- 102100023132 Transcription factor Jun Human genes 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 1
- 238000007239 Wittig reaction Methods 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- LXRZVMYMQHNYJB-UNXOBOICSA-N [(1R,2S,4R)-4-[[5-[4-[(1R)-7-chloro-1,2,3,4-tetrahydroisoquinolin-1-yl]-5-methylthiophene-2-carbonyl]pyrimidin-4-yl]amino]-2-hydroxycyclopentyl]methyl sulfamate Chemical compound CC1=C(C=C(S1)C(=O)C1=C(N[C@H]2C[C@H](O)[C@@H](COS(N)(=O)=O)C2)N=CN=C1)[C@@H]1NCCC2=C1C=C(Cl)C=C2 LXRZVMYMQHNYJB-UNXOBOICSA-N 0.000 description 1
- HFIVLLBFACNAFN-UHFFFAOYSA-N [1-amino-2-[2-(4-methoxyphenyl)ethylamino]ethyl]phosphonic acid Chemical compound COc1ccc(CCNCC(N)P(O)(O)=O)cc1 HFIVLLBFACNAFN-UHFFFAOYSA-N 0.000 description 1
- JQGCPOUOBUJYDT-UHFFFAOYSA-N [3-(cyclopenten-1-yl)pyrrol-1-yl]-tri(propan-2-yl)silane Chemical compound CC(C)[Si](C(C)C)(C(C)C)N1C=CC(C=2CCCC=2)=C1 JQGCPOUOBUJYDT-UHFFFAOYSA-N 0.000 description 1
- XLIJUKVKOIMPKW-BTVCFUMJSA-N [O].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O Chemical compound [O].OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O XLIJUKVKOIMPKW-BTVCFUMJSA-N 0.000 description 1
- 230000001594 aberrant effect Effects 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 125000000641 acridinyl group Chemical group C1(=CC=CC2=NC3=CC=CC=C3C=C12)* 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 208000005298 acute pain Diseases 0.000 description 1
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001447 alkali salts Chemical class 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 230000002152 alkylating effect Effects 0.000 description 1
- SRVFFFJZQVENJC-IHRRRGAJSA-N aloxistatin Chemical compound CCOC(=O)[C@H]1O[C@@H]1C(=O)N[C@@H](CC(C)C)C(=O)NCCC(C)C SRVFFFJZQVENJC-IHRRRGAJSA-N 0.000 description 1
- VLSMHEGGTFMBBZ-UHFFFAOYSA-N alpha-Kainic acid Natural products CC(=C)C1CNC(C(O)=O)C1CC(O)=O VLSMHEGGTFMBBZ-UHFFFAOYSA-N 0.000 description 1
- 150000001370 alpha-amino acid derivatives Chemical class 0.000 description 1
- 235000008206 alpha-amino acids Nutrition 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 125000004202 aminomethyl group Chemical group [H]N([H])C([H])([H])* 0.000 description 1
- 239000000908 ammonium hydroxide Substances 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000002399 angioplasty Methods 0.000 description 1
- 239000000730 antalgic agent Substances 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 229940058303 antinematodal benzimidazole derivative Drugs 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000008365 aqueous carrier Substances 0.000 description 1
- 238000005899 aromatization reaction Methods 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- QXNDZONIWRINJR-UHFFFAOYSA-N azocane Chemical compound C1CCCNCCC1 QXNDZONIWRINJR-UHFFFAOYSA-N 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- CSKNSYBAZOQPLR-UHFFFAOYSA-N benzenesulfonyl chloride Chemical compound ClS(=O)(=O)C1=CC=CC=C1 CSKNSYBAZOQPLR-UHFFFAOYSA-N 0.000 description 1
- 150000001556 benzimidazoles Chemical class 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- RROBIDXNTUAHFW-UHFFFAOYSA-N benzotriazol-1-yloxy-tris(dimethylamino)phosphanium Chemical compound C1=CC=C2N(O[P+](N(C)C)(N(C)C)N(C)C)N=NC2=C1 RROBIDXNTUAHFW-UHFFFAOYSA-N 0.000 description 1
- JHVLLYQQQYIWKX-UHFFFAOYSA-N benzyl 2-bromoacetate Chemical compound BrCC(=O)OCC1=CC=CC=C1 JHVLLYQQQYIWKX-UHFFFAOYSA-N 0.000 description 1
- VZOVOHRDLOYBJX-UHFFFAOYSA-N benzyl 4-oxopiperidine-1-carboxylate Chemical compound C1CC(=O)CCN1C(=O)OCC1=CC=CC=C1 VZOVOHRDLOYBJX-UHFFFAOYSA-N 0.000 description 1
- KSCRVOKQPYZBHZ-IXPOFIJOSA-N benzyl n-[(2s)-1-[[(2s)-1-[[(2s)-1-(1,3-benzothiazol-2-yl)-1-oxo-3-[(3s)-2-oxopyrrolidin-3-yl]propan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]carbamate Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C[C@H]1C(NCC1)=O)C(=O)C=1SC2=CC=CC=C2N=1)C(C)C)C(=O)OCC1=CC=CC=C1 KSCRVOKQPYZBHZ-IXPOFIJOSA-N 0.000 description 1
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 1
- 230000002146 bilateral effect Effects 0.000 description 1
- 239000013060 biological fluid Substances 0.000 description 1
- 239000003738 black carbon Substances 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- UWTDFICHZKXYAC-UHFFFAOYSA-N boron;oxolane Chemical compound [B].C1CCOC1 UWTDFICHZKXYAC-UHFFFAOYSA-N 0.000 description 1
- 208000029028 brain injury Diseases 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 239000008366 buffered solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- JDRMYOQETPMYQX-UHFFFAOYSA-N butanedioic acid monomethyl ester Natural products COC(=O)CCC(O)=O JDRMYOQETPMYQX-UHFFFAOYSA-N 0.000 description 1
- 125000004106 butoxy group Chemical group [*]OC([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- OSVHLUXLWQLPIY-KBAYOESNSA-N butyl 2-[(6aR,9R,10aR)-1-hydroxy-9-(hydroxymethyl)-6,6-dimethyl-6a,7,8,9,10,10a-hexahydrobenzo[c]chromen-3-yl]-2-methylpropanoate Chemical compound C(CCC)OC(C(C)(C)C1=CC(=C2[C@H]3[C@H](C(OC2=C1)(C)C)CC[C@H](C3)CO)O)=O OSVHLUXLWQLPIY-KBAYOESNSA-N 0.000 description 1
- YTIVTFGABIZHHX-UHFFFAOYSA-N butynedioic acid Chemical compound OC(=O)C#CC(O)=O YTIVTFGABIZHHX-UHFFFAOYSA-N 0.000 description 1
- DVECBJCOGJRVPX-UHFFFAOYSA-N butyryl chloride Chemical compound CCCC(Cl)=O DVECBJCOGJRVPX-UHFFFAOYSA-N 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 1
- 150000001716 carbazoles Chemical class 0.000 description 1
- 125000000609 carbazolyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3NC12)* 0.000 description 1
- 229910002091 carbon monoxide Inorganic materials 0.000 description 1
- 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
- 230000021523 carboxylation Effects 0.000 description 1
- 238000006473 carboxylation reaction Methods 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 210000004413 cardiac myocyte Anatomy 0.000 description 1
- 230000003293 cardioprotective effect Effects 0.000 description 1
- 210000001168 carotid artery common Anatomy 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 102000013515 cdc42 GTP-Binding Protein Human genes 0.000 description 1
- 108010051348 cdc42 GTP-Binding Protein Proteins 0.000 description 1
- 208000037887 cell injury Diseases 0.000 description 1
- 230000004709 cell invasion Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 208000015114 central nervous system disease Diseases 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 125000001309 chloro group Chemical group Cl* 0.000 description 1
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 108091006090 chromatin-associated proteins Proteins 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 230000003920 cognitive function Effects 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940126086 compound 21 Drugs 0.000 description 1
- 229940125877 compound 31 Drugs 0.000 description 1
- 229940125796 compound 3d Drugs 0.000 description 1
- 229940126540 compound 41 Drugs 0.000 description 1
- 229940125872 compound 4d Drugs 0.000 description 1
- 229940126115 compound 4f Drugs 0.000 description 1
- 229940125880 compound 4j Drugs 0.000 description 1
- 230000009091 contractile dysfunction Effects 0.000 description 1
- 150000001879 copper Chemical class 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013058 crude material Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- WEPUZBYKXNKSDH-UHFFFAOYSA-N cyclopentanecarbonyl chloride Chemical compound ClC(=O)C1CCCC1 WEPUZBYKXNKSDH-UHFFFAOYSA-N 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000002716 delivery method Methods 0.000 description 1
- 230000000779 depleting effect Effects 0.000 description 1
- 239000002274 desiccant Substances 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- OKGXJRGLYVRVNE-UHFFFAOYSA-N diaminomethylidenethiourea Chemical compound NC(N)=NC(N)=S OKGXJRGLYVRVNE-UHFFFAOYSA-N 0.000 description 1
- NPOMSUOUAZCMBL-UHFFFAOYSA-N dichloromethane;ethoxyethane Chemical compound ClCCl.CCOCC NPOMSUOUAZCMBL-UHFFFAOYSA-N 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- KPUWHANPEXNPJT-UHFFFAOYSA-N disiloxane Chemical class [SiH3]O[SiH3] KPUWHANPEXNPJT-UHFFFAOYSA-N 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000012039 electrophile Substances 0.000 description 1
- 239000003480 eluent Substances 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 150000002081 enamines Chemical class 0.000 description 1
- 230000008694 endothelial dysfunction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000006353 environmental stress Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- LJQKCYFTNDAAPC-UHFFFAOYSA-N ethanol;ethyl acetate Chemical compound CCO.CCOC(C)=O LJQKCYFTNDAAPC-UHFFFAOYSA-N 0.000 description 1
- AMQZZSZCLSVKLO-ARJAWSKDSA-N ethyl (z)-3-cyanoprop-2-enoate Chemical compound CCOC(=O)\C=C/C#N AMQZZSZCLSVKLO-ARJAWSKDSA-N 0.000 description 1
- YWKVMGDEOUPQGN-UHFFFAOYSA-N ethyl 2-[4-[2-(3-hydroxy-1-azabicyclo[2.2.2]octan-3-yl)ethynyl]phenyl]acetate Chemical compound C1=CC(CC(=O)OCC)=CC=C1C#CC1(O)C(CC2)CCN2C1 YWKVMGDEOUPQGN-UHFFFAOYSA-N 0.000 description 1
- WHQLQYRFIHPMNA-UHFFFAOYSA-N ethyl acetate;oxolane Chemical compound C1CCOC1.CCOC(C)=O WHQLQYRFIHPMNA-UHFFFAOYSA-N 0.000 description 1
- WUDNUHPRLBTKOJ-UHFFFAOYSA-N ethyl isocyanate Chemical compound CCN=C=O WUDNUHPRLBTKOJ-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 210000000416 exudates and transudate Anatomy 0.000 description 1
- 239000010685 fatty oil Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012065 filter cake Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 210000001559 fluids and secretion Anatomy 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- AWJWCTOOIBYHON-UHFFFAOYSA-N furo[3,4-b]pyrazine-5,7-dione Chemical compound C1=CN=C2C(=O)OC(=O)C2=N1 AWJWCTOOIBYHON-UHFFFAOYSA-N 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-L glutamate group Chemical group N[C@@H](CCC(=O)[O-])C(=O)[O-] WHUUTDBJXJRKMK-VKHMYHEASA-L 0.000 description 1
- 125000000350 glycoloyl group Chemical group O=C([*])C([H])([H])O[H] 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 208000018706 hematopoietic system disease Diseases 0.000 description 1
- 125000004404 heteroalkyl group Chemical group 0.000 description 1
- 150000002391 heterocyclic compounds Chemical class 0.000 description 1
- 210000004295 hippocampal neuron Anatomy 0.000 description 1
- 238000010562 histological examination Methods 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 102000055590 human KDR Human genes 0.000 description 1
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
- 150000007857 hydrazones Chemical class 0.000 description 1
- 150000002430 hydrocarbons Chemical group 0.000 description 1
- 238000005984 hydrogenation reaction Methods 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000003463 hyperproliferative effect Effects 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 150000002475 indoles Chemical class 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 230000009878 intermolecular interaction Effects 0.000 description 1
- 238000000185 intracerebroventricular administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 230000000302 ischemic effect Effects 0.000 description 1
- 125000005956 isoquinolyl group Chemical group 0.000 description 1
- 125000001786 isothiazolyl group Chemical group 0.000 description 1
- 125000000842 isoxazolyl group Chemical group 0.000 description 1
- VLSMHEGGTFMBBZ-OOZYFLPDSA-N kainic acid Chemical compound CC(=C)[C@H]1CN[C@H](C(O)=O)[C@H]1CC(O)=O VLSMHEGGTFMBBZ-OOZYFLPDSA-N 0.000 description 1
- 229950006874 kainic acid Drugs 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- RENRQMCACQEWFC-UGKGYDQZSA-N lnp023 Chemical compound C1([C@H]2N(CC=3C=4C=CNC=4C(C)=CC=3OC)CC[C@@H](C2)OCC)=CC=C(C(O)=O)C=C1 RENRQMCACQEWFC-UGKGYDQZSA-N 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 1
- HQEIPVHJHZTMDP-JEDNCBNOSA-N methyl (2s)-pyrrolidine-2-carboxylate;hydrochloride Chemical compound Cl.COC(=O)[C@@H]1CCCN1 HQEIPVHJHZTMDP-JEDNCBNOSA-N 0.000 description 1
- MUTCAPXLKRYEPR-ITWZMISCSA-N methyl (e,3r,5s)-7-[4-bromo-2,3-bis(4-fluorophenyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyhept-6-enoate Chemical compound COC(=O)C[C@H](O)C[C@H](O)\C=C\N1C(C(C)C)=C(Br)C(C=2C=CC(F)=CC=2)=C1C1=CC=C(F)C=C1 MUTCAPXLKRYEPR-ITWZMISCSA-N 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 201000007309 middle cerebral artery infarction Diseases 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 108090001035 mitogen-activated protein kinase kinase kinase 12 Proteins 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 102000035118 modified proteins Human genes 0.000 description 1
- 108091005573 modified proteins Proteins 0.000 description 1
- VDCLSGXZVUDARN-UHFFFAOYSA-N molecular bromine;pyridine;hydrobromide Chemical compound Br.BrBr.C1=CC=NC=C1 VDCLSGXZVUDARN-UHFFFAOYSA-N 0.000 description 1
- IBMRTYCHDPMBFN-UHFFFAOYSA-N monomethyl glutaric acid Chemical compound COC(=O)CCCC(O)=O IBMRTYCHDPMBFN-UHFFFAOYSA-N 0.000 description 1
- HDZGCSFEDULWCS-UHFFFAOYSA-N monomethylhydrazine Chemical compound CNN HDZGCSFEDULWCS-UHFFFAOYSA-N 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 230000007659 motor function Effects 0.000 description 1
- 238000007040 multi-step synthesis reaction Methods 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 206010028320 muscle necrosis Diseases 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- WWECJGLXBSQKRF-UHFFFAOYSA-N n,n-dimethylformamide;methanol Chemical compound OC.CN(C)C=O WWECJGLXBSQKRF-UHFFFAOYSA-N 0.000 description 1
- NGGXACLSAZXJGM-UHFFFAOYSA-N n-(diaminomethylidene)acetamide Chemical compound CC(=O)N=C(N)N NGGXACLSAZXJGM-UHFFFAOYSA-N 0.000 description 1
- QAPTWHXHEYAIKG-RCOXNQKVSA-N n-[(1r,2s,5r)-5-(tert-butylamino)-2-[(3s)-2-oxo-3-[[6-(trifluoromethyl)quinazolin-4-yl]amino]pyrrolidin-1-yl]cyclohexyl]acetamide Chemical compound CC(=O)N[C@@H]1C[C@H](NC(C)(C)C)CC[C@@H]1N1C(=O)[C@@H](NC=2C3=CC(=CC=C3N=CN=2)C(F)(F)F)CC1 QAPTWHXHEYAIKG-RCOXNQKVSA-N 0.000 description 1
- XZMHJYWMCRQSSI-UHFFFAOYSA-N n-[5-[2-(3-acetylanilino)-1,3-thiazol-4-yl]-4-methyl-1,3-thiazol-2-yl]benzamide Chemical compound CC(=O)C1=CC=CC(NC=2SC=C(N=2)C2=C(N=C(NC(=O)C=3C=CC=CC=3)S2)C)=C1 XZMHJYWMCRQSSI-UHFFFAOYSA-N 0.000 description 1
- RWIVICVCHVMHMU-UHFFFAOYSA-N n-aminoethylmorpholine Chemical compound NCCN1CCOCC1 RWIVICVCHVMHMU-UHFFFAOYSA-N 0.000 description 1
- OOTKJPZEEVPWCR-UHFFFAOYSA-N n-methyl-1-pyridin-2-ylmethanamine Chemical compound CNCC1=CC=CC=N1 OOTKJPZEEVPWCR-UHFFFAOYSA-N 0.000 description 1
- DNBWGFKLIBQQSL-UHFFFAOYSA-N n-methyl-1-pyridin-4-ylmethanamine Chemical compound CNCC1=CC=NC=C1 DNBWGFKLIBQQSL-UHFFFAOYSA-N 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000001577 neostriatum Anatomy 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000000626 neurodegenerative effect Effects 0.000 description 1
- 239000002581 neurotoxin Substances 0.000 description 1
- 231100000618 neurotoxin Toxicity 0.000 description 1
- 229960003966 nicotinamide Drugs 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 239000002840 nitric oxide donor Substances 0.000 description 1
- 239000012457 nonaqueous media Substances 0.000 description 1
- 210000004940 nucleus Anatomy 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000004006 olive oil Substances 0.000 description 1
- 235000008390 olive oil Nutrition 0.000 description 1
- 239000010502 orange oil Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 125000001181 organosilyl group Chemical group [SiH3]* 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 230000001590 oxidative effect Effects 0.000 description 1
- 230000020477 pH reduction Effects 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- XGISHOFUAFNYQF-UHFFFAOYSA-N pentanoyl chloride Chemical compound CCCCC(Cl)=O XGISHOFUAFNYQF-UHFFFAOYSA-N 0.000 description 1
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000001792 phenanthrenyl group Chemical group C1(=CC=CC=2C3=CC=CC=C3C=CC12)* 0.000 description 1
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000000039 preparative column chromatography Methods 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- OVARTBFNCCXQKS-UHFFFAOYSA-N propan-2-one;hydrate Chemical compound O.CC(C)=O OVARTBFNCCXQKS-UHFFFAOYSA-N 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000000561 purinyl group Chemical group N1=C(N=C2N=CNC2=C1)* 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000003226 pyrazolyl group Chemical group 0.000 description 1
- GAAWKLUURLVNGE-UHFFFAOYSA-N pyrrolo[3,4-c]carbazole Chemical compound C1=CC=C2C3=C4C=NC=C4C=CC3=NC2=C1 GAAWKLUURLVNGE-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000005493 quinolyl group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 238000011552 rat model Methods 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- RWWYLEGWBNMMLJ-YSOARWBDSA-N remdesivir Chemical compound NC1=NC=NN2C1=CC=C2[C@]1([C@@H]([C@@H]([C@H](O1)CO[P@](=O)(OC1=CC=CC=C1)N[C@H](C(=O)OCC(CC)CC)C)O)O)C#N RWWYLEGWBNMMLJ-YSOARWBDSA-N 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 208000032253 retinal ischemia Diseases 0.000 description 1
- 238000011808 rodent model Methods 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229940043230 sarcosine Drugs 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 239000011669 selenium Substances 0.000 description 1
- 229910052711 selenium Inorganic materials 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- XGVXKJKTISMIOW-ZDUSSCGKSA-N simurosertib Chemical compound N1N=CC(C=2SC=3C(=O)NC(=NC=3C=2)[C@H]2N3CCC(CC3)C2)=C1C XGVXKJKTISMIOW-ZDUSSCGKSA-N 0.000 description 1
- 230000003007 single stranded DNA break Effects 0.000 description 1
- 230000005783 single-strand break Effects 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 150000003385 sodium Chemical class 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 238000000527 sonication Methods 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 102000009076 src-Family Kinases Human genes 0.000 description 1
- 108010087686 src-Family Kinases Proteins 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000001117 sulphuric acid Substances 0.000 description 1
- 235000011149 sulphuric acid Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 210000001258 synovial membrane Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- XJJBXZIKXFOMLP-ZETCQYMHSA-N tert-butyl (2s)-pyrrolidine-2-carboxylate Chemical compound CC(C)(C)OC(=O)[C@@H]1CCCN1 XJJBXZIKXFOMLP-ZETCQYMHSA-N 0.000 description 1
- MRXPDEOWDKBHHK-UHFFFAOYSA-N tert-butyl 3-amino-3-sulfanylidenepropanoate Chemical compound CC(C)(C)OC(=O)CC(N)=S MRXPDEOWDKBHHK-UHFFFAOYSA-N 0.000 description 1
- 150000003509 tertiary alcohols Chemical class 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- FPGGTKZVZWFYPV-UHFFFAOYSA-M tetrabutylammonium fluoride Chemical compound [F-].CCCC[N+](CCCC)(CCCC)CCCC FPGGTKZVZWFYPV-UHFFFAOYSA-M 0.000 description 1
- UGNWTBMOAKPKBL-UHFFFAOYSA-N tetrachloro-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(Cl)=C(Cl)C1=O UGNWTBMOAKPKBL-UHFFFAOYSA-N 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical compound C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- VXKWYPOMXBVZSJ-UHFFFAOYSA-N tetramethyltin Chemical compound C[Sn](C)(C)C VXKWYPOMXBVZSJ-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000003557 thiazoles Chemical class 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 150000003556 thioamides Chemical class 0.000 description 1
- 238000001685 time-resolved fluorescence spectroscopy Methods 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- AQRLNPVMDITEJU-UHFFFAOYSA-N triethylsilane Chemical compound CC[SiH](CC)CC AQRLNPVMDITEJU-UHFFFAOYSA-N 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 229930195735 unsaturated hydrocarbon Natural products 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000003828 vacuum filtration Methods 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000007998 vessel formation Effects 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 150000003738 xylenes Chemical class 0.000 description 1
- QNLXXQBCQYDKHD-UHFFFAOYSA-K ytterbium(iii) bromide Chemical compound Br[Yb](Br)Br QNLXXQBCQYDKHD-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Definitions
- the present invention relates to novel multicyclic compounds and the use thereof. More particularly, the present invention relates to novel multicyclic compounds and their use, for example, for the mediation of enzyme activity.
- Poly(ADP-ribose) polymerase (PARP, also called poly(ADP-ribose) synthetase, or PARS) is a nuclear enzyme which catalyzes the synthesis of poly(ADP-ribose) chains from NAD + in response to single-stranded DNA breaks as part of the DNA repair process (de Murcia et al. Trends Biochem. Set. 1994, /9,172; Alvarez-Gonzalez et al. MoI. Cell. Biochem. 1994, 138, 33.).
- the chromatin-associated protein substrates for ADP- ribosylation which include histones, DNA metabolizing enzymes and PARP itself, are modified on surface glutamate residues.
- PARP catalyzes attachment of one ADP-ribose unit to the protein (initiation), followed by polymerization of as many as 200 ADP-ribose monomers (elongation) via 2'-l" glycosidic linkages. In addition, PARP catalyzes branching of the polymer at a lower frequency.
- the role of PARP in the DNA repair process is incompletely defined.
- the binding of PARP to nicked double-stranded DNA is suggested to facilitate the repair process by transiently blocking DNA replication or recombination.
- the subsequent poly(ADP- ribosyl)ation of PARP and histones may result in introduction of a substantial negative charge, causing repulsion of the modified proteins from the DNA.
- the chromatin structure is then proposed to relax, enhancing the access of DNA repair enzymes to the site of damage. Excessive activation of PARP in response to cell damage or stress is hypothesized to result in cell death (Sims et al. Biochemistry 1983, 22, 5188; Yamamoto et al. Nature 1981, 294, 284).
- Activation of PARP by DNA strand breaks may be mediated by nitric oxide (NO) or various reactive oxygen intermediates.
- NO nitric oxide
- PARP may catalyze a massive amount of poly(ADP-ribosyl)ation, depleting the cell's levels of NAD + .
- levels of ATP may decrease precipitously (since synthesis of one molecule of NAD + requires four molecuies of ATP) and the cell may die through depletion of its energy stores.
- Inhibitors of PARP may also display neuroprotective efficacy in animal models of stroke.
- the potent PARP inhibitor DPQ (3,4-dihydro-5-[4-(l-piperidinyl)butoxy]-l(2H)- isoquinolinone) (Suto et al., U.S. Pat. No. 5,177,075) provided a 54% reduction in infarct volume in a rat model of focal cerebral ischemia (permanent MCAo and 90 min bilateral occlusion of the common carotid artery) following i.p. dosing (10 mg/kg) two hours prior to and two hours after the initiation of ischemia (Takahashi et al. Brain Res. 1997, 829, 46).
- Treatment with 3-AB also enhanced functional recovery 24 hours after ischemia, attenuated the decrease in NAD + levels in ischemic tissues, and decreased the synthesis of poly(ADP-ribose) polymers as determined . by immunohistochemistry.
- PARP Activation of PARP has been implicated in the functional deficits that may result from traumatic brain injury and spinal cord injury.
- PARP "7" mice displayed significantly improved motor and cognitive function as compared to PARP +/+ mice (Whalen et al. J. Cereh. Blood Flow Metab. 1999, 19, 835). Peroxynitrite production and PARP activation have also been demonstrated in spinal cord-injured rats (Scott et al. Ann. Neurol. 1999, 45, 120). These results suggest that inhibitors of PARP may provide protection from loss of function following head or spinal trauma.
- the role of PARP as a mediator of cell death following ischemia and reperfusion may not be limited to the nervous system.
- a particularly useful application of a PARP inhibitor might involve administration concurrent with a treatment designed to reperfuse the affected area of the heart, including angioplasty or a clot-dissolving drug such as tPA.
- the activity of PARP is also implicated in the cellular damage that occurs in a variety of inflammatory diseases. Activation of macrophages by pro-inflammatory stimuli may result in the production of nitric oxide and superoxide anion, which combine to generate peroxynitrite, resulting in formation of DNA single-strand breaks and activation of PARP.
- the role of PARP as a mediator of inflammatory disease is supported by experiments employing PARP " ⁇ mice or inhibitors of PARP in a number of animal models. For example, joints of mice subjected to collagen-induced arthritis contain nitrotyrosine, consistent with generation of peroxynitrite (Szabo et al. J. Clin. Invest. 1998, 100, 723).
- the PARP inhibitor 5-iodo-6-amino-l ,2-benzopyrone reduced the incidence and severity of arthritis in these animals, decreasing the severity of necrosis and hyperplasia of the synovium as indicated by histological examination.
- 3-AB inhibited the histological injury, pleural exudate formation and mononuclear cell infiltration characteristic of the inflammatory process (Cuzzocrea et al. Eur. J. Pharmacology 1998, 342, 67).
- the activation of PARP is involved in the induction of experimental diabetes initiated by the selective beta cell toxin streptozocin (SZ). Substantial breakage of DNA may be induced by SZ, resulting in the activation of PARP and depletion of the cell's energy stores as described above in Yamamoto et al.(1981). In cells derived from PARP " ' " mice, exposure to reactive oxygen intermediates results in attenuated depletion OfNAD + and enhanced cell viability relative to wild-type cells (Heller et al. J. Biol. Chem. 1995, 270, 11176). Similar effects were observed in wild-type cells treated with 3-AB.
- protein kinases play a critical role in the control of cells.
- kinases are known to be involved in cell growth and differentiation. Aberrant expression or mutations in protein kinases have been shown to lead to uncontrolled cell proliferation, such as malignant tumor growth, and various defects in developmental processes, including cell migration and invasion, and angiogenesis. Protein kinases are therefore critical to the control, regulation, and modulation of cell proliferation in diseases and disorders associated with abnormal cell proliferation.
- Protein kinases have also been implicated as targets in central nervous system disorders such as Alzheimer's disease, inflammatory disorders such as psoriasis, bone diseases such as osteoporosis, atherosclerosis, restenosis, thrombosis, metabolic disorders such as diabetes, and infectious diseases such as viral and fungal infections.
- kinase regulation is cellular signaling from receptors at the cell surface to the nucleus.
- the pattern of expression, ligand availability, and the array of downstream signal transduction pathways that are activated by a particular receptor determine the function of each receptor.
- a pathway includes a cascade of kinases in which members of the growth factor receptor tyrosine kinases deliver signals via phosphorylation, to other kinases such as Src tyrosine kinase, and the Raf, Mek and Erk serine/threonine kinase families. Each of these kinases is represented by several family members that play related but functionally distinct roles.
- the loss of regulation of the growth factor signaling pathway is a frequent occurrence in cancer as well as other disease states (Fearon, Genetic Lesions in Human Cancer, Molecular Oncology 1996, 143-178).
- VEGF vascular endothelial growth factor
- VEGFR tyrosine kinases Suppression of formation of new blood vessels by inhibition of the VEGFR tyrosine kinases would have utility in a variety of diseases, including treatment of solid tumors, diabetic retinopathy and other intraocular neovascular syndromes, macular degeneration, rheumatoid arthritis, psoriasis, and endometriosis.
- SAPK stress-activated protein kinase pathway
- JNKs c-jun N-terminal kinases
- the JNKs are mitogen-activated protein kinases (MAPKs) that are encoded by three distinct genes, jnkl,jnk2 and jnk3, which can be alternatively spliced to yield a variety of different JNK isoforms (Gupta et al., EMBO J 1996, 15, 2760).
- the isoforms differ in their ability to interact with and phosphorylate their target substrates.
- Activation of INK is performed by two MAPK kinases (MAPKK), MKK4 and MKK7.
- MKK4 is an activator of JNK as well as an additional MAPK, p38, while MKK7 is a selective activator of INK.
- MLK4 and MKK7 A number of MAPKK kinases are responsible for activation of MKK4 and MKK7, including the MEKK family and the mixed lineage kinase, or MLK family.
- the MLK family is comprised of six members, including MLKl, MLK2, MLK3, MLK6, dual leucine zipper kinase (DLK) and leucine zipper-bearing kinase (LZK).
- MLK2 is also known as MST (Katoh, et al. Oncogene, 1994, 10, 1447).
- kinases are proposed to be upstream of the MAPKKKs, including but not restricted to germinal center kinase (GCK), hematopoietic progenitor kinase (HPK), and Rac/cdc42.
- GCK germinal center kinase
- HPK hematopoietic progenitor kinase
- Rac/cdc42 Rac/cdc42.
- Specificity within the pathway is contributed, at least in part, by scaffolding proteins that bind selected members of the cascade.
- the INK interacting protein- 1 (JIP-I) binds HPKl, DLK or MLK3, MKK7 and JNK, resulting in a module which enhances JNK activation (Dickens et al. Science 1997, 277, 693).
- Manipulation of the activity of the SAPK pathway can have a wide range of effects, including promotion of both cell death and cell survival in response to various pro- apoptotic stimuli.
- down-regulation of the pathway by genetic disruption of the gene encoding JNK3 in the mouse provided protection against kainic acid-induced seizures and prevented apoptosis of hippocampal neurons (Yang et al. Nature 1997, 389, 865).
- inhibitors of the JNK pathway such as JIP-I inhibit apoptosis (Dickens, supra).
- the activity of the JNK pathway appears to be protective in some instances.
- Thymocytes in which MKK4 has been deleted display increased sensitivity to CD95- and CD3 mediated apoptosis (Nishina et al. Nature 1997, 385, 350).
- Overexpression of MLK3 leads to transformation of NIH 3T3 fibroblasts (Hartkamp et al. Cancer Res. 1999, 59, 2195).
- An area the present invention is directed toward is identification of compounds that modulate the MLK members of the SAPK pathway and promote either cell death or cell survival.
- Inhibitors of MLK family members would be anticipated to lead to cell survival and demonstrate therapeutic activity in a variety of diseases, including chronic neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease and Huntington's disease and acute neurological conditions such as cerebral ischemia, traumatic brain injury and spinal injury.
- Inhibitors of MLK members leading to inhibition of the SAPK pathway (JNK activity) would also display activity in inflammatory diseases and cancer.
- MAP kinase family of proteins An additional member of the MAP kinase family of proteins is the p38 kinase. Activation of this kinase has been implicated in the production of proinflammatory cytokines such as IL-I and TNF. Inhibition of this kinase could therefore offer a treatment for disease states in which disregulated cytokine production is involved.
- CDKs cyclin dependent kinases
- Inhibitors of kinases involved in mediating or maintaining particular disease states represent novel therapies for these disorders.
- Examples of such kinases include Src, raf, the cyclin-dependerit kinases (CDK) 1, 2, and 4 and the checkpoint kinases Chkl and Cdsl in cancer, CDK2 or PDGF-R kinase in restenosis, CDK5 and GSK3 kinases in
- PARP or kinase inhibitors have been reported in the literature including Banasik et al. J. Biol. Chem. 1992, 267, 1569 and Banasik et al. MoI. Cell. Biochem.
- PARP inhibiting compounds have been the subject of patents.
- compounds that are described as PARP inhibitors are disclosed in WO 99/08680, WO 99/11622, WO 99/11623, WO 99/11624, WO 99/11.628, WO 99/11644, WO 99/11645, WO 99/11649, WO 99/59973, WO 99/59975 and U.S. Pat. No. 5,587,384.
- Structurally related compounds which are described as having activities other than PARP inhibition, are disclosed in WO 99/47522, EP 0695755, and WO 96/28447.
- Other structurally related compounds, their syntheses and precursors are disclosed in Piers et al. J. Org. Chem. 2000, 65, 530, Berlinck et al. J. Org. Chem. 1998, 63, 9850, McCort et al. Tetrahedron Lett. 1999, 40, 6211, Mahboobi et al. Tetrahedron 1996, 52, 6363, Rewcastle et al. J. Med. Chem. 1996, 39, 918, Harris et al. Tetrahedron Lett.
- PARP and kinase inhibitors are an important class of compounds requiring further discovery, exploration, and development. Although, a wide variety of PARP and kinase inhibitors are known, many suffer from problems such as toxicity, poor solubility, and limited efficacy, which prevent practical therapeutic use and preclude further development into effective drugs. Thus, there is a current and immediate need for new PARP and kinase inhibitors for the treatment of PARP and kinase related diseases. The present invention is directed to this, as well as other important ends.
- the present invention is directed, in part, to novel multicyclic compounds. Specifically, in one embodiment, there are provided compounds of formula I:
- Another aspect of the invention relates to compounds of formula Ia:
- Another aspect of the invention relates to multicyclic compounds of formula Ila:
- a further aspect of the invention relates to compounds of formula Ilaa:
- the present invention further encompasses a method of inhibiting PARP, VEGFR2, or MLK3 activity comprising contacting said PARP, VEGFR2, or MLK3 with a compound of formula I:
- each of A and B is, independently,
- J is: wherein each n and m is, independently, O or 1; each of J 1 and J 2 is, independently, carbonyl, lower alkylcarbonyl, arylcarbonyl, carbonyloxy, sulfonyl, amino, lower alkylamino, lower dialkylamino, amido, lower alkylamido, lower dialkylamido, lower alkyloxycarbonylamino, aryloxycarbonylamino, amidino, guanidino, oxygen, sulphur, lower alkoxy, lower aryloxy, aralkoxy, lower alkyl, C 3 to C 7 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, sulfonylamido, alkylsulfonylamido, arylsulfonylamido, an amino acid, or a protected amino acid; and
- J 3 is: hydrogen, halo, hydroxy, thio, cyano, sulfonic acid, carboxyl, lower alkyl, aryloxycarbonyl, alkyloxycarbonyl, phosphonic acid, lower alkyl, lower alkyl ester of phosphonic acid, or aryl ester of phosphonic acid.
- a method for treating or preventing a neurodegenerative disease comprising administering to a mammal a therapeutically effective amount of a compound of formula I:
- Y and Z together with the carbon atoms to which they are attached, form: a substituted or unsubstituted aryl group, wherein said aryl group is monocyclic or bicyclic and said substituted aryl group has at least one substituent J; a substituted or unsubstituted bicyclic heteroaryl group, wherein said substituted bicyclic heteroaryl group has at least one substituent J; or a C 3 to C 5 heteroaryl group; each of E and F is, independently, lower alkyl; or
- E and F together with the atoms to which they are attached, form: a substituted or unsubstituted C 4 to C 7 cycloalkyl group wherein said substituted cycloalkyl group has at least one substituent J; a substituted or unsubstituted C 3 to Ce heterocycloalkyl group wherein said substituted heterocycloalkyl group has at least one substituent J; a substituted or unsubstituted heterocycloalkyl group endocyclically comprising at least one group G wherein said substituted heterocycloalkyl group comprising G has at least one substituent J; a substituted or unsubstituted aryl group, wherein said substituted aryl group has at least one group J; or a substituted or unsubstituted heteroaryl group, wherein said substituted heteroaryl group has at least one group J; R 2 is: hydrogen, lower alkyl, lower alkyl having at least one substituent J; formyl; acetyl, lower al
- J is: wherein each n and m is, independently, O or 1; each of J 1 and J 2 is, independently, carbonyl, lower alkylcarbonyl, arylcarbonyl, carbonyloxy, sulfonyl, amino, lower alkylamino, lower dialkylamino, amido, lower alkylamido, lower dialkylamido, lower alkyloxycarbonylamino, aryloxycarbonylamino, amidino, guanidino, oxygen, sulphur, lower alkoxy, lower aryloxy, aralkoxy, lower alkyl, C3 to C 7 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, sulfonylamido, alkylsulfonylamido, aryls
- a method for treating traumatic central nervous system injuries or preventing neuronal degradation associated with traumatic central nervous system injuries comprising administering to a mammal a therapeutically effective amount of a compound of formula I:
- each of A and B is, independently,
- Y and Z together with the carbon atoms to which they are attached, form: a substituted or uns ⁇ bstituted aryl group, wherein said aryl group is monocyclic or bicyclic and said substituted aryl group has at least one substituent J; a substituted or unsubstituted bicyclic heteroaryl group, wherein said substituted bicyclic heteroaryl group has at least one substituent J; or a C 3 to C5 heteroaryl group; each of E and F is, independently, lower alkyl; or
- E and F together with the atoms to which they are attached, form: a substituted or unsubstituted C 4 to C 7 cycloalkyl group wherein said substituted cycloalkyl group has at least one substituent J; a substituted or unsubstituted C3 to Ce heterocycloalkyl group wherein said substituted heterocycloalkyl group has at least one substituent J; a substituted or unsubstituted heterocycloalkyl group endocyclically comprising at least one group G wherein said substituted heterocycloalkyl group comprising G has at least one substituent J; a substituted or unsubstituted aryl group, wherein said substituted aryl group has at least one group J; or a substituted or unsubstituted heteroaryl group, wherein said substituted heteroaryl group has at least one group J; R 2 is: hydrogen, lower alkyl, lower alkyl having at least one substituent J; formyl; acetyl, lower al
- J is: J 3 -(J 2 ) n -(J 1 )m wherein each n and rn is, independently, 0 or 1; each of J 1 and J 2 is, independently, carbonyl, lower alkylcarbonyl, arylcarbonyl, carbonyloxy, sulfonyl, amino, lower aUcylamino, lower dialkylamino, amido, lower alkylamido, lower dialkylamido, lower alkyloxycarbonylamino, aryloxycarbonylamino, amidino, guanidino, oxygen, sulphur, lower alkoxy, lower aryloxy, aralkoxy, lower alkyl, C 3 to C 7 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, s
- each of A and B is, independently,
- E and F together with the atoms to which they are attached, form: a substituted or unsubstituted C 4 to C 7 cycloalkyl group wherein said substituted cycloalkyl group has at least one substituent J; a substituted or unsubstituted C 3 to Ce heterocycloalkyl group wherein said substituted heterocycloalkyl group has at least one substituent J; a substituted or unsubstituted heterocycloalkyl group endocyclically comprising at least one group G wherein said substituted heterocycloalkyl group comprising G has at least one substituent J; a substituted or unsubstituted aryl group, wherein said substituted aryl • group has at least one group J; or a substituted or unsubstituted heteroaryl group, wherein said substituted heteroaryl group has at least one group J; R 2 is: hydrogen, lower alkyl, lower alkyl having at least one substituent J; formyl; acetyl, lower
- each of J 1 and J 2 is, independently, carbonyl, lower alkylcarbonyl, arylcarbonyl, carbonyloxy, sulfonyl, amino, lower alkylamino, lower dialkylamino, amido, lower alkylamido, lower dialkylamido, lower alkyloxycarbonylamino, aryloxycarbonylamino, amidino, guanidino, oxygen, sulphur, lower alkoxy, lower aryloxy, aralkoxy, lower alkyl, C 3 to C 7 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, sulfonylamido, alkylsulfonylamido, arylsulfonylamido, an amino acid, or a protected amino acid; and
- J 3 is: hydrogen, halo, hydroxy, thio, cyano, sulfonic acid, carboxyl, lower alkyl, aryloxycarbonyl, alkyloxycarbonyl, phosphonic acid, lower alkyl, lower alkyl ester of phosphonic acid, or aryl ester of phosphonic acid.
- a method for suppressing the formation of blood vessels in a mammal comprising administering to a mammal a pharmaceutically effective amount of a compound of formula I:
- each of A and B is, independently,
- J 3 -(J 2 )n-(J 1 )m wherein each n and m is, independently, O or 1; each of J 1 and J 2 is, independently, carbonyl, lower alkylcarbonyl, arylcarbonyl, carbonyloxy, sulfonyl, amino, lower alkylamino, lower dialkylamino, amido, lower alkylamido, lower dialkylamido, lower alkyloxycarbonylamino, aryloxycarbonylamino, amidino, guanidino, oxygen, sulphur, lower alkoxy, lower aryloxy, aralkoxy, lower alkyl, C 3 to C 7 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, sulfonylamido, alkylsulfonylamido, arylsulfonylamido, an amino acid, or a protected amino acid; and J 3 is: hydrogen, halo, hydroxy
- Y and Z together with the carbon atoms to which they are attached, form: a substituted or unsubstituted aryl group, wherein said aryl group is monocyclic or bicyclic and said substituted aryl group has at least one substituent J; a substituted or unsubstituted bicyclic heteroaryl group, wherein said substituted bicyclic heteroaryl group has at least one substituent J; or a C 3 to C 5 heteroaryl group; each of E and F is, independently, lower alkyl; or E and F, together with the atoms to which they are attached, form: a substituted or unsubstituted C 4 to C 7 cycloalkyl group wherein said substituted cycloalkyl group has at least one substituent J; a substituted or unsubstituted C 3 to C 6 heterocycloalkyl group wherein said substituted heterocycloalkyl group has at least one substituent J; a substituted or imsubstituted heterocycloalkyl
- R 2 Is: hydrogen, lower alkyl, lower alkyl having at least one substituent J; formyl; acetyl, lower alkanoyl, lower alkanoyl having at least one substituent J, lower alkylsulfonyl, arylsulfonyl, an amino acid, or a protected amino acid; each of R 3 and R 4 is, independently, hydrogen, lower alkyl, aryl, lower alkyl having at least one substituent J, or aryl having at least one substituent J;
- J 3- J 2 ⁇ -(J 1 )!!! wherein each n and m is, independently, O or 1; each of J 1 and J 2 is, independently, carbonyl, lower alkylcarbonyl, arylcarbonyl, carbonyloxy, sulfonyl, amino, lower alkylamino, lower dialkylamino, amido, lower alkylamido, lower dialkylamido, lower alkyloxycarbonylamino, aryloxycarbonylamino, amidino, guanidino, oxygen, sulphur, lower alkoxy, lower aryloxy, aralkoxy, lower alkyl, C 3 to C 7 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, sulfonylamido, alkylsulfonylamido, arylsulfonylamido, an amino acid, or a protected amino acid; and J 3 is: hydrogen, halo, hydroxy, thio
- Y and Z together with the carbon atoms to which they are attached, form: a substituted or unsubstituted aryl group, wherein said aryl group is monocyclic or bicyclic and said substituted aryl group has at least one substituent J; a substituted or unsubstituted bicyclic heteroaryl group, wherein said substituted bicyclic heteroaryl group has at least one substituent J; or a C 3 to C 5 heteroaryl group; each of E and F is, independently, lower alkyl; or
- E and F together with the atoms to which they are attached, form: a substituted or unsubstituted C 4 to C 7 cycloalkyl group wherein said substituted cycloalkyl group has at least one substituent J; a substituted or unsubstituted C 3 to Ce heterocycloalkyl group wherein said substituted heterocycloalkyl group has at least one substituent J; a substituted or unsubstituted heterocycloalkyl group endocyclically comprising at least one group G wherein said substituted heterocycloalkyl group comprising G has at least one substituent J; a substituted or unsubstituted aryl group, wherein said substituted aryl group has at least one group J; or a substituted or unsubstituted heteroaryl group, wherein said substituted heteroaryl group has at least one group J; R 2 is: hydrogen, lower alkyl, lower alkyl having at least one substituent J; formyl; acetyl, lower al
- each of J 1 and J 2 is, independently, carbonyl, lower alkylcarbonyl, arylcarbonyl, carbonyloxy, sulfonyl, amino, lower alkylamino, lower dialkylarnino, amido, lower alkylamido, lower dialkylamido, lower alkyloxycarbonylamino, aryloxycarbonylamino, amidino, guanidino, oxygen, sulphur, lower alkoxy, lower aryloxy, aralkoxy, lower alkyl, C 3 to C 7 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, sulfonylamido, alkylsulfonylamido, arylsulfonylamido, an amino acid, or a protected amino acid; and J 3 is: hydrogen, halo, hydroxy,
- Y and Z together with the carbon atoms to which they are attached, form: a substituted or unsubstituted aryl group, wherein said aryl group is monocyclic or bicyclic and said substituted aryl group has at least one substituent J; a substituted or unsubstituted bicyclic heteroaryl group, wherein said substituted bicyclic heteroaryl group has at least one substituent J; or a C 3 to C5 heteroaryl group; each of E and F is, independently, lower alkyl; or E and F, together with the atoms to which they are attached, form: a substituted or unsubstituted C 4 to C 7 cycloalkyl group, wherein said substituted cycloalkyl group has at least one substituent J; a substituted or unsubstituted C 3 to C 6 heterocycloalkyl group wherein said substituted heterocycloalkyl group has at least one substituent J; a substituted or unsubstituted heterocycloalky
- each of J 1 and J 2 is, independently, carbonyl, lower alkylcarbonyl, arylcarbonyl, carbonyloxy, sulfonyl, amino, lower alkylamino, lower dialkylamino, amido, lower alkylamido, lower dialkylamido, lower alkyloxycarbonylamino, aryloxycarbonylamino, amidino, guanidino, oxygen, sulphur, lower alkoxy, lower aryloxy, aralkoxy, lower alkyl, C 3 to C 7 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, sulfonylamido, alkylsulfonylamido, arylsulfonylamido, an amino acid, a protected amino acid, aminocarbonyloxy, arylamino
- a method for treating or preventing a neurodegenerative disease comprising administering to a mammal a therapeutically effective amount of a compound of formula Ia:
- each of A and B is, independently,
- each of J 1 and J 2 is, independently, carbonyl, lower alkylcarbonyl, arylcarbonyl, carbonyloxy, sulfonyl, amino, lower alkylamino, lower dialkylamino, amido, lower alkylamido, lower dialkylamido, lower alkyloxycarbonylamino, aryloxycarbonylamino, amidino, guanidino, oxygen, sulphur, lower alkoxy, lower aryloxy, aralkoxy, lower alkyl, C 3 to C 7 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, sulfonylamido, alkylsulfonylamido, arylsulfonylamido, an amino acid, a protected amino acid, aminocarbonyloxy, arylaminocarbony
- a method for treating traumatic central nervous system injuries or preventing neuronal degradation associated with traumatic central nervous system injuries comprising administering to a mammal a therapeutically effective amount of a compound of formula Ia:
- Y and Z together with the carbon atoms to which they are attached, form: a substituted or unsubstituted aryl group, wherein said aryl group is monocyclic or bicyclic and said substituted aryl group has at least one substituent J; a substituted or unsubstituted bicyclic heteroaryl group, wherein said substituted bicyclic heteroaryl group has at least one substituent J; or a C 3 to C 5 heteroaryl group; each of E and F is, independently, lower alkyl; or E and F, together with the atoms to which they are attached, form: a substituted or unsubstituted C 4 to C 7 cycloalkyl group, wherein said substituted cycloalkyl group has at least one substituent J; a substituted or unsubstituted C 3 to C 6 heterocycloalkyl group wherein said substituted heterocycloalkyl group has at least one substituent J; a substituted or unsubstituted heterocycloalky
- each of J 1 and J 2 is, independently, carbonyl, lower alkylcarbonyl, arylcarbonyl, carbonyloxy, sulfonyl, amino, lower alkylamino, lower dialkylamino, amido, lower alkylamido, lower dialkylamido, lower alkyloxycarbonylamino, aryloxycarbonylamino, amidino, guanidino, oxygen, sulphur, lower alkoxy, lower aryloxy, aralkoxy, lower alkyl, C3 to C 7 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, sulfonylamido, alkylsulfonylamido, arylsulfonylamido, an amino acid, a protected amino acid, aminocarbonyloxy, arylaminocarbonyl
- J 3 is: hydrogen, halo, hydroxy, thio, cyano, sulfonic acid, carboxyl, lower alkyl, aryloxycarbonyl, alkyloxycarbonyl, phosphonic acid, lower alkyl, lower alkyl ester of phosphonic acid, aryl ester of phosphonic acid, aminocarbonyloxy, heteroaryl, or heterocycloalkyl; and any two adjacent J groups can combine to form -X-(CH 2 ) P -X-, wherein X is independently O or NH, and p is 1 or 2.
- a method is provided for treating cerebral ischemia, cardiac ischemia, inflammation, endotoxic shock, or diabetes comprising administering to a mammal a pharmaceutically effective amount of a compound of formula Ia:
- Y and Z together with the carbon atoms to which they are attached, form: a substituted or unsubstituted aryl group, wherein said aryl group is monocyclic or bicyclic and said substituted aryl group has at least one substituent J; a substituted or unsubstituted bicyclic heteroaryl group, wherein said substituted bicyclic heteroaryl group has at least one substituent J; or a C 3 to Cs heteroaryl group; each of E and F is, independently, lower alkyl; or E and F, together with the atoms to which they are attached, form: a substituted or unsubstituted C 4 to C 7 cycloalkyl group, wherein said substituted cycloalkyl group has at least one substituent J; a substituted or unsubstituted C 3 to C 6 heterocycloalkyl group wherein said substituted heterocycloalkyl group has at least one substituent J; a substituted or unsubstituted heterocycloalky
- each of J 1 and J 2 is, independently, carbonyl, lower alkylcarbonyl, arylcarbonyl, carbonyloxy, sulfonyl, amino, lower alkylamino, lower dialkylamino, amido, lower alkylamido, lower dialkylamido, lower alkyloxycarbonylamino, aryloxycarbonylamino, amidino, guanidino, oxygen, sulphur, lower alkoxy, lower aryloxy, aralkoxy, lower alkyl, C 3 to C 7 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, sulfonylamido, alkylsulfonylamido, arylsulfonylamido, an amino acid, a protected amino acid, aminocarbonyloxy, arylamino
- a method for suppressing the formation of blood vessels in a mammal comprising administering to a mammal a pharmaceutically effective amount of a compound of formula Ia:
- Y and Z together with the carbon atoms to which they are attached, form: a substituted or unsubstituted aryl group, wherein said aryl group is monocyclic or bicyclic and said substituted aryl group has at least one substituent J; a substituted or unsubstituted bicyclic heteroaryl group, wherein said substituted bicyclic heteroaryl group has at least one substituent J; or a C 3 to C 5 heteroaryl group; each of E and F is, independently, lower alkyl; or E and F, together with the atoms to which they are attached, form: a substituted or unsubstituted C 4 to C 7 cycloalkyl group, wherein said substituted cycloalkyl group has at least one substituent J; a substituted or unsubstituted C 3 to C 6 heterocycloalkyl group wherein said substituted heterocycloalkyl group has at least one substituent J; a substituted or unsubstituted heterocycloalky
- each of J 1 and J 2 is, independently, carbonyl, lower alkylcarbonyl, arylcarbonyl, carbonyloxy, sulfonyl, amino, lower alkylamino, lower dialkylamino, amido, lower alkylamido, lower dialkylamido, lower alkyloxycarbonylamino, aryloxycarbonylamino, amidino, guanidino, oxygen, sulphur, lower alkoxy, lower aryloxy, aralkoxy, lower alkyl, C3 to C 7 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, sulfonylamido, alkylsulfonylamido, arylsulfonylamido, an amino acid, a protected amino acid, aminocarbonyloxy, arylarninocarbony
- a method for treating cellular proliferative disorders comprising administering to a mammal a pharmaceutically effective amount of a compound of formula Ia:
- Y and Z together with the carbon atoms to which they are attached, form: a substituted or unsubstituted aryl group, wherein said aryl group is monocyclic or bicyclic and said substituted aryl group has at least one substituent J; a substituted or unsubstituted bicyclic heteroaryl group, wherein said substituted bicyclic heteroaryl group has at least one substituent J; or a C 3 to Cs heteroaryl group; each of E and F is, independently, lower alkyl; or E and F, together with the atoms to which they are attached, form: a substituted or unsubstituted C 4 to C 7 cycloalkyl group, wherein said substituted cycloalkyl group has at least one substituent J; a substituted or unsubstituted C 3 to Ce heterocycloalkyl group wherein said substituted heterocycloalkyl group has at least one substituent J; a substituted or unsubstituted heterocycloalkyl
- each of J 1 and J 2 is, independently, carbonyl, lower alkylcarbonyl, arylcarbonyl, carbonyloxy, sulfonyl, amino, lower alkylamino, lower dialkylamino, amido, lower alkylamido, lower dialkylamido, lower alkyloxycarbonylamino, aryloxycarbonylamlno, amidino, guanidino, oxygen, sulphur, lower alkoxy, lower aryloxy, aralkoxy, lower alkyl, C 3 to C 7 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, sulfonylamido, alkylsulfonylamido, arylsulfonylamido, an amino acid, a protected amino acid, aminocarbonyloxy, arylamin
- a method for treating cancer comprising administering to a mammal a pharmaceutically effective amount of a compound of formula Ia:
- Y and Z together with the carbon atoms to which they are attached, form: a substituted or unsubstituted aryl group, wherein said aryl group is monocyclic or bicyclic and said substituted aryl group has at least one substituent J; a substituted or unsubstituted bicyclic heteroaryl group, wherein said substituted bicyclic heteroaryl group has at least one substituent J; or a C 3 to C 5 heteroaryl group; each of E and F is, independently, lower alkyl; or E and F, together with the atoms to which they are attached, form: a substituted or unsubstituted C 4 to C 7 cycloalkyl group, wherein said substituted cycloalkyl group has at least one substituent J; a substituted or unsubstituted C 3 to C 6 heterocycloalkyl group wherein said substituted heterocycloalkyl group has at least one substituent J; a substituted or unsubstituted heterocycloalky
- J is: wherein each of n and m is, independently, O or 1; each of J 1 and J 2 is, independently, carbonyl, lower alkylcarbonyl, arylcarbonyl, carbonyloxy, sulfonyl, amino, lower alkylamino, lower dialkylamino, amido, lower alkylamido, lower dialkylamido, lower alkyloxycarbonylamino, aryloxycarbonylamino, amidino, guanidino, oxygen, sulphur, lower alkoxy, lower aryloxy, aralkoxy, lower alkyl, C 3 to C 7 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, sulfonylamido, alkylsulfonylamido, ary
- Figure 1 shows a schematic including a compound within the scope of the present invention and precursors thereto.
- Figure 2 shows a general synthetic strategy for preparing compounds within the scope of the present invention.
- Figure 3 shows another general synthetic strategy for preparing compounds within the scope of the present invention.
- Figure 4 shows yet another general synthetic strategy for preparing compounds within the scope of the present invention.
- Figure 5 shows still another general synthetic strategy for preparing compounds within the scope of the present invention.
- Figure 6 shows yet another general synthetic strategy for preparing compounds within the scope of the present invention.
- Figure 7 shows a synthetic strategy for preparing benzimidazole derivatives within the scope of the present invention.
- Figure 8 shows a synthetic strategy for preparing compounds within the scope of the invention.
- Figure 9 shows synthetic strategy for preparing compounds within the scope of the present invention.
- the present invention is directed, in part, to new multicyclic compounds that may be highly useful in connection with the inhibition of PARP, VEGFR2, MLK3, or other enzymes.
- the new compounds are described in more detail below.
- the present invention relates to novel multicyclic compounds of formula I:
- each of A and B is, independently,
- each of J 1 and J 2 is, independently, carbonyl, lower alkylcarbonyl, arylcarbonyl, carbonyloxy, sulfonyl, amino, lower alkylamino, lower dialkylamino, amido, lower alkylamido, lower dialkylamido, lower alkyloxycarbonylamino, aryloxycarbonylamino, amidino, guanid ⁇ no, oxygen, sulphur, lower alkoxy, lower aryloxy, aralkoxy, lower alkyl, C 3 to C 7 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, sulfonylamido, alkylsulfonylamido, arylsulfonylaraido, an amino acid, or a protected amino acid; and
- the present invention provides compounds of formula Ia:
- Y and Z together with the carbon atoms to which they are attached, form: a substituted or unsubstituted aryl group, wherein said aryl group is monocyclic or bicyclic and said substituted aryl group has at least one substituent J; a substituted or unsubstituted bicyclic heteroaryl group, wherein said substituted bicyclic heteroaryl group has at least one substituent J; or a C 3 to C 5 heteroaryl group; each of E and F is, independently, lower alkyl; or E and F, together with the atoms to which they are attached, form: a substituted or unsubstituted C 4 to C 7 cycloalkyl group, wherein said substituted cycloalkyl group has at least one substituent J; a substituted or unsubstituted C3 to Ce heterocycloalkyl group wherein said substituted heterocycloalkyl group has at least one substituent J; a substituted or unsubstituted heterocycloalkyl
- J is: wherein each of n and m is, independently, O or 1; each of J 1 and J 2 is, independently, carbonyl, lower alkylcarbonyl, arylcarbonyl, carbonyloxy, sulfonyl, amino, lower alkylamino, lower dialkylamino, amido, lower alkylamido, lower dialkylamido, lower alkyloxycarbonylamino, aryloxycarbonylamino, amidino, guanidino, oxygen, sulphur, lower alkoxy, lower aryloxy, aralkoxy, lower alkyl, C 3 to C 7 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, sulfonylamido, alkylsulfonylamido, ary
- the present invention includes compounds of formula I or Ia where E and F combined together with the carbon atoms to which they are attached, form a C 5 cycloalkyl group.
- each of E and F is, independently, lower alkyl; or E and F, together with the carbon atoms to which they are attached, form: a substituted or unsubstituted C 4 to C 7 cycloalkyl group, wherein said substituted cycloalkyl group has at least one substituent J; a substituted or unsubstituted C 3 to Ce heterocycloalkyl group wherein said substituted heterocycloalkyl group has at least one substituent J; a substituted or unsubstituted heterocycloalkyl group endocyclically comprising at least one group G wherein said substituted heterocycloalkyl group comprising G has at least one substituent J; a substituted or unsubsti
- R 1 is: hydrogen, lower alkyl, lower alkyl having at least one substituent J, formyl, acetyl, lower alkanoyl, lower alkanoyl having at least one substituent J, lower alkylsulfonyl, lower arylsulfonyl, an amino acid, or a protected amino acid
- R 2 is: hydrogen, lower alkyl, lower alkyl having at least one substituent J; formyl; acetyl, lower alkanoyl, lower alkanoyl having at least one substituent J, lower alkylsulfonyl, arylsulfonyl, an amino acid, or a protected amino acid
- each of R 3 and R 4 is, independently, hydrogen, lower alkyl, aryl, lower alkyl having at least one substituent J,
- each of J 1 and J 2 is, independently, carbonyl, lower alkylcarbonyl, arylcarbonyl, carbonyloxy, sulfonyl, amino, lower alkylamino, lower dialkylamino, amido, lower alkylamido, lower dialkylamido, lower alkyloxycarbonylamino, aryloxycarbonylamino, amidino, guanidino, oxygen, sulphur, lower alkoxy, lower aryloxy, aralkoxy, lower alkyl, C 3 to C 7 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, sulfonylamido, alkylsulfonylamido, arylsulfonylamido, an amino acid, or a protected amino acid; and J 3 is: hydrogen, halo, hydroxy, thi
- each of X 1 and X 2 is, independently, hydrogen, halo, group J, lower alkyl, lower alkyl having at least one substituent J, substituted or unsubstituted C 3 to C 7 cycloalkyl wherein said substituted cycloalkyl group has at least one substituent J, substituted or unsubstituted C2 to Ce heterocycloalkyl wherein said substituted heterocycloalkyl group has at least one substituent J, substituted or unsubstituted aryl wherein said substituted aryl group has at least one substituent J, substituted or unsubstituted heteroaryl wherein said substituted heteroaryl group has at least one substituent J; or X 1 and X 2 , together with the atoms to which they are attached, form: a substituted or unsubstituted C
- each of E and F is, independently, lower alkyl; or E and F 3 together with the carbon atoms to which they are attached, form: a substituted or unsubstituted C 4 to C 7 cycloalkyl group, wherein said substituted cycloalkyl group has at least one substituent J; a substituted or unsubstituted C3 to C ⁇ heterocycloalkyl group wherein said substituted heterocycloalkyl group has at least one substituent J; a substituted or unsubstituted heterocycloalkyl group endocyclically comprising at least one group G wherein said substituted heterocycloalkyl group comprising G has at least one substituent J; a substituted or unsubstituted aryl group wherein said substituted aryl group has at least one group J; or a substituted or unsubstituted heteroaryl group wherein said substituted heteroaryl group has at least one group J; or a substituted or unsubstituted heteroaryl group wherein
- R 1 is: hydrogen, lower alkyl, lower alkyl having at least one substituent J, formyl, acetyl, lower alkanoyl, lower alkanoyl having at least one substituent J, lower alkylsulfonyl, lower arylsulfonyl, an amino acid, or a protected amino acid
- R 2 is: hydrogen, lower alkyl, lower alkyl having at least one substituent J; formyl; acetyl, lower alkanoyl, lower alkanoyl having at least one substituent J, lower alkylsulfonyl, arylsulfonyl, an amino acid, or a protected amino acid
- each of R 3 and R 4 is, independently, hydrogen, lower alkyl, aryl, lower alkyl having at least one substituent J,
- J 3 -Q 2 n-(J l )m wherein each of n and m is, independently, O or 1; each of J 1 and J 2 is, independently, carbonyl, lower alkylcarbonyl, arylcarbonyl, carbonyloxy, sulfonyl, amino, lower alkylamino, lower dialkylamino, amido, lower alkylamido, lower dialkylamido, lower alkyloxycarbonylamino, aryloxycarbonylamino, amidino, guanidino, oxygen, sulphur, lower alkoxy, lower aryloxy, aralkoxy, lower alkyl, C 3 to C 7 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, sulfonylamido, alkylsulfonylamido, arylsulfonylamido, an amino acid, or a protected amino acid; and J 3 is: hydrogen, halo, hydroxy
- each of X 1 and X 2 is, independently, hydrogen, halo, group J, lower alkyl, lower alkyl having at least one substituent J, substituted or unsubstituted C 3 to C 7 cycloalkyl wherein said substituted cycloalkyl group has at least one substituent J, substituted or unsubstituted C 2 to Ce heterocycloalkyl wherein said substituted heterocycloalkyl group has at least one substituent J, substituted or unsubstituted aryl wherein said substituted aryl group has at least one substituent J, substituted or unsubstituted heteroaryl wherein said substituted heteroaryl group has at least one substituent J; or X 1 and X 2 , together with the atoms to which they are attached, form: a substituted or unsubstituted C
- Preferred embodiments of the present invention include compounds of formula Ha or IIaa wherein: each of A and B is, independently,
- Preferred embodiments of the present invention include compounds of formula Ha or IIaa wherein: each of A and B is, independently,
- each of E and F is, independently, lower alkyl
- E and F together with the carbon atoms to which they are attached, form: a substituted or unsubstituted C 4 to C 7 cycloalkyl group, wherein said substituted cycloalkyl group has at least one substituent J; a substituted or unsubstituted C 3 to C & heterocycloalkyl group wherein said substituted heterocycloalkyl group has at least one substituent J; a substituted or unsubstituted heterocycloalkyl group endocyclically comprising at least one group G wherein said substituted heterocycloalkyl group comprising G has at least one substituent J; a substituted or unsubstituted aryl group wherein said substituted aryl group has at least one group J; or a substituted or unsubstituted heteroaryl group wherein said substituted heteroaryl group has at least one group J;
- R 1 is: hydrogen, lower alkyl, lower alkyl having at least one substituent J, formyl, acetyl, lower alkanoyl, lower alkanoyl having at least one substituent J, lower alkylsulfonyl, lower arylsulfonyl, an amino acid, or a protected amino acid
- R 2 is: hydrogen, lower alkyl, lower alkyl having at least one substituent J; formyl; acetyl, lower alkanoyl, lower alkanoyl having at least one substituent J, lower alkylsulfonyl, arylsulfonyl, an amino acid, or a protected amino acid
- each of R 3 and R 4 is, independently, hydrogen, lower alkyl, aryl, lower alkyl having at least one substituent J,
- J 3 -(J 2 )n-Q rl )m wherein each of n and m is, independently, 0 or 1; each of J 1 and J 2 is, independently, carbonyl, lower alkylcarbonyl, arylcarbonyl, carbonyloxy, sulfonyl, amino, lower alkylamino, lower dialkylamino, amido, lower alkylamido, lower dialkylamido, lower alkyloxycarbonylamino, aryloxycarbonylamino, amidino, guanidino, oxygen, sulphur, lower alkoxy, lower aryloxy, aralkoxy, lower alkyl, C 3 to C 7 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, sulfonylamido, alkylsulfonylamido, arylsulfonylamido, an amino acid, or a protected amino acid; and J 3 Is: hydrogen, hal
- each of X 1 and X 2 is, independently, hydrogen, halo, group J, lower alkyl, lower alkyl having at least one substituent J, substituted or unsubstituted C 3 to C 7 cycloalkyl wherein said substituted cycloalkyl group has at least one substituent J, substituted or unsubstituted C 2 to C 6 heterocycloalkyl wherein said substituted heterocycloalkyl group has at least one substituent J, substituted or unsubstituted aryl wherein said substituted aryl group has at least one substituent J, substituted or unsubstituted heteroaryl wherein said substituted heteroaryl group has at least one substituent J; or X 1 and X 2 , together with the atoms to which they are attached, form: a substituted or unsubstituted C 4 to C 7 cycloalkyl group wherein said substituted cycloalkyl group has at least
- each of E and F is, independently, lower alkyl; or E and F, together with the carbon atoms to which they are attached, form: a substituted or unsubstituted C 4 to C 7 cycloalkyl group, wherein said substituted cycloalkyl group has at least one substituent J; a substituted or unsubstituted C3 to Ce heterocycloalkyl group wherein said substituted heterocycloalkyl group has at least one substituent J; a substituted or unsubstituted heterocycloalkyl group endocyclically comprising at least one group G wherein said substituted heterocycloalkyl group comprising G has at least one substituent J; a substituted or unsubstituted aryl group wherein said substituted
- R 1 is: hydrogen, lower alkyl, lower alkyl having at least one substituent J, formyl, acetyl, lower alkanoyl, lower alkanoyl having at least one substituent J, lower alkylsulfonyl, lower arylsulfonyl, an amino acid, or a protected amino acid
- R 2 is: hydrogen, lower alkyl, lower alkyl having at least one substituent J; formyl; acetyl, lower alkanoyl, lower alkanoyl having at least one substituent J, lower alkylsulfonyl, arylsulfonyl, an amino acid, or a protected amino acid
- each of R 3 and R 4 is, independently, hydrogen, lower alkyl, aryl, lower alkyl having at least one substituent J, or
- Additional preferred embodiments of the present invention include compounds of formula ⁇ b or IIbb wherein: each A and B is, independently,
- each of E and F is, independently, lower alkyl; or E and F, together with the carbon atoms to which they are attached, form: a substituted or unsubstituted C 4 to C 7 cycloalkyl group, wherein said substituted cycloalkyl group has at least one substituent J; a substituted or unsubstituted C 3 to C ⁇ $ heterocycloalkyl group wherein said substituted heterocycloalkyl group has at least one substituent J; a substituted or unsubstituted heterocycloalkyl group endocyclically comprising within the ring structure at least one group G wherein said substituted heterocycloalkyl group comprising G has at least one substituent J; a substituted or unsubstituted aryl group wherein said substituted aryl group has at least one group J; or a substituted or unsubstituted heteroaryl group wherein said substituted heteroaryl group has at least one group J; G is:
- R 1 is: hydrogen, lower alkyl, lower alkyl having at least one substituent J, formyl, acetyl, lower alkanoyl, lower alkanoyl having at least one substituent J, lower alkylsulfonyl, lower arylsulfonyl, an amino acid, or a protected amino acid
- R 2 is: hydrogen, lower alkyl, lower alkyl having at least one substituent J; formyl; acetyl, lower alkanoyl, lower alkanoyl having at least one substituent J, lower alkylsulfonyl, arylsulfonyl, an amino acid, or a protected amino acid
- each of R 3 and R 4 is, independently, hydrogen, lower alkyl, aryl, lower alkyl having at least one substituent J,
- J 3 -Q 2 )n-Q l )m wherein each of n and m is, independently, O or 1; each of J 1 and J 2 is, independently, carbonyl, lower alkylcarbonyl, arylcarbonyl, carbonyloxy, sulfonyl, amino, lower alkylamino, lower dialkylamino, amido, lower alkylamido, lower dialkylamido, lower alkyloxycarbonylamino, aryloxycarbonylamino, amidino, guanidino, oxygen, sulphur, lower alkoxy, lower aryloxy, aralkoxy, lower alkyl, C 3 to C 7 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, sulfonylamido, alkylsulfonylamido, arylsulfonylamido, an amino acid, or a protected amino acid; and J 3 is: hydrogen, halo, hydroxy
- compounds of formula III have E and F combined together with the atoms to which they are attached to form a C 5 cycloalkyl group.
- compounds of formula Ilia there are provided compounds of formula Ilia:
- MIa wherein: each of A and B is, independently,
- each of E and F is, independently, lower alkyl; or E and F, together with the carbon atoms to which they are attached, form: a substituted or unsubstituted C 4 to C 7 cycloalkyl group, wherein said substituted cycloalkyl group has at least one substituent J; a substituted or unsubstituted C 3 to Ce heterocycloalkyl group wherein said substituted heterocycloalkyl group has at least one substituent J; a substituted or unsubstituted heterocycloalkyl group endocyclically comprising within the ring structure at least one group G wherein said substituted heterocycloalkyl group comprising G has at least one substituent J; a substituted or unsubstituted aryl group wherein said substituted aryl group has at least one group J; or a substituted or unsubstituted heteroaryl group wherein said substituted heteroaryl group has at least one group J; G is:
- R 1 is: hydrogen, lower alkyl, lower alkyl having at least one substituent J, formyl, acetyl, lower alkanoyl, lower alkanoyl having at least one substituent J, lower alkylsulfonyl, lower arylsulfonyl, an amino acid, or a protected amino acid
- R 2 is: hydrogen, lower alkyl, lower alkyl having at least one substituent J; formyl; acetyl, lower alkanoyl, lower alkanoyl having at least one substituent J, lower alkylsulfonyl, arylsulfonyl, an amino acid, or a protected amino acid
- each of R 3 and R 4 is, independently, hydrogen, lower alkyl, aryl, lower alkyl having at least one substituent J, or
- each of J 1 and J 2 is, independently, carbonyl, lower alkylcarbonyl, arylcarbonyl, carbonyloxy, sulfonyl, amino, lower alkylamino, lower dialkylamino, amido, lower alkylamido, lower dialkylamido, lower alkyloxycarbonylamino, aryloxycarbonylamino, amidino, guanidino, oxygen, sulphur, lower alkoxy, lower aryloxy, aralkoxy, lower alkyl, C 3 to C 7 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, sulfonylamido, alkylsulfonylamido, arylsulfonylamido, an amino acid, or a protected amino acid; and
- J 3 is: hydrogen, halo, hydroxy, thio, cyano, sulfonic acid, carboxyl, lower alkyl, aryloxycarbonyl, alkyloxycarbonyl, phosphonic acid, lower alkyl, lower alkyl ester of phosphonic acid, aryl ester of phosphonic acid, aminocarbonyloxy, heteroaryl, or heterocycloalkyl; and any two adjacent J groups can combine to form -X-(CH 2 ) P -X-, wherein X is independently O or NH, and p is 1 or 2; and each of X 1 and X 2 is, independently, hydrogen, halo, group J, lower alkyl, lower alkyl having at least one substituent J, substituted or unsubstituted C3 to C 7 cycloalkyl wherein said substituted cycloalkyl group has at least one substituent J, substituted or unsubstituted C 2 to C ⁇ heterocycloalkyl wherein said substituted hetero
- compounds of formula IV there are provided compounds of formula IV:
- each of A and B is, independently,
- each of E and F is, independently, lower alkyl; or E and F, together with the carbon atoms to which they are attached, form: a substituted or unsubstituted C 4 to C 7 cycloalkyl group, wherein said substituted cycloalkyl group has at least one substituent J; a substituted or unsubstituted C 3 to Ce heterocycloalkyl group wherein said substituted heterocycloalkyl group has at least one substituent J; a substituted or unsubstituted heterocycloalkyl group endocyclically comprising within at least one group G wherein said substituted heterocycloalkyl group comprising G has at least one substituent J; a substituted or unsubstituted aryl group wherein said substituted or unsubstituted aryl group wherein said substituted or unsubstituted aryl group wherein said substituted or unsubstituted aryl group wherein said substituted or unsubstituted aryl group wherein
- V is N(R'), O, or S;
- R 1 is: hydrogen, lower alkyl, lower alkyl having at least one substituent J, formyl, acetyl, lower alkanoyl, lower alkanoyl having at least one substituent J, lower alkylsulfonyl, lower arylsulfonyl, an amino acid, or a protected amino acid;
- R 2 is: hydrogen, lower alkyl, lower alkyl having at least one substituent J; formyl; acetyl, lower alkanoyl, lower alkanoyl having at least one substituent J, lower alkylsulfonyl, arylsulfonyl, an amino acid, or a protected amino acid;
- each of R 3 and R 4 is, independently, hydrogen, lower alkyl, aryl, lower alkyl having at least one substituent J, or aryl having at least one substituent J.
- J is:
- J 3 "(J 2 )n-(j')m wherein each of n and m is, independently, 0 or 1; each of J 1 and J 2 is, independently, carbonyl, lower alkylcarbonyl, arylcarbonyl, carbonyloxy, sulfonyl, amino, lower alkylamino, lower dialkylamino, amido, lower alkylamido, lower dialkylamido, lower alkyloxycarbonylamino, aryloxycarbonylamino, amidino, guanidino, oxygen, sulphur, lower alkoxy, lower aryloxy, aralkoxy, lower alkyl, C 3 to C 7 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, sulfonylamido, alkylsulfonylamido, arylsulfonylamido, an amino acid, or a protected amino acid; and J 3 is: hydrogen, halo, hydroxy
- each of E and F is, independently, lower alkyl; or E and F, together with the carbon atoms to which they are attached, form: a substituted or unsubstituted C 4 to C 7 cycloalkyl group, wherein said substituted cycloalkyl group has at least one substituent J; a substituted or unsubstituted C 3 to C ⁇ heterocycloalkyl group wherein said substituted heterocycloalkyl group has at least one substituent J; a substituted or unsubstituted heterocycloalkyl group endocyclically comprising within at least one group G wherein said substituted heterocycloalkyl group comprising G has at least one substituent J; a substituted or unsubstituted aryl group wherein said substituted aryl group has at least one group J; or a substituted or unsubstituted heteroaryl group wherein said substituted heteroaryl group has at least one group J; or a substituted or unsubstituted heteroaryl group where
- R 1 is: hydrogen, lower alkyl, lower alkyl having at least one substituent J, fbrmyl, acetyl, lower alkanoyl, lower alkanoyl having at least one substituent J, lower alkylsulfonyl, lower arylsulfonyl, an amino acid, or a protected amino acid
- R 2 is: hydrogen, lower alkyl, lower alkyl having at least one substituent J; formyl; acetyl, lower alkanoyl, lower alkanoyl having at least one substituent J, lower alkylsulfonyl, arylsulfonyl, an amino acid, or a protected amino acid
- each of R 3 and R 4 is, independently, hydrogen, lower alkyl, aryl, lower alkyl having at least one substituent J, fbrmyl, acetyl, lower alkanoyl, lower alkanoyl having at least one substituent J, lower alkylsulfon
- each of J 1 and J 2 is, independently, carbonyl, lower alkylcarbonyl, arylcarbonyl, carbonyloxy, sulfonyl, amino, lower alkylamino, lower dialkylamino, amido, lower alkylamido, lower dialkylamido, lower alkyloxycarbonylamino, aryloxycarbonylamino, amidino, guanidino, oxygen, sulphur, lower alkoxy, lower aryloxy, aralkoxy, lower alkyl, C 3 to C 7 cycloalkyl, heterocycloalkyl, aryl, heteroaryl, sulfonylamido, alkylsulfonylamido, arylsulfonylamido, an amino acid, or a protected amino acid; and
- Further preferred embodiments include compounds of formula IV, that may be particularly important with regard to inhibition of PARP, in which A and B are both CO, R 2 and J are both H, E and F, together with the atoms to which they are attached, form a cyclopentyl group, and V is either NH (Ia, see Table 1) or N-(Lysine-2 HCl )(lk, see Table 1). Additionally, the compound of formula IV wherein A and B are both CO, R 2 is H, V is NH, E and F, together with the atoms to which they are attached, form a cyelopentyl group, and J is NH 2 CH 2 3-substituent (2p, see Table 2) comprises a further preferred embodiment.
- Additional preferred embodiments of the compounds described herein include those where groups E and F, when taken together with the atoms to which they are attached, form a group other than imidazolyl.
- R 1 is: hydrogen, lower alkyl, lower alkyl having at least one substituent J, formyl, acetyl, lower alkanoyl, lower alkanoyl having at least one substituent J, lower alkylsulfonyl, or lower arylsulfonyl
- R 2 is: hydrogen, lower alkyl, lower alkyl having at least one substituent J; formyl; acetyl, lower alkanoyl, lower alkanoyl having at least one substituent J, lower alkylsulfonyl, or arylsulfonyl
- each of R 3 and R 4 is, independently, hydrogen or lower alkyl
- J is independently at each substituent J
- X 1 and X 2 together with the atoms to which they are attached, form: a substituted or uns ⁇ bstituted aryl group wherein said substituted aryl group has at least one substituent J; or a substituted or unsubstituted heteroaryl group wherein said substituted heteroaryl group has at least one substituent J.
- J 1 and J 2 is, independently, carbonyl, amino, carbonyloxy, lower alkylamino, lower dialkylamino or lower alkoxy.
- J 3 is hydrogen, halo, hydroxyl, cyano, NO 2 , lower alkyl, heteroaryl or hetercycloalkyl.
- J 1 and J 2 is, independently, carbonyl, amino, carbonyloxy, lower alkylamino, lower dialkylamino or lower alkoxy.
- J 3 is hydrogen, halo, hydroxyl, cyano, NO 2 , lower alkyl, heteroaryl or hetercycloalkyl.
- J 1 and J 2 is, independently, carbonyl, amino, carbonyloxy, lower alkylamino, lower dialkylamino or lower alkoxy.
- J 3 is hydrogen, halo, hydroxyl, cyano, NO 2 , lower alkyl, heteroaryl or hetercycloalkyl.
- R 2 is hydrogen, lower alkyl or lower alkyl having at least one substituent J 4 ; J is independently at each occurrence:
- J 3 is: hydrogen, halo, hydroxy, cyano, NO 2 , carboxyl, lower alkyl, aryloxycarbonyl, alkyloxycarbonyl, heteroaryl, or heterocycloalkyl; and J 4 is independently at each occurrence:
- each of J 5 and J 6 is, independently, carbonyl, lower alkylcarbonyl, arylcarbonyl, carbonyloxy, amino, lower alkylamino, lower dialkylamino, amido, lower alkylamido, lower dialkylamido, lower alkoxy, lower alkyl, C 3 to C 7 cycloalkyl, heterocycloalkyU aryl, or a heteroaryl; and
- J 7 Is: hydrogen, halo, hydroxy, cyano, NO 2 , carboxyl, lower alkyl, aryloxycarbonyl, alkyloxycarbonyl, heteroaryl, or heterocycloalkyl; and X 1 and X 2 , together with the atoms to which they are attached, form: a substituted or unsubstituted phenyl group wherein said substituted phenyl group has at least one substituent J; or a substituted or unsubstituted heteroaryl group wherein said substituted heteroaryl group has at least one substituent J and where said heteroaryl is pyridine or pyridine-N-oxide.
- J 1 and J 2 is, independently, carbonyl, amino, carbonyloxy, lower alkylamino, lower dialkylamino or lower alkoxy.
- J 3 is hydrogen, halo, hydroxyl, cyano, NO 2 , lower alkyl, heteroaryl or hetercycloalkyl.
- J 1 and J 2 is, independently, carbonyl, amino, carbonyloxy, lower alkylamino, lower dialkylamino or lower alkoxy.
- J 3 is hydrogen, halo, hydroxyl, cyano, NO 2 , lower alkyl, heteroaryl or hetercycloalkyl.
- E and F together with the carbon atoms to which they are attached, form: a substituted or unsubstituted C 5 cycloalkyl group;
- R 1 is hydrogen or lower alkyl having at least one substituent J;
- R 2 is lower alkyl having at least one substituent J 4 ;
- J is independently at each occurrence: wherein each of n and m is, independently, 0 or 1 ;
- each of J 1 and J 2 is ⁇ , independently, carbonyl, lower alkylcarbonyl, arylcarbonyl, carbonyloxy, amino, lower alkylamino, lower dialkylamino, amido, lower alkylamido, lower dialkylamido, lower alkoxy, lower alkyl, C 3 to C 7 cycloalkyl, heterocycloalkyl, aryl, or a heteroaryl; and
- J 3 Is: hydrogen, halo, hydroxy, cyano, NO 2 , carboxyl, lower alkyl, aryloxycarbonyl, alkyloxycarbonyl, heteroaryl, or heterocycloalkyl; and J 4 is independently at each occurrence: J 7 -(J 6 )n-(J 5 )m- wherein each of n and m is, independently, 0 or 1; each of J 5 and J 6 is, independently, carbonyl, lower alkylcarbonyl, arylcarbonyl, carbonyloxy, amino, lower alkylamino, lower dialkylamino, amido, lower alkylamido, lower dialkylamido, lower alkoxy, lower alkyl, C 3 to C 7 cycloalkyl, heterocycloalkyl, aryl, or a heteroaryl; and
- J 7 is: hydrogen, halo, hydroxy, cyano, NO 2 , carboxyl, lower alkyl, aryloxycarbonyl, alkyloxycarbonyl, heteroaryl, or heterocycloalkyl; and X 1 and X 2 , together with the atoms to which they are attached, form: a substituted or unsubstituted phenyl group wherein said substituted phenyl group has at least one substituent J; or a substituted or unsubstituted heteroaryl group wherein said substituted heteroaryl group has at least one substituent J and where said heteroaryl is pyridine or pyridine-N-oxide.
- the compound of the invention as described herein where each of J 5 and J 6 is, independently, lower alkyl, lower dialkylamino or heterocycloalkyl.
- J 7 is hydrogen or heterocycloalkyl.
- X 1 and X 2 together with the atoms to which they are attached, form a phenyl with at least one substituent J.
- J 4 is methylaminodimethyl, methylarninodiethyl, 4-methylmorpholine or 4-methyl ⁇ iperazinyl- CH 2 .
- alkyl refers to a saturated straight, branched, or cyclic hydrocarbon of Ci to C 20 - Alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, t-butyl, n-pentyl, cyclopentyl, isopentyl, neopentyl, n-hexyl, isohexyl, cyclohexyl, cyclooctyl, adamantyl, 3-methylpentyl, 2,2-dimethylbutyl, and 2,3-dimethylbutyl.
- lower alkyl refers to a Ci to C 6 saturated straight chain, branched, or cyclic hydrocarbon.
- Lower alkyl groups include, but are not limited to, methyl, ethyl, n-propyl, isopropyl, n-butyl. isobutyl, t-butyl, n-pentyl, cyclopentyl, isopentyl, neopentyl, n-hexyl, isohexyl, cyclohexyl, 3-methylpentyl, 2,2-dimethylbutyl, and 2,3-dimethylbutyl.
- cycloalkyl and “C n cycloalkyl” are meant to refer to a monocyclic saturated or partially unsaturated hydrocarbon group.
- C n in this context, wherein n is an integer, denotes the number of carbon atoms comprising the ring of the cycloalkyl group. For instance, C 6 cycloalkyl indicates a six-membered ring.
- the bonds connecting the endocyclic carbon atoms of a cycloalkyl group may be single or part of a fused aromatic moiety, so long as the cycloalkyl group is not aromatic.
- cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and cycloheptyl.
- heterocycloalkyl or “C n heterocycloalkyl” are meant to refer to a monocyclic saturated or partially unsaturated cyclic radical which, besides carbon atoms, contains at least one heteroatom as ring members.
- hetero atoms include, but are not limited to, oxygen, nitrogen, sulfur, selenium, and phosphorus atoms.
- C n denotes the number of carbon atoms comprising the ring, but is not indicative of the total number of atoms in the ring.
- C 4 heterocycloalkyl includes rings with five or more ring members, wherein four of the ring members are carbon and the remaining ring members are heteroatoms.
- the bonds connecting the endocyclic atoms of a heterocycloalkyl group may be part of a fused aromatic moiety, so long as the heterocycloalkyl group is not aromatic.
- heterocycloalkyl groups include, but are not limited to, 2-pyrrolidinyl, 3-pyrrolidinyl, piperdinyl, 2-tetrahydrofuranyl, 3-tetrahydrofuranyl, 2-tetrahydrothienyl, and 3- tetrahydrothienyl.
- aryl refers to a mono-, di-, tri-, or multinuclear aromatic ring system of 6 to 10 ring atoms. Non-limiting examples include phenyl, naphthyl, anthracenyl, and phenanthrenyl.
- heteroaryl refers to an aromatic ring system having from 5 to 10 ring atoms comprising carbon and at least one heteroatom ring member such as an oxygen, nitrogen or sulfur.
- the nitrogen heteroatom may be optionally oxidized for example pyridine-N-oxide or 1-oxy-pyridinyl.
- Non-limiting examples are pyrryl, pyridinyl, furyl, 1,2,4-thiadiazolyl, pyrimidyl, thienyl, isothiazolyl, imidazolyl, tetrazolyl, pyrazinyl, pyrimidyl, quinolyl, isoquinolyl, benzothienyl, isobenzofuryl, pyrazolyl, indolyl, purinyl, carbazolyl, benzimidazolyl, isoxazolyl, and acridinyl.
- aralkyl is meant to refer to aryl-substituted alkyl radicals such as benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, and diphenylethyl.
- lower aralkyl is meant to refer to aryl-substituted lower alkyl radicals. Non-limiting examples include benzyl, diphenylmethyl, triphenylmethyl, phenylethyl, and diphenylethyl.
- aralkoxy is meant to refer to the group RO- wherein R is an aralkyl group as defined above.
- lower aralkoxy is meant to refer to the group RO- wherein R is a lower aralkyl group as defined above.
- alkoxy is meant to refer to RO-, wherein R is an alkyl group as defined above.
- lower alkoxy is meant to refer to RO-, wherein R is a lower alkyl group as defined above.
- Non-limiting examples include methoxy, ethoxy, and tert-butyloxy.
- aryloxy is meant to refer to RO-, wherein R is an aryl group as defined above.
- lower alkylamino and “lower dialkylamino” refer to an amino group that bears one or two lower alkyl substituents, respectively.
- amino and “carbonylamino,” as used herein, are meant to refer to
- alkylamido is meant to refer to -C(O)NR- wherein R is an alkyl group as defined above.
- dialkylamido is meant to refer to -C(O)NR 5 R" wherein R' and R" are, independently, alkyl groups as defined above.
- lower alkylamido is meant to refer to -C(O)NR- wherein R is a lower alkyl group as defined above.
- lower dialkylamido is meant to refer to -C(O)NR 3 R" wherein R' and R" are, independently, lower alkyl groups as defined above.
- alkanoyl and alkylcarbonyl refer to RC(O)- wherein R is an alkyl group as defined above.
- lower alkanoyl and “lower alkylcarbonyl” as used herein, refer to RC(O)- wherein R is a lower alkyl group as defined above.
- alkanoyl groups include acetyl, trifluoroacetyl, hydroxyacetyl, propionyl, butyryl, valeryl, and 4-methylvaleryl.
- arylcarbonyl refers to RC(O)- wherein R is an aryl group as defined above.
- aryloxycarbonyl as used herein, is meant to refer to ROC(O)- wherein R is an aryl group as defined above.
- halo refers to fiuoro, chloro, bromo, or iodo.
- alkylsulfonyl is meant to refer to the group RSO 2 - wherein R is an alkyl group as defined above.
- arylsulfonyl is meant to refer to the group RSO 2 - wherein R is an aryl group as defined above.
- alkyloxycarbonylamino is meant to refer to the group
- lower alkyloxycarbonylamino is meant to refer to the group ROC(O)N(H)- wherein R is a lower alkyl group as defined above.
- aryloxycarbonylamino is meant to refer to the group ROC(O)N(H)- wherein R is an aryl group as defined above.
- sulfonylamido is meant to refer to the group -SO 2 C(O)NH-.
- alkylsulfonylamido is meant to refer to the group
- arylsulfonylamido is meant to refer to the group RSO 2 C(O)NH- wherein R is an aryl group as defined above.
- lower alkyl ester of phosphonic acid is meant to refer to the group -P(O)(OR' )(OR") wherein R' and R" are lower alkyl as defined above.
- aryl ester of phosphonic acid is meant to refer to the group -P(O)(OR')(OR") wherein R' and R" are aryl as defined above.
- aminocarbonyloxy is meant to refer to the group RR 3 N-C(O)-O- wherein R and R' are an alkyl group as defined above.
- arylaminocarbonyloxy is meant to refer to the group
- Ar-N(R)-C(O)-O- wherein Ar is aryl, as defined above, and R is an alkyl group as defined above.
- heteroarylarninocarbonyloxy is meant to refer to the group het- Ar-N(R)-C(O)-O- wherein het-Ar is heteroaryl, as defined above, and R is an alkyl group as defined above.
- amino acid means a molecule containing both an amino group and a carboxyl group. It includes an " ⁇ -amino acid” which is well known to one skilled in the art as a carboxylic acid that bears an amino functionality on the carbon adjacent to the carboxyl group. Amino acids can be naturally occurring or non-naturally occurring.
- Protected amino acids refer to amino acids, as described above, comprising protecting groups.
- the amino group of an amino acid may be protected with t-butoxycarbonyl or benzyloxycarbonyl groups.
- the carboxyl group of the amino acid may be protected as alkyl and aralkyl esters.
- alcohol groups of amino acids can be protected as alkyl ethers, aralkyl ethers, and silyl ethers.
- endocyclically comprising is meant to describe a cyclic chemical moiety that includes a specified chemical group as a ring forming member.
- a furanyl group endocyclically comprises an oxygen atom because the oxygen atom is a member of the ring structure.
- groups E and F may be combined together with the atoms to which they are attached to form a heterocycloalkyl group.
- This heterocycloalkyl group may endocyclically comprise the chemical group G, meaning that at least one atom of group G is a ring forming member.
- E and F may be combined together with the atoms to which they are attached to form the heterocycloalkyl group endocyclically comprising group G, wherein G, in this instance, is N(CHa).
- the term "therapeutically effective amount” is meant to refer to an amount of compound of the present invention that will elicit a desired therapeutic or prophylactic effect or response when administered according to the desired treatment regimen.
- the term “contacting” means bringing together, either directly or indirectly, one or more molecules with another, thereby facilitating intermolecular interactions. Contacting may occur in vitro, ex vivo, or in vivo.
- cellular proliferative disorders is meant to refer to malignant as well as non-malignant cell populations which differ from the surrounding tissue both morphologically and genotypically.
- Types of cellular proliferative disorders include, for example, solid tumors, cancer, diabetic retinopathy, intraocular neovascular syndromes, macular degeneration, rheumatoid arthritis, psoriasis, and endometriosis.
- the present invention features methods for preparing the multicyclic compounds described herein which are useful as inhibitors of PARP, VEGFR2, and MLK3.
- the method consists of a multistep synthesis starting with the necessary heterocyclic compounds.
- Figure 1 outlines the general synthesis of compounds of the present invention for the case when the heterocyclic starting material is an indole.
- an indole A which is unsubstituted or substituted in positions 4-7 on the indole ring, is treated serially, for example, with butyllithium, carbon dioxide, t- butyllithium and a ketone B (having substituents E and F) to provide a 2-substituted indolyl tertiary alcohol C.
- This tertiary alcohol is eliminated, for example, under acidic conditions using hydrochloric acid or toluenesulfonic acid, to afford a substituted 2- vinylindole, D.
- Di els- Alder cycloaddition of D with a dienophile such as, but not limited to, maleimide (E) affords the cycloaddition intermediate F.
- Aromatization of the cycloaddition intermediate for example, with oxygen in the presence of a catalyst such as palladium or platinum or with an oxidant such as DDQ or tetrachloroquinone, produces carbazole G.
- carbazole G contains bromoacetyl or substituted 2-bromoacyl substituents, as shown in Figure 4, the bromine can be displaced by various nucleophiles to give further embodiments of the present invention. Alternately, the 2-bromoacyl group may be reacted with various thioamides to give substituted thiazoles.
- dienophiles other than maleimide (E) may be used in the Diels- Alder reaction, and include for example, dialkyl fumarate, fumaric acid, dialkyl maleate, maleic acid, maleic anhydride, dialkyl acetylenedicarboxylate or alkyl 3- cyanoacrylate.
- the intermediates resulting from cycloaddition with these dienophiles give imides, or the corresponding lactams as shown in Figure 5.
- anyhdrides obtained from maleic anhydride cycloaddition or by dehydration of diacids, afford imides when treated with bis(trimethylsilyl)amine or urea.
- the anhydrides afford six-membered hydrazones when treated with hydrazine.
- the lactams are obtained by separating the cyano ester isomers, aromatizing each isomer, and reducing the cyano ester to the lactam, as shown in Figure 5. Imides may also be reduced to lactams by well established methods known to those skilled in the art.
- Indole— type compounds of the present invention are prepared according to the scheme shown in Figure 6.
- substituted vinyl pyrrole starting materials are prepared by the reaction of a pyrrole with an enamine of a ketone as described in the literature (Heterocycles 1974, 2, 575-584).
- a substituted 2-vinyl pyrrole is reacted with various dienophiles, such as those described above, to afford a cycloaddition intermediate which is a precursor to embodiments of the present invention.
- a nitrogen protecting group such as a silyl protecting group, particularly triisopropyl silyl, may used throughout as depicted in Figure 6.
- heterocyclic precursors may be prepared by analogous reactions.
- a substituted 5-vinyl imidazole is reacted with various dienophiles, such as those described above, to afford a cycloaddition intermediate which can be further modified by reactions well known to those skilled in the art to give benzimidazole precursors.
- a substituted 5-vinyl 1,2,3-triazole or 4- vinyl thiazole can be reacted with various dienophiles as above to also afford cycloaddition intermediates leading to embodiments of the invention.
- the benzimidazole-type compounds of the present invention can also be prepared according to the method shown in Figure 7, in which preformed benzimidozoles serve as starting materials.
- an optionally substituted 2-vinyl benzofuran or 2-vinyl benzothiophene can be reacted with various dienophiles, such as those listed previously, to afford a cycloaddition intermediate. Modification of the cycloaddition intermediate can lead to imides, lactams, and related compounds of the present invention.
- the compounds of the present invention are PARP inhibitors.
- the potency of the inhibitor can be tested by measuring PARP activity in vitro or in vivo.
- a preferred assay monitors transfer of radiolabeled ADP-ribose units from [ 32 P]NAD + to a protein acceptor such as histone or PARP itself. Routine assays for PARP are disclosed in Purnell and Whish, Biochem. J. 1980, 185, 775, incorporated herein by reference.
- the compounds of the present invention are also VEGFR2 or MLK3 inhibitors. The potency of the inhibitor can be tested by measuring VEGFR2 or MLK3 activity in vitro or in vivo.
- a preferred assay for VEGFR2 kinase activity involves the phosphorylation of a protein substrate immobilized on a microtiter plate. The resulting phosphotyrosine residue is detected with an anti-phosphotyrosine antibody conjugated to a europium chelate, allowing quantitation of the product by time- resolved fluorometry. Similar assay methods have been employed for the detection of the tyrosine kinase c-src, as described in Braunwalder et al. Anal. Biochem. 1996, 238, 159, incorporated herein by reference.
- a preferred assay method for MLK3 utilizes phosphorylation of a protein substrate, such as myelin basic protein, with [ ⁇ - 32 P]ATP, followed by isolation of the acid-insoluble 32 P-phosphoprotein product on a filtration plate. Analogous methods were employed for the assay of protein kinase C, as reported in Pitt and Lee, J. Biomol. Screening 1996, 1, 47, incorporated herein by reference.
- Enzyme activity can be reduced or inhibited by contacting the enzyme with at least one compound described herein.
- the contacting can occur either in vitro, in vivo, or ex vivo.
- Contacting can also be promoted by use of contacting media which enhances the rate of mixing of enzyme and inhibitor.
- Preferred media include water, water-based solutions, buffered solutions, water-miscible solvents, enzyme-solubilizing solutions, and any combination thereof.
- Contacting cells containing the enzyme in vivo preferably employs the inhibitor to be delivered in proximity to the enzyme associated with the cell in a biologically compatible medium.
- Preferred biologically compatible media include water, water-based solutions, saline, biological fluids and secretions, and any other non-toxic material that may effectively deliver inhibitor to the vicinity of the enzyme in a biological system.
- the compounds described herein can be used to prevent or treat the onset or progression of any disease or condition related to PARP activity in mammals, especially humans.
- Such conditions include traumatic injury to the central nervous system, such as brain and spinal cord injuries, and the neuronal degradation associated with traumatic injury to the central nervous system.
- Related conditions and diseases treatable by methods of the present invention include vascular strokes, cardiac ischemia, cerebral ischemia, cerebrovascular disorders such as multiple sclerosis, and neurodegenerative diseases such as Alzheimer's, Huntington's, and Parkinson's diseases.
- PARP related conditions or diseases treatable by the compounds described herein include inflammation such as pleurisy and colitis, endotoxic shock, diabetes, cancer, arthritis, cardiac ischemia, retinal ischemia, skin aging, chronic and acute pain, hemorrhagic shock, and others.
- a patient can be administered one or more compounds described herein to prevent or minimize damage to the brain.
- Patients with symptoms of Alzheimer's, Huntington's, or Parkinson's disease can be treated with compounds of the present invention to halt the progression of the disease or alleviate symptoms.
- PARP inhibitors may also be used to treat patients suffering from cancer. For instance, cancer patients can be administered the present compounds in order to augment the anti-tumor effects of chemotherapy.
- the compounds described herein can be used to prevent or treat the progression of any disease or condition related to kinase activity (such as VEGFR2 or MLK3 activities) in mammals, especially humans.
- the compounds described herein may be used to treat conditions related to MLK3 activity such as chronic neurodegenerative diseases as, for example, Alzheimer's disease, Parkinson's disease, and Huntington's disease, and acute neurological conditions such as cardiac ischemia, cerebral ischemia, as well as traumatic brain and spinal injuries.
- the compounds described herein can also be useful in the treatment of inflammatory diseases and cancer related to MLK3 activity.
- the compounds described herein can be used to inhibit VEGFR2 which may lead to suppression of formation of new blood vessels.
- Such compounds can therefore be useful in the treatment of conditions associated with new blood vessel formations such as, for example, solid tumors, diabetic retinopathy, and other intraocular neovascular syndromes, macular degeneration, rheumatoid arthritis, psoriasis, and endometriosis.
- the compounds described herein are preferably administered to mammals in a therapeutically effective amount. Dosage may vary depending on the compound, the potency of the compound, the type of disease, and the diseased state of the patient, among other variables.
- Dosage amount can be measured by administration of pre-measured dosing means or unit dosages in the form of tablets, capsules, suppositories, powders, emulsions, elixirs, syrups, ointments, creams, or solutions.
- PARP or kinase inhibitors may be administered by any route that drugs are conventionally administered.
- routes of administration include intraperitoneal, intravenous, intramuscular, subcutaneous, intrathecal, intracheal, intraventricular, oral, buccal, rectal, parenteral, intranasal, transdermal or intradermal. Administration may be systemic or localized.
- compositions will generally include an inert diluent carrier or an edible carrier.
- Pharmaceutically compatible binding agents, and/or adjuvant materials can be included as part of the composition.
- Tablets, pills, capsules, troches and the like can contain any of the following ingredients, or compounds of a similar nature: a binder such as microcrystalline cellulose, gum tragacanth or gelatin; an excipient such as starch or lactose, a dispersing agent such as alginic acid, Primogel, or corn starch; a lubricant such as magnesium stearate; a glidant such as colloidal silicon dioxide; a sweetening agent such as sucrose or saccharin; or a flavoring agent such as peppermint, methyl salicylate, or orange flavoring.
- a binder such as microcrystalline cellulose, gum tragacanth or gelatin
- an excipient such as starch or lactose, a dispersing agent such as alginic acid, Primogel, or corn starch
- a lubricant such as magnesium stearate
- a glidant such as colloidal silicon dioxide
- a sweetening agent such as sucrose or
- dosage unit forms can contain various other materials that modify the physical form of the dosage unit, for example, coatings of sugar, shellac, or enteric agents.
- a syrup may contain, in addition to the active compounds, sucrose as a sweetening agent and certain preservatives, dyes, colorings, and flavorings.
- Alternative preparations for administration include sterile aqueous or nonaqueous solutions, suspensions, and emulsions.
- nonaqueous solvents are dimethylsulfoxide, alcohols, propylene glycol, polyethylene glycol, vegetable oils such as olive oil and injectable organic esters such as ethyl oleate.
- Aqueous carriers include mixtures of alcohols and water, buffered media, and saline.
- Intravenous vehicles include fluid and nutrient replenishers, electrolyte replenishers, such as those based on Ringer's dextrose, and the like. Preservatives and other additives may also be present such as, for example, antimicrobials, anti-oxidants, chelating agents, inert gases, and the like.
- Preferred methods of administration of the present compounds to mammals include intraperitoneal injection, intramuscular injection, and intravenous infusion.
- Various liquid formulations are possible for these delivery methods, including saline, alcohol, DMSO, and water based solutions.
- the concentration of inhibitor may vary according to dose and volume to be delivered and can range from about 1 to about 1000 mg/mL.
- Other constituents of the liquid formulations can include, preservatives, inorganic salts, acids, bases, buffers, nutrients, vitamins, or other pharmaceuticals such as analgesics or additional PARP and kinase inhibitors.
- Particularly preferred formulations for administration of the present compounds are detailed in the following publications that describe administration of known PARP inhibitors and are incorporated herein by reference in their entireties; Kato, T.
- Compounds of the present invention also may take the form of a pharmacologically acceptable salt, hydrate, solvate, or metabolite.
- Pharmacologically acceptable salts include basic salts of inorganic and organic acids, including but not limited to hydrochloric acid, hydrobromic acid, sulphuric acid, phosphoric acid, methanesulphonic acid, ethanesulfonic acid, malic acid, acetic acid, oxalic acid, tartaric acid, citric acid, lactic acid, fumaric acid, succinic acid, maleic acid, salicylic acid, benzoic acid, phenylacetic acid, mandelic acid and the like.
- PARP activity was monitored by transfer of radiolabeled ADP-ribose units from [ 32 P]NAD + to a protein acceptor such as histone or PARP itself.
- the assay mixtures contained 100 mM Tris (pH 8.0), 2 mM DTT, 10 mM MgCl 2 , 20 ug/ml DNA (nicked by sonication), 20 mg/ml histone Hl, 5 ng recombinant human PARP, and inhibitor or DMSO ( ⁇ 2.5% (v/v)) in a final volume of 100 uL.
- the reactions were initiated by the addition of 100 ⁇ M NAD + supplemented with 2 uCi [ 32 P]NAD + AnL and maintained at room temperature for 12 minutes.
- a 96-well FluoroNUNC MaxiSorp plate was coated with 100 ⁇ L/well of recombinant human PLC- ⁇ /GST substrate solution at a concentration of 40 ⁇ g/mL in Tris- buffered saline (TBS).
- TBS Tris- buffered saline
- the VEGFR2 activity was assayed in a 100 ⁇ L assay mixture containing 50 mM HEPES (pH 7.4), 30 ⁇ M ATP, 10 mM MnCl 2 , 0.1% BSA, 2% DMSO, and 150 ng/mL recombinant human baculovirus-expressed human VEGFR2 cytoplasmic domain (prephosphorylated for 60 min at 4°C in the presence of 30 ⁇ M ATP and 10 mM MnCl 2 prior to use). The kinase reaction was allowed to proceed at 37°C for 15 min. The europium-labeled anti-phosphotyrosine detection antibody was added at 1:5000 dilution in block buffer (3% BSA in TBST).
- the activity assay for MLK3 was performed in Millipore Multiscreen plates. Each 50 ⁇ L assay mixture contained 50 mM HEPES (pH 7.0), 1 mM EGTA, 10 mM MgCl 2 , 1 mM DTT, 25 mM ⁇ -glycerophosphate, 100 ⁇ M ATP, 1 ⁇ Ci [ ⁇ - 32 P]ATP, 0.1% BSA, 500 ⁇ g/mL myelin basic protein, 2% DMSO, various concentrations of test compounds, and 2 ⁇ g/mL of baculoviral human GST-MLKl kinase domain. Samples were incubated for 15 min at 37°C.
- the reaction was stopped by adding ice-cold 50% TCA and the proteins were allowed to precipitate for 30 min at 4°C.
- the plates were allowed to equilibrate for 1-2 hours prior to counting in the Wallac MicroBeta 1450 Plus scintillation counter.
- Examples 5 to 10 present PARP, VEGFR2, and MLK3 inhibiting data for compounds of the present invention.
- IC 50 values were determined as described in Examples 1 and 2.
- inhibiting data is presented as percent inhibition at a specified concentration.
- Compounds are tabulated together with compound number, substituents, and enzyme inhibition data.
- a and J vary as listed below.
- VEGFR2 and MLK3 inhibiting data for compounds 11a to 13b of formula IV wherein V is NR 1 .
- Table 5 contains percent inhibition data for MLK3 and VEGFR2 enzymes at the concentrations specified unless indicated otherwise. For some entries, an IC 50 value is reported.
- PAKP, VEGFR2, and MLK3 inhibiting data for compounds 14 and 15 of formula IV wherein J is H, and R 2 i •_s H.
- 1 H NMR spectra were recorded on a GE QE Plus instrument (300 MHz) using tetramethylsilane as an internal standard. Electrospray mass spectra were recorded on a VG platform JJ instrument (Fisons Instruments).
- Figure 1 depicts the syntheses of intermediates, precursors, and starting materials for compounds of the present invention.
- the synthesis of Ia is also depicted therein.
- Intermediate C was prepared in the following manner. To a cooled (-78 0 C) solution of indole (A, 2Og, 171 mmol) in dry THF (80 mL) was slowly (over 30 min) added 2.5 M nBuLi in hexanes (68.40 mL, 171 mmol). The mixture was stirred at -78°C for another 30 min, brought to room temperature and stirred for 10 min and cooled back to -78°C. Carbon dioxide gas was then bubbled into the reaction mixture for 15 min, followed by additional stirring of 15 min.
- reaction mixture was quenched by dropwise addition of water (10 mL) followed by saturated NH 4 Cl solution (100 mL). Ethyl ether (300 mL) was added to the flask and the mixture was stirred for 10 min at room temperature. The organic layer was separated, dried (MgSO 4 ), concentrated and triturated with ethyl ether (40 mL). The separated solid was filtered, washed with cold ether and dried under high vacuum to give 22.40 g of compound C as a white solid. Another crop of 4.88 g was obtained from mother liquor and washings.
- Compound F is characterized as a yellow amorphous solid; 1 H- NMR (DMSOd 6 ) ⁇ 11.15 (s, IH), 10.89 (s, IH), 7.65 (d, IH), 7.23 (d, 2H), 6.91 (m, 2H), 4.24 (d, IH), 3.30 (m, 2H), 2.60 (m, IH), 2.14 (m, IH), 1.92 (m, IH), 1.45 (m, 3H), 1.13 (m, IH). MS m/e 279 (M-H) " .
- Compound G (Ia, 5,7,8,9,10,ll-hexahydrocyclopent[a]pyrrolo[3 5 4-c]carbazole-
- Compound G also identified as Ia, occurs as a yellow amorphous solid showing R t 10.90 min; 1 H-NMR (DMSO-d 6 ) ⁇ 11.80 (s, IH), 10.90 (s, IH), 8.70 (s, IH), 7.50 (m, 2H), 7.20 (t, IH), 3.25 (2 sets oft, 4H), 2.25 (broad m, 2H); MS m/e 275 (M-H).
- the following examples are preparations of precursors and compounds within the scope of the present invention.
- Example 13 Preparation of Ic. To a slurry of sodium hydride (60% in oil, 0.016 g, 0.4 mmol) in dry DMF (2 mL) was slowly added Ia (0.1 g, 0.36 mmol) in dry DMF (3 mL). After the evolution of H 2 - gas ceased, benzyl 4-bromobutyronitrile (0.08 g, 0.54 mmol) in dry DMF (1 mL) was added to the reaction flask. The mixture was stirred at 60 0 C for 1.5 h, poured into a mixture of ice and water (ca. 10 g) and filtered. The residue was washed with methanol and dried to give 0.08 g of Ic.
- Ic is characterized as a yellow amorphous solid; R, 14.31 min; 1 H-NMR (DMSOd 6 ) ⁇ 11.90 (s, IH), 8.70 (d, IH), 7.50 (m, 2H), 7.25 (t, IH), 3.70 (t, 2H), 3.25 (2 sets oft, 4H), 2.50 (t, 2H), 2.25 (m, 2H), 1.90 (m, 2H); MS m/e 342 (M- H).
- Compound Id is characterized as a yellow amorphous solid; R, 16.59 min; 1 H-NMR (DMSO-de) ⁇ 11.90 (s, IH), 8.70 (d, IH), 7.50 (m, 2H), 7.25 (t, IH), 3.70 (m, 4H), 3.25 (2 sets oft, 4H), 2.25 (m, 2H), 2.10 (m, 2H); MS m/e 351 and 353 (M-H for different isotopes of chlorine).
- Example 15 Preparation of Ie.
- a solution of Ib (0.042 g, 0.1 mmol) in DMF (10 mL) was hydrogenated in a Paar apparatus in presence OfPd(OH) 2 (0.020 g) and 1 drop of cone. HCl at 40 psi for 2 h.
- the reaction mixture was then filtered through a Celite® pad and concentrated to give a residue that was triturated with methanol to generate 0.018 g ofle.
- Compound 1 e is characterized as a yellow amorphous solid; R/ 12.18 min; 1 H-NMR (DMSO-d ⁇ ) ⁇ 11.90 (s, IH), 8.70 (d, IH) 5 7.50 (m, 2H), 7.25 (t, IH), 3.70 (t, 2H), 3.50 (t, 2H), 3.40 (broad, IH), 3.25 (2 sets oft, 4H), 2.25 (m, 2H), 1.80 (m, 2H); MS m/e 333 (M-H).
- Compound Ig is characterized as a yellow amorphous solid; R, 12.91 min; 1 H-NMR (DMSOd 6 ) ⁇ 11.90 (s, IH) 5 8.70 (d, IH), 7.50 (m, 2H), 7.25 (t, IH), 3.70 (t, 2H), 3.25 (m, 6H), 2.25 (m, 10H), 1.80 (m, 2H); MS m/e 404 (M+H).
- Compound Ij is characterized as a yellow amorphous solid; R* 16.19 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.10 (s, IH), 8.70 (d, IH), 8.10 (d, 2H), 7.70 (m, 3H), 7.50 (m, 2H), 7.30 (t, IH), 3.25 (2 sets oft, 4H), 2.25 (m, 2H); MS m/e 415 (M-H).
- Compound Ik is characterized as a yellow amorphous solid; R 1 5.93 min; 1 H-NMR (DMSOd 6 ) ⁇ 12.20 (s, IH), 8.80 (d, IH), 8.70 (broad, 3H), 8.00 (broad, 3H), 7.60 (m, 2H), 7.30 (t, IH), 5.00 (broad, IH), 3.25 (m, 4H), 2.70 (broad, 2H), 2.25 (m, 2H), 2.00 (2 sets of broad, 2H), 1.50 (broad m, 4H); MS m/e 406 (M+2H).
- Example 21 Preparation of 11. This compound was prepared following the same procedure as described before for the synthesis of Ik. Thus, starting from 0.1 g of Ia and 0.14 g of Boc-beta-alanine, 0.025 g of 11 was obtained. 11 is characterized as a yellow amorphous solid; R* 7.45 min; H- NMR (DMSO-d 6 ) ⁇ 12.20 (s, IH), 8.70 (d, IH) 5 8.00 (broad, 3H), 7.50 (m, 2H), 7.25 (t, IH), 3.30 (t, 2H), 3.25 (m, 6H), 2.25 (m, 2H); MS m/e 348 (M+H).
- Compound Ip is characterized as a yellow amorphous solid; R, 14.59 min; 1 H-NMR (DMSOd 6 ) ⁇ 12.00 (s, IH), 8.50 (d, IH), 7.50 (m, 2H), 7.25 (m, 6H), 5.10 (s, 2H), 4.50 (s, 2H), 3.25 (m, 4H), 2.25 (m, 2H); MS m/e 423 (M-H).
- Compound Io is characterized as a yellow amorphous solid; R, 9.06 min; 1 H-NMR (DMSO-d ⁇ ) ⁇ 11.90 (s, IH), 8.75 (d, IH), 7.50 (m, 2H), 7.25 (t, IH), 3.60 (t, 2H), 3.25 (2 sets oft, 4H), 2.60 (t, 2H), 2.50 (q, 4H), 2.25 (m, 2H), 0.80 (t, 6H); MS m/e 376 (M+H).
- Compound Ip is characterized as a yellow amorphous solid; R, 10.36 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, IH), 8.75 (d, IH), 7.50 (m, 2H), 7.25 (t, IH), 4.25 (s, 2H), 4.00-3.00 (broad, IH), 3.25 (m, 4H), 2.25 (m, 2H); MS m/e 333 (M-H).
- Example 27 Preparation of Ir.
- EDCI 0.012 g, 0.063 mmol
- HOBt- ammonia complex 0.017 g, 0.112 mmol; 1.12 g of the complex was prepared by reacting 1.30 g of HOBt and 1.1 mL of 28% ammonium hydroxide in 10 mL of acetone, followed by removal of the solvents).
- the ice-bath was removed and the mixture was stirred overnight. It was then poured into a mixture of ice and water (ca. 10 g) and filtered. The residue was washed several times with water and dried under high vacuum to generate 0.012 g of Ir.
- Compound Ir is characterized as a yellow solid; R, 9.28 min; MS m/e 332 (M-H).
- Is is characterized as a yellow solid; R, 13.07 min 1 H-NMR (DMSO-d ⁇ ) ⁇ 12.00 (s, IH), 8.75 (d, IH), 7.80 (m, 4H), 7.50 (m, 2H), 7.25 (t, IH), 5.50 (s, 2H), 3.25 (m, 4H), 2.25 (m, 2H); MS m/e 434 (M- H).
- the bis(t-butoxycarbonyl)-lysyl derivative was prepared as described for Ik, and purified by chromatography (CH 2 Cl 2 -Et 2 O) to give a yellow glass. MS m/e 613 (MH-Na) + .
- the product is characterized as a yellow amorphous solid with properties; R* 12.39 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, IH), 11.00 (s, IH), 8.70 (s, IH), 7.60 (d, IH), 7.50 (d, IH), 3.25 (2 sets oft, 4H), 2.25 (broad m, 2H); MS m/e 353 and 355 (M-H for different isotopes of bromine).
- this compound was prepared following the same multistep procedure as described for the synthesis of Ia from indole.
- the compound 2c is characterized as an orange amorphous solid; R/ 11.50 min; 1 H-NMR (DMSO-d ⁇ ) ⁇ 12.00 (s, IH), 11.00 (s, IH), 8.50 (d, IH), 7.50 (m, IH), 7.30 (t, IH), 3.25 (2 sets oft, 4H), 2.25 (broad m, 2H). MS m/e 293 (M-H).
- This compound was prepared following the same procedure as described before for the synthesis of 2e. Based on 0.2 g of Ia starting material, 0.2 g of 2f was obtained. The compound 2f is characterized as a yellow amorphous solid; R, 11.96 min; 1 H-NMR
- Compound 2g is characterized as a yellow amorphous solid; R r 5.77 min; 1 H-NMR (DMSO-de) ⁇ 12.25 (s, IH), 11.00 (s, IH), 9.50 (s, IH), 8.20 (d, IH), 7.50 (d, IH), 3.70 (s, 2H), 3.25 (2 sets oft, 4H), 2.50 (broad, 4H), 2.25 (broad m, 6H), 2,10 (t, 3H). MS m/e 417 (M+H).
- Compound 2h is characterized as a yellow amorphous solid; R, 6.50 min; 1 H-NMR (DMSO-de) ⁇ 12.25 (s, IH), 11.00 (s, IH), 9.50 (s, IH), 8.20 (d, IH), 7.60 (d, IH), 3170 (s, 2H), 3.50 (broad, 4H), 3.25 (2 sets oft, 4H), 2.40 (broad, 4H), 2.25 (broad m, 2H); MS m/e 404 (M+H).
- Example 40 Preparation of 2i.
- a mixture of 2e (0.040 g, 0.1 mmol), triethylamine (0.011 g, 0.11 mmol) and piperidine (0.009 g, 0.11 mmol) in dry DMF (3 mL) was stirred at room temperature for 0.5 h, poured into a mixture of ice and water (ca. 10 g) and filtered. The residue was washed several times with water and dried under high vacuum to generate 0.034 g of 2i.
- Compound 2i is characterized as a yellow amorphous solid; R, 7.32 min; 1 H-NMR
- Compound 2j is characterized as a dark brown amorphous solid; R, 7.04 min; 1 H-NMR (DMSOd 6 ) 6 12.25 (broad, IH), 11.00 (broad, IH), 9.50 (s, IH), 8.20 (d, IH), 7.50 (d, IH), 3.70 (s, 2H), 3.25 (2 sets oft, 4H), 2.60 (q, 4H), 2.25 (broad m, 2H), 1.00 (t, 6H). MS m/e 390 (M+H).
- Compound 2k is characterized as a yellow amorphous solid; R / 9.20 min (broad); 1 H-NMR (DMSOd 6 ) ⁇ 12.20 (s, IH), 11.00 (s, IH), 9.40 (s, IH), 8.20 (d,lH), 7.60 (d, IH), 4.10 (s, 2H), 3.40 (s, 2H), 3.25 (2 sets oft, 4H), 2.40 (s, 3H), 2.25 (broad m, 2H), 1.40 (s, 9H); MS m/e 461 (M+H).
- Compound 21 is characterized as a yellow amorphous solid; R, 6.34 min (broad); 1 H-NMR (DMSOd 6 ) ⁇ 12.20 (s 5 IH), 11.00 (s, IH), 9.40 (s, IH), 8.10 (d, IH), 7.60 (d, IH), 4.70 (s, 2H), 3.70 (s, 2H), 3.50 (broad, 2H), 3.25 (2 sets oft, 4H), 2.70 (s, 3H), 2.25 (broad m, 2H); MS m/e 406 (M+H).
- Compound 2n is characterized as a yellow amorphous solid; R f 9.28 min; 1 H-NMR (DMSO-d ⁇ ) ⁇ 12.50 (s, IH), 11.00 (s, IH), 9.30 (s, IH), 8.50 (s, IH), 8.20 (d, IH), 8.00 (s, IH), 7.50 (d, IH), 6.00 (s, 2H), 3.25 (2 sets oft, 4H), 2.25 (broad m, 2H);
- CuCN method A mixture of 2a (0.1 g, 0.28 mmol), CuCN (0.075 g, 0.85 mmol) and l-methyl-2-pyrrolidinone (4 mL) was heated at 175 0 C in a sealed tube overnight, cooled to room temperature, passed through a silica pad, concentrated to a small volume and poured into water (20 mL). The precipitated solid was filtered, washed with water, dried and purified by column chromatography (eluant: EtOAc) to generate 0.006 g of 2o.
- EtOAc column chromatography
- Zn(CN) 2 method A mixture of 2a (2.33 g, 6.56 mmol) and Zn(CN) 2 (1.56 g, 13.3 mmol) were dissolved in DMF (22 mL) under nitrogen. Pd(Ph 3 P) 4 (1.17 g, 0.10 mmol, 15 mol%) was added, and the mixture was stirred at 125 0 C for 80 min. The warm solution was vacuum filtered through Celite® and the pad rinsed with hot DMF. The filtrate was diluted with two volumes of water.
- EDCI (30 mg, 0.156 mmol) was added to a suspension of 3-(aminomethyl)- 5,7,8,9,10,1 l-hexahydrocyclopent[a]pyrrolo[3 > 4-c]carbazole-5(6H),7-dione hydrochloride (2p, 31 mg, 0.10 mmol), NMM (15 uL, 13 mmol), HOBT-H 2 O (16 mg, 0.10 mmol), and acetic acid (10 mg, 0.17 mmol) in DMF (0.5 mL). All solids dissolved 10 min. After 2 days, water (4 mL) was added.
- NMM 14 mg, 0.14 mmol was added to a mixture of 3-(aminomethyl)- 5,7,8,9,10,1 l-hexahydrocyclopent[a]pyrrolo[3 3 4-c]carbazole-5(6H),7-dione hydrochloride (2p, 15 mg, 0.045 mmol) and dW-butyl dicarbonate (18 mg, 0.082 mmol) in DMF (1 mL). After 2 hr, the mixture was filtered, and water (5 mL) was added. The precipitate was collected and rinsed with 3% citric acid, saturated NaHCO3, and water, then dried to afford the product (12 mg, 67% yield) as a golden-brown solid.
- Example 62 Preparation of 2ae. To a suspension of 5a (0.1 g, 0.36 mmol) in methylene chloride (2 mL) at 0 0 C, was slowly added chlorosulfonic acid (0.05 g, 0.4 mmol). The reaction mixture was stirred at 0 0 C for another 30 min, then stirred at room temperature overnight and filtered. The residue was washed successively with methylene chloride and ether. It was then purified by preparative HPLC to generate 0.008 g of 2ae.
- chlorosulfonic acid 0.05 g, 0.4 mmol
- Compound 2ae is a yellow amorphous solid; R, 4.89 min (broad); 1 H-NMR (DMSOd 6 ) ⁇ 12.00 (s, IH), 11.00 (s, IH), 9.10 (s, IH), 7.75 (d, IH), 7.40 (d, IH), 3.25 (2 sets oft, 4H), 2.50 (s, IH), 2.25 (broad m, 2H); MS m/e 355 (M-H).
- Example 62b Preparation of 2ag
- a slurry of example 5c (3O5mg, 1.06mmol) in 1,4-dioxane (15ml) and concentrated hydrochloric acid (15) was heated to reflux for 72h.
- the dioxane was removed by rotary evaporation and the product was collected by suction filtration, washed with water to neutrality and air-dried to constant weight to give 315mg (97%) of the title compound as a tan to light brown solid.
- MS: m/e 305 (M-H) + .
- example 2ag (20mg, 0.065mmol) in DMF (3ml) was added 1- hydroxybenzotriazole (HOBt, 13mg, 0.098) and benzotriazol-1-yloxy- tris(dimethylamino)phosphonium hexafluorophosphate (BOP, 43mg, 0.098mmol).
- BOP benzotriazol-1-yloxy- tris(dimethylamino)phosphonium hexafluorophosphate
- Example 62h Preparation of 2 am This compound was prepared according to the procedure described above for example 2ai except product isolation was achieved by evaporation of DMF, stirring the residue with 50% methanol/ether (2ml) and washing the resulting precipitate with ether (2x3ml). From .example 2ag (20mg, 0.065mmol) and N D -methylhistamine dihydrochloride (21mg, 0.104mmol) was obtained 5mg (19%) of the title compound as a light brown solid. MS: 414 (M+H) + .
- Oxalyl chloride (1.0 mL, 1.45 g, 11.4 mmol) was added to a stirred suspension of aluminum chloride (1.50 g, 11.3 mmol) in 1,2-dichloroethane (20 mL) at 20 0 C. After 1 min, Ia (1.00 g, 3.62 mmol) was added and the mixture was stirred for 40 min, then poured into 20 g of ice and water (gas evolution) and stirred for 10 min. The precipitate was collected by vacuum filtration and rinsed with water, IM HCl, and water, then dried to give 1.11 g (95% yield) of crude 2bd contaminated with 17% of the dimeric ketone.
- Oxalyl chloride (0.010 mL, 14.5 mg, 0.114 mmol) was added to crude 2bd (28 mg, 0.0875 mmol) in DMF (0.28 mL) 0 0 C. After 1 h at 20 0 C, excess HCl was removed with ' a nitrogen stream, and 2-(N,N-dimethylamino)ethylamine (24 mg, 0.27 mmol) was added. After Ih, the precipitate was collected, dried, and suspended in 0.5 mL 0.1 M HCl. The precipitate (consisting of dimeric ketone in the crude starting material) was discarded and the supernatant was lyophilized to give the hydrochloride of 2cg.
- Compound 3a is characterized as a yellow amorphous solid; R, 6.68 min; 1 H-NMR (DMSOd 6 ) ⁇ 12.00 (s, IH), 11.00 (s, IH), 9.00 (s, IH), 7.75 (d, IH), 7.50 (d, IH), 7.00 (s, IH), 3.50 (broad, 2H), 3.25 (2 sets oft, 4H), 2.25 (broad m, 2H). MS m/e 375 (M+H).
- Compound 3b is characterized as a yellow amorphous solid; R 1 10.14 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, IH), 11.00 (s, IH), 9.30 (s, IH), 8.00 (d, IH), 7.70 (s, IH), 7.50 (d, IH), 3.25 (2 sets oft, 4H), 2.70 (s, 3H), 2.25 (broad m, 2H); MS m/e 374 (M+H).
- Compound 3e is characterized as a yellow amorphous solid; R, 12.23 min; 1 H-NMR (DMSOd 6 ) ⁇ 12.00 (s, IH), 10.90 (s, IH), 9.20 (s, IH), 8.20 (broad, 3H), 8.00 (d, IH), 7.80 (broad, IH), 7.50 (d, IH), 6.80 (s, IH), 4.00 (m, IH), 3.50 (broad, 2H), 3.25 (2 sets oft, 4H), 2.25 (broad m, 2H), 1.70 (broad, 4H); MS m/e 646 (M+H).
- Compound 3c is characterized as a yellow amorphous solid; R, 12.90 min; 1 H-NMR (DMSO-d ⁇ ) ⁇ 12.00 (s, IH) 5 10.90 (s, IH), 9.40 (s, IH), 8.00 (d, IH), 7.60 (s, IH), 3.25 (2 sets oft, 4H), 2.70 (s, 3H), 2.25 (broad m, 2H); MS m/e 452 and 454 (M+H for different isotopes of bromine).
- Example 2f (0.1 g, 0.24 mmol), thiourea (0.03 g, 0.4 mmol) and ethanol (3 mL) was heated at 75-80 0 C in a sealed tube overnight. On cooling, a precipitate appeared that was filtered, washed several times with cold ethanol and ether and dried under high vacuum to generate 0.075 g of 3d.
- Compound 3d is characterized as a yellow amorphous solid; R, 8.07 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.20 (s, IH), 11.00 (s, IH), 9.00 (s, IH), 8.80 (b, 2H), 7.70 (dd, 2H), 3.25 (2 sets oft, 4H), 2.40 (s, 3H), 2.25 (broad m, 2H). MS m/e 389 (M+H).
- Example 68 Preparation of 3f .
- Compound 3g is characterized as a yellow amorphous solid; R, 8.25 min; 1 H-NMR (DMSOd 6 ) ⁇ 12.00 (s, IH), 10.90 (s, IH), 9.30 (s, IH), 8.20 (broad, 4H), 8.00 (d, IH), 7.60 (d, IH), 7.50 (s, IH), 3.25 (2 sets oft, 4H), 2.25 (broad m, 2H); MS m/e All (M+H).
- Compound 3i is characterized as a yellow amorphous solid; R, 10.57 min; 1 H-NMR (DMSO-de) ⁇ 12.20 (s, IH) 5 12.00 (s, IH), 11.00 (s, IH), 9.30 (s, IH), 8.00 (d, IH), 7.60 (d, IH), 7.40 (s, IH), 3.25 (2 sets oft, 4H), 2.25 (broad m, 2H), 2.10 (s, 3H). MS m/e 415 (M-H).
- Compound 3j is characterized as a brown amorphous solid; R, 12.81 min; 1 H-NMR (DMSO-de) ⁇ 12.00 (s, IH), 11.00 (s, IH), 9.30 (s, IH), 8.30 (t, IH), 8.00 (d, IH), 7.80 (s, IH), 7.60 (d, IH), 7.30 (m, 5H), 5.00 (s, 2H) 3 4.50 (broad, 2H), 3.25 (2 sets oft, 4H), 2.25 (broad m, 2H). MS m/e 545 (M+Na), 523 (M+H).
- Compound 3k is characterized as a yellow amorphous solid; R, 7.36 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, IH), 11.00 (s, IH), 9.30 (s, IH), 8.60 (broad, 3H), 8.10 (d, IH), 8.00 (s, IH), 7.60 (d, IH), 4.50 (broad, 2H), 3.25 (2 sets oft, 4H), 2.25 (broad m, 2H). MS m/e 389 (M+H).
- Compound 31 is characterized as a brown amorphous solid; R, 7.41 min; 1 H-NMR (DMSO-d 6 ) ⁇ 11.80 (s, IH) 5 11.60 (s, IH), 11.30 (s, IH), 10.80 (s, IH), 9.10 (s, IH), 7.80 (d, IH), 7.50 (d, IH), 7.20 (s, IH), 3.25 (2 sets oft, 4H), 2.25 (broad m, 2H), 2.10 (s, 3H). MS m/e 400 (M+H).
- Example 75 Preparation of 3m To a mixture of 3k (0.015 g, 0.032 mmol) and triethylamine (0.007 g, 0.07 mmol) in DMF (1 mL) at room temperature was added methanesulfonyl chloride (0.004 g, 0.035 mmol). The mixture was stirred for 30 min, poured over ice- water (1 mL) and filtered. The residue was washed with water and ether and dried to generate 0.005 g of 3m.
- Compound 3m is characterized as a yellow amorphous solid; K t 9.95 min; 1 H-NMR (DMSO-de) ⁇ 12.00 (s, IH), 11.00 (s, IH), 9.30 (s, IH), 8.10 (m, 2H), 7.80 (s, IH), 7.60 (d, IH), 4.50 (s, 2H), 3.25 (2 sets oft, 4H), 2.40 (s, 3H), 2.25 (broad m, 2H). MS m/e 489 (M+Na), 467 (M+H).
- the compound 3n is characterized as a yellow amorphous solid; R, 9.31 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, IH), 11.00 (s, IH), 9.30 (s, IH), 8.70 (t, IH), 8.00 (d, IH), 7.80 (s, IH), 7.60 (d, IH), 4.60 (s, 2H), 3.25 (2 sets oft, 4H), 2.25 (broad m, 2H) 5 1.90 (s, 3H). MS m/e 453 (M+Na), 431 (M+H).
- Compound 3o is characterized as a yellow amorphous solid; R, 9.38 min; 1 H-NMR (DMSOd 6 ) ⁇ 12.00 (s, IH), H.00 (s, IH), 9.30 (s, IH), 8.00 (d, IH), 7.80 (s, IH), 7.60 (d, IH), 7.40 (broad, IH), 6.70 (broad, IH), 4.50 (s, 2H), 3.25 (2 sets oft, 4H), 3.10 (q, 2H), 2.25 (broad m, 2H), 1.00 (t, 3H). MS m/e 482 (M+Na), 460 (M+H),
- Compound 3p is characterized as a yellow amorphous solid; R, 11.73 min; 1 H-NMR (DMSO-d ⁇ ) ⁇ 12.00 (s, IH), 11.00 (s, IH), 9.30 (s, IH), 8.10 (d, IH), 8.00 (s, IH), 7.60 (d, IH), 5.00 (s, 2H), 3.25 (2 sets oft, 4H), 2.25 (broad m, 2H), 1.30 (s, 9H). MS m/e 516 (M+Na), 494 (M+H).
- Example 79 Preparation of 3q A mixture of 2e (0.05 g, 0.126 mmol), 2-(t-butoxycarbonyl)thioacetamide (0.024 g, 0.137 mmol) and ethanol (2 mL) was heated at 75-80 0 C in a sealed tube overnight. On cooling, a precipitate appeared that was filtered, washed several times with ethyl acetate and ether and dried under high vacuum to generate 0.02 g of 3q.
- Compound 3t is characterized as a yellow amorphous solid; R / 10.52 min; ' 1 H-NMR (DMSOd 6 ) ⁇ 12.00 (s, IH), 11.00 (s, IH), 9.30 (s, IH), 8.70 (broad t, IH), 8.00 (d, IH), 7.70 (s, IH), 7.50 (d, IH), 4.60 (d, 2H), 3.25 (2 sets oft, 4H), 3.00 (m, IH), 2.25 (broad m, 2H), 1.00 (d, 6H). MS m/e 481 (M+Na), 458 (M+H).
- Compound 3u is characterized as a yellow amorphous solid; R « 10.64 min; 1 H- NMR (DMSOd 6 ) ⁇ 12.00 (s, IH), 11.00 (s, IH), 9.30 (s, IH), 8.70 (broad t, IH), 8.00 (d, IH), 7.70 (s, IH), 7.50 (d, IH), 4.60 (d, 2H) 5 3.25 (2 sets oft, 4H), 2.25 (broad m, 2H), 2.10 (t, 2H), 1.50 (m, 2H), 0.70 (t, 3H). MS m/e 481 (M+Na), 458 (M+H).
- Compound 3v is characterized as a yellow amorphous solid; R, 11.40 min; 1 H- NMR (DMSOd 6 ) ⁇ 12.00 (s, IH), 11.00 (s, IH), 9.30 (s, IH), 8.70 (t, IH), 8.00 (d, IH), 7.70 (s, IH) 5 7.50 (d, IH), 4.60 (d, 2H), 3.25 (2 sets oft, 4H), 2.25 (broad m, 2H), 2.10 (t, 2H), 1.50 (m, 2H), 1.20 (m, 2H), 0.70 (t, 3H). MS m/e 495 (M+Na), 473 (M+H).
- Compound 3w is characterized as a yellow amorphous solid; R, 10.34 min; 1 H-NMR (DMSOd 6 ) ⁇ 12.00 (s, IH), 11.00 (s, IH), 9.30 (s, IH), 9.00 (broad t, IH), 8.00 (d, IH), 7.75 (s, IH), 7.60 (d, IH), 4.60 (d, 2H), 3.25 (m, 4H), 2.25 (broad m, 2H), 1.60 (m, IH), 0.70 (broad, 4H). MS m/e 479 (M+Na), 457 (M+H).
- Compound 3y is characterized as a yellow amorphous solid; R, 15.67 min; 1 H-NMR (DMSOd 6 ) ⁇ 12.00 (s, IH), 11.00 (s, IH), 9.30 (s, IH), 8.10 (d, IH), 7.90 (s, IH), 7.60 (d, IH), 5.50 (s, 2H), 3.25 (2 sets oft, 4H), 2.25 (broad m, 2H), 1.20 (s, 9H). MS m/e 472 (M-H).
- Compound 3z is characterized as a yellow amorphous solid; R, 11.24 min; 1 H-NMR (DMSO-de) ⁇ 12.00 (s, IH), 11.00 (s, IH), 9.40 (s, IH), 8.10 (d, IH), 8.00 (s, IH), 7.60 (d, IH), 5.20 (s, 2H), 3.60 (s, 3H), 3.25 (2 sets oft, 4H), 2.25 (broad m, 2H). MS m/e 450 (M-H).
- Compound 3aa is characterized as a yellow amorphous solid; R, 13.77 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.00 (s, IH), 11.00 (s, IH), 9.40 (s, IH), 8.80 (s, IH), 8.20 (s, IH), 8.10 (d, IH), 7.60 (d, IH) 5 7.20 (s, IH), 3.25 (2 sets of broad, 4H), 2.25 (broad m, 2H). MS m/e 425 (M-H).
- Compound 4a is characterized as a yellow amorphous solid; R, 8.82 min (broad); 1 H-NMR (DMSO-d ⁇ ) ⁇ 12.20 (s, IH), 11.00 (s, IH), 9.40 (s, IH), 8.10 (d, IH), 7.50 (d, IH), 4.30 (d, IH), 4.10 (d, IH), 3.60 (m, IH), 3.50 (s, 3H), 3.25 (2 sets oft, 4H), 2.70 (q, IH), 2.25 (broad m, 2H), 2.10 (m, IH), 1.70 (m, 4H); MS m/e 446 (M+H).
- Compound 4b is characterized as a yellow amorphous solid; R, 9.73 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.20 (s, IH), 11.00 (s, IH), 9.50 (s, IH), 8.20 (d, IH), 7.60 (d, IH), 4.20 (dd, 2H), 3.50 (m, IH), 3.30 (m, IH), 3.25 (2 sets oft, 4H), 3.00 (m, IH), 2.80 (m, IH) 5 2.25 (broad m, 2H), 2.00 (m, IH), 1.80 (m, 2H) 3 1.30 (s, 9H). MS m/e 488 (M+H).
- Compound 4c is characterized as a yellow amorphous solid; R, 6.64 min; 1 H-NMR (DMSOd 6 ) ⁇ 12.20 (s, IH), 1 LOO (s, IH), 9.40 (s, IH), 8.20 (d, IH), 7.60 (d, IH), 4.80 (dd, 2H), 4.20 (broad, IH), 3.50 (broad, IH), 3.40- 2.80 (m, 6H), 2.25 (broad m, 2H).2.00 (m, 4H). MS m/e 432 (M+H).
- Example 94 Preparation of 4d A mixture of 2m (0.02 g, 0.053 mmol), NMM (0.01 Ig, 0.1 mmol), TBTU (0.034 g, 0.1 mmol) in dry DMF (2 mL) was stirred for 5 min. A solution of H 2 N(CH 2 ) 2 NH*Boc (0.01 g, 0.054 mmol) in DMF (1 mL) was added to the reaction flask and the mixture was stirred at room temperature overnight. It was then poured into water (5 mL) and filtered. The residue was washed with small volumes of water and ether, respectively, and dried under high vacuum to generate 0.015 g of 4d.
- Compound 4d is characterized as a yellow amorphous solid; R, 11.19 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.20 (s, IH), 11.00 (s, IH), 9.40 (s, IH), 8.10 (d, IH), 8.00 (broad, IH), 7.50 (d, IH), 6.70 (broad, IH), 3.40-2.70 (a series of m, 8H), 2.50 (m, 4H), 2.25 (broad m, 2H), 1.20 (s, 9H). MS m/e 517 (M-H).
- Compound 4j is characterized as a yellow amorphous solid; R, 7.99 min; 1 H-NMR (DMSOd 6 ) ⁇ 12.20 (s, IH), 11.00 (s, IH), 9.40 (s, IH), 8.10 (d, IH), 7.50 (d, IH) 5 4.60 and 4.20 (2 sets of rotameric m ⁇ IH), 3.70-1.70 (a series ofm, 16H). MS m/e 472 (M-H).
- Compound 41 is characterized as a yellow amorphous solid; R 1 8.03 min; 1 H-NMR (DMSOd 6 ) ⁇ 12.00 (s, IH), 10.90 (s, IH), 10.80 (s, IH) 5 9.10 (s, IH), 8.00 (d, IH), 7.50 (d, IH), 3.40-3.25 (3 sets oft, 6H), 2.50 (t, 2H), 2.25 (broad m, 2H). MS m/e 371 (M-H).
- Example 108 Preparation of 4r A mixture of 4q (0.1 g, 0.184 mmol) and 4 N HCl in dioxane (3 mL) was stirred at room temperature for 30 min and filtered. The residue was washed with small volumes of dioxane and ether and dried under high vacuum to generate 0.071 g of 4r.
- Compound 4r is characterized as a yellow amorphous solid; R, 6.68 min; 1 H-NMR (DMSO-d ⁇ ) ⁇ 12.20 (s, IH), 11.00 (s, IH), 9.40 (s, IH), 9.30 (2 sets of broad, 2H), 8.10 (d, IH), 7.50 (d, IH), 3.70-2.80 (a series of m, 16H), 2.25 (broad m, 2H). MS m/e 443 (M-H).
- Compound 4s is characterized as a yellow amorphous solid; R, 12.95 min; 1 H-NMR (DMSO-de) ⁇ 12.20 (s, 5 IH), 11.00 (s, IH), 9.40 (s, IH), 8.10 (d, IH), 7.50 (d, IH), 3.50 (m, 2H), 3.30-3.00 (m, 8H), 2.60 (m, 2H), 2.25 (broad m, 2H), 1.80 (broad m, 2H), 1.60 (2 sets of m, 8H). MS m/e 470 (M-H).
- N-Bromosuccinimide (190 mg, 1.07 mmol) was added to 5,7,8,9,10,11- hexahydrocyclopent[a]pyrrolo[3,4-c]carbazole-7(6H)-one (250 mg, 0.954 mmol) dissolved in DMF (7.5 mL). After 24 hr, the solvent was evaporated and the residue refluxed with water (5 mL) for 5 min. After cooling to 20 0 C, the precipitate was collected, affording the product (328 mg, 100 % yield) as a yellow solid, mp ⁇ 350 0 C (d). MS m/e 341, 343 (M+H) + .
- Tetrakis(triphenylphosphine)palladium 14 mg, 0.012 mmol was added under nitrogen to a mixture of 3-bromo-5,7,8,9,10,l l-hexahydrocyclopent[a]pyrrolo[3,4- c]carbazole-7(6H)-one (59 mg, 0.17 mmol) and tetramethyltin (38 mg, 0.20 mmol) in DMF (2 mL). The mixture was heated to 140 0 C for 4hr, cooled to 20 °C, then filtered through a mixture of diatomaceous earth and silica gel. The solvent was evaporated from the filtrate, and the product, a yellow solid, was isolated by chromatography (EtOAc- EtOH, 75:25). MS m/e 211 (M+H) + .
- Pindur Synthesis, 1989, 364-367
- maleimide 9 mg, 1.0 mmol
- the mixture was cooled to rt and the resulting solid was washed with hot water (10 X 5 ml) to give the Diels- Alder adduct (91 mg, 68 %, MS m/e 267 (M-H) ' ).
- the adduct was dried in vacuo for 3 hrs and added to the solution of DDQ (2.5 eq) in 5 ml of toluene. The dark brown solution was stirred at 40 0 C for 7 hrs and 20 0 C overnight, then evaporated to dryness.
- Example 124 Preparation of 6g This compound was prepared according to the same procedure as for Ik using, instead, 2c as starting material.
- Compound 6g is characterized as a yellow amorphous solid; R, 6.72 min; 1 H-NMR (DMSO-d 6 ) ⁇ 12.50 (s, IH), 8.60 (broad, 3H), 8.50 (d, IH), 8.00 (broad, 3H), 7.70 (m, IH), 7.50 (t, IH), 5.00 (broad, IH), 3.25 (m, 4H), 2.70 (broad, 2H), 2.25 (m, 2H), 2.00 (2 sets of broad, 2H), 1.50 (broad m, 4H).
- MS m/e 423 M+2H).
- the bis(t-butoxycarbonyl)-lysyl derivative was prepared from 5b as described for Ik, and purified by chromatography (CHaCl 2 -EtOAc 75 :25) to give an orange-yellow glass.
- the BOC groups were hydrolyzed by treatment with 2M HCl in dioxane for 2.5 hr to afford the product as a tan solid. R t 8.43 min. MS m/e 469 and 471 (M+H) + , 341 and 343 (M+H-Lysyl) + .
- the bis(t-butoxycarbonyl)-lysyl derivative was prepared from 5c as described for Ik.
- the BOC groups were hydrolyzed by treatment with 2M HCl in dioxane for 2.5 hr to afford the product.
- R 1 7.40 min.
- DDQ 39 mg, 0.17 mmol, 220 mol %) was added to solution of ethyl 4-cyano- 1,2,3,4,5, 10-hexahydrocyclopenta[a]carbazole-5-carboxylate (24 mg, 0.078 mmol) in toluene (12 mL). The solution immediately turned dark brown, and was stirred at 20 0 C for 1.5 hr. The solvent was evaporated. The residue was dissolved in EtOAc and rinsed with dilute aqueous ascorbic acid and twice with saturated NaHCC»3.
- ester 12e To a solution of ester 12e (2.1 mg, 0.005 mmol) in EtOH (4.0 mL) was added 1 N NaOH (300 uL), and the mixture was warmed to 70 0 C for 0.5 h. After the reaction was cooled, solvent was removed by rotary evaporation. The residue was taken up in water (1 mL) and acidified to pH 3 with 1 N aqueous HCl. Solvent was removed by rotary evaporation and the residue triturated with water. The product was dried under vacuum (1.1 mg, 56%).
- Example 159 Preparation of 12n The procedure described for 12a was repeated with 5-methylindole in place of indole.
- 13 C NMR (DMSO-d 6 ) ⁇ 171.3, 170.6, 149.3, 145.1, 139.0, 138.8, 130.6, 130.2, 129.4, 125.8, 124.4, 121.6, 121.1, 119.3, 116.2, 114.2, 112.3, 21.6.
- Example 163 Preparation of 12r To a mixture of imide compound 12q (20.1 mg, 0.052 mmol), in THF (2 mL) was added a 2M solution OfLiBH 4 in THF (200 uL). After 2 h, the reaction mixture was quenched with MeOH, then water, then 1 N HCl (5 drops). This mixture was neutralized with a solution of aqueous NaHCO 3 and extracted into EtOAc. The organic layer was washed with brine, dried over Na 2 SO 4 , and solvent was removed by rotary evaporation.
- Example 164 Preparation of 12s A mixture of bromide compound 12p (21.2 mg, 0.058 mmol), PdCl 2 (PPh3) 2 (4.6 mg, 0.007 mmol), 2-(tributylstannyl)thiophene (75 uL) and DMF (2 mL) was warmed to 100 0 C for 20 h. The reaction mixture was cooled, filtered through a pad of celite with the aid of DMF (3 x 1 mL) and the filtrate was reduced by rotary evaporation. The residue was triturated with ether (3 x 3 mL), and pentane (10 x 2 mL) and dried under vacuum
Abstract
Description
Claims
Priority Applications (13)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
MX2008016348A MX2008016348A (en) | 2006-06-19 | 2007-06-19 | Cycloalkanopyrrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors. |
CA2655014A CA2655014C (en) | 2006-06-19 | 2007-06-19 | Cycloalkanopyrrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors |
AU2007261464A AU2007261464B2 (en) | 2006-06-19 | 2007-06-19 | Novel multicyclic compounds and the use thereof |
ES07809679T ES2416309T3 (en) | 2006-06-19 | 2007-06-19 | Novel multicyclic compounds and their use |
EP07809679.9A EP2066324B1 (en) | 2006-06-19 | 2007-06-19 | Cycloalkanopyrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors |
PL07809679T PL2066324T3 (en) | 2006-06-19 | 2007-06-19 | Cycloalkanopyrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors |
NZ573643A NZ573643A (en) | 2006-06-19 | 2007-06-19 | CYCLOALKANOPYRROLOCARBAZOLE DERIVATIVES AND THE USE THEREOF AS PARP, VEGFR2 AND MLK3 INHIBITORS which are useful in the treatment of neurodegenerative diseases |
SI200731252T SI2066324T1 (en) | 2006-06-19 | 2007-06-19 | Cycloalkanopyrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors |
CN200780029096.2A CN101500563B (en) | 2006-06-19 | 2007-06-19 | Cycloalkanopyrolocarbazole derivatives and the use thereof as PARP, VEGFR2 and MLK3 inhibitors |
DK07809679.9T DK2066324T3 (en) | 2006-06-19 | 2007-06-19 | CYCLOALKANPYRROLOCARBAZOLD DERIVATIVES AND USE THEREOF AS PARP, VEGFR2 AND MLK3 INHIBITORS |
JP2009516545A JP5385133B2 (en) | 2006-06-19 | 2007-06-19 | Novel polycyclic compounds and uses thereof |
IL195821A IL195821A (en) | 2006-06-19 | 2008-12-09 | 5(6h),7-dioxo-6-(4-methylpiperazin-1-yl)-5,7,8,9,10,11-hexahydrocyclopent[g]phenyl/pyrido[b]pyrrolo[3,4-e]indole derivatives, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments |
HK09109830.6A HK1131747A1 (en) | 2006-06-19 | 2009-10-23 | Cycloalkanopyrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US11/455,356 | 2006-06-19 | ||
US11/455,356 US20060276497A1 (en) | 2000-05-09 | 2006-06-19 | Novel multicyclic compounds and the use thereof |
Publications (3)
Publication Number | Publication Date |
---|---|
WO2007149451A2 true WO2007149451A2 (en) | 2007-12-27 |
WO2007149451A3 WO2007149451A3 (en) | 2008-02-21 |
WO2007149451B1 WO2007149451B1 (en) | 2008-04-10 |
Family
ID=38695490
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2007/014300 WO2007149451A2 (en) | 2006-06-19 | 2007-06-19 | Cycloalkanopyrrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors |
Country Status (17)
Country | Link |
---|---|
US (2) | US20060276497A1 (en) |
EP (1) | EP2066324B1 (en) |
JP (1) | JP5385133B2 (en) |
CN (1) | CN101500563B (en) |
AU (1) | AU2007261464B2 (en) |
CA (1) | CA2655014C (en) |
CY (1) | CY1114153T1 (en) |
DK (1) | DK2066324T3 (en) |
ES (1) | ES2416309T3 (en) |
HK (1) | HK1131747A1 (en) |
IL (1) | IL195821A (en) |
MX (1) | MX2008016348A (en) |
NZ (1) | NZ573643A (en) |
PL (1) | PL2066324T3 (en) |
PT (1) | PT2066324E (en) |
SI (1) | SI2066324T1 (en) |
WO (1) | WO2007149451A2 (en) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010060968A1 (en) * | 2008-11-27 | 2010-06-03 | Cephalon France | Regioselective reduction of fused pyrrolocarbazoles-5,7-diones |
WO2011141909A2 (en) | 2010-05-10 | 2011-11-17 | Radikal Therapeutics Inc. | Lipoic acid and nitroxide derivatives and uses thereof |
WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
WO2019175132A1 (en) | 2018-03-13 | 2019-09-19 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
EP3594343A1 (en) | 2015-07-23 | 2020-01-15 | Institut Curie | Use of a combination of dbait molecule and parp inhibitors to treat cancer |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2671517C (en) * | 2006-11-20 | 2015-01-27 | Cephalon, Inc. | Method of radio-sensitizing tumors using a radio-sensitizing agent |
WO2008151323A1 (en) * | 2007-06-08 | 2008-12-11 | University Of Massachusetts | Mixed lineage kinases and metabolic disorders |
DK2470540T3 (en) * | 2009-08-26 | 2016-08-01 | Cephalon Inc | Novel forms a multi-cyclic compound |
US9260459B2 (en) | 2012-06-25 | 2016-02-16 | Kyowa Hakko Kirin Co., Ltd. | 4,6-hexadecadiene-2,4-dicarboxylic acid derivative |
KR101514320B1 (en) | 2013-06-14 | 2015-04-22 | 재단법인 의약바이오컨버젼스연구단 | Novel pharmaceutical composition for preventing or treating cancer |
WO2015121876A1 (en) | 2014-02-14 | 2015-08-20 | Council Of Scientific & Industrial Research | Novel tricyclic compounds and preparation thereof |
US9771325B2 (en) | 2014-02-14 | 2017-09-26 | Council Of Scientific & Industrial Research | Tricyclic compounds and preparation thereof |
RU2017120655A (en) | 2014-11-26 | 2018-12-14 | Сефалон, Инк. | CRYSTAL FORM OF PARP INHIBITORS |
CN107619386B (en) * | 2017-08-26 | 2020-10-13 | 湘潭大学 | Aromatic ring [ c ] carbazole derivative and synthesis method thereof |
EP3766104A1 (en) | 2018-03-12 | 2021-01-20 | Solar Junction Corporation | Chirped distributed bragg reflectors for photovoltaic cells and other light absorption devices |
CN110028439B (en) * | 2019-04-25 | 2020-11-13 | 四川大学 | Phthalimide derivative and preparation method and application thereof |
WO2024026129A2 (en) * | 2022-07-29 | 2024-02-01 | Ensem Therapeutics, Inc. | Tricyclic aryl derivatives, and compositions and methods thereof |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4912107A (en) | 1988-09-29 | 1990-03-27 | Goedecke Aktiengesellschaft | Pyrrolocarbazole derivatives, compositions containing them, and methods for using them |
WO1996011933A1 (en) | 1994-10-14 | 1996-04-25 | Cephalon, Inc. | Fused pyrrolocarbazoles |
EP0768311A1 (en) | 1995-03-09 | 1997-04-16 | Kyowa Hakko Kogyo Co., Ltd. | Pyrrolocarbazole derivatives |
WO1998009967A1 (en) | 1996-09-09 | 1998-03-12 | Kyowa Hakko Kogyo Co., Ltd. | Pyrrolocarbazole derivatives |
WO1999041276A1 (en) | 1998-02-12 | 1999-08-19 | Molecumetics Ltd. | β-SHEET MIMETICS AND METHODS RELATING TO THE USE THEREOF |
WO1999065911A1 (en) | 1998-06-16 | 1999-12-23 | Ortho-Mcneil Pharmaceutical, Inc. | OCTAHYDROPYRROLO-[3,4-c]CARBAZOLES USEFUL AS ANALGESIC AGENTS |
JP4230385B2 (en) | 2004-03-05 | 2009-02-25 | 本田技研工業株式会社 | Follow-up control device |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5177075A (en) * | 1988-08-19 | 1993-01-05 | Warner-Lambert Company | Substituted dihydroisoquinolinones and related compounds as potentiators of the lethal effects of radiation and certain chemotherapeutic agents; selected compounds, analogs and process |
US5166204A (en) * | 1989-11-01 | 1992-11-24 | Toyama Chemical Co., Ltd. | Isoindole derivatives and salts thereof and antitumor agent comprising the same |
US5587384A (en) * | 1994-02-04 | 1996-12-24 | The Johns Hopkins University | Inhibitors of poly(ADP-ribose) synthetase and use thereof to treat NMDA neurotoxicity |
CA2245029A1 (en) * | 1998-03-13 | 1999-09-13 | University Of British Columbia | Granulatimide compounds as g2 checkpoint inhibitors |
US7122679B2 (en) * | 2000-05-09 | 2006-10-17 | Cephalon, Inc. | Multicyclic compounds and the use thereof |
US7169802B2 (en) * | 2003-12-23 | 2007-01-30 | Cephalon, Inc. | Fused pyrrolocarbazoles |
US7241779B2 (en) * | 2003-12-23 | 2007-07-10 | Cephalon, Inc. | Fused pyrrolocarbazoles |
-
2006
- 2006-06-19 US US11/455,356 patent/US20060276497A1/en not_active Abandoned
-
2007
- 2007-06-19 ES ES07809679T patent/ES2416309T3/en active Active
- 2007-06-19 CN CN200780029096.2A patent/CN101500563B/en not_active Expired - Fee Related
- 2007-06-19 DK DK07809679.9T patent/DK2066324T3/en active
- 2007-06-19 WO PCT/US2007/014300 patent/WO2007149451A2/en active Application Filing
- 2007-06-19 JP JP2009516545A patent/JP5385133B2/en not_active Expired - Fee Related
- 2007-06-19 MX MX2008016348A patent/MX2008016348A/en active IP Right Grant
- 2007-06-19 AU AU2007261464A patent/AU2007261464B2/en not_active Ceased
- 2007-06-19 NZ NZ573643A patent/NZ573643A/en not_active IP Right Cessation
- 2007-06-19 SI SI200731252T patent/SI2066324T1/en unknown
- 2007-06-19 PL PL07809679T patent/PL2066324T3/en unknown
- 2007-06-19 EP EP07809679.9A patent/EP2066324B1/en not_active Not-in-force
- 2007-06-19 CA CA2655014A patent/CA2655014C/en not_active Expired - Fee Related
- 2007-06-19 PT PT78096799T patent/PT2066324E/en unknown
-
2008
- 2008-12-09 IL IL195821A patent/IL195821A/en active IP Right Grant
-
2009
- 2009-10-23 HK HK09109830.6A patent/HK1131747A1/en not_active IP Right Cessation
-
2010
- 2010-11-18 US US12/949,254 patent/US8716493B2/en not_active Expired - Fee Related
-
2013
- 2013-07-11 CY CY20131100589T patent/CY1114153T1/en unknown
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4912107A (en) | 1988-09-29 | 1990-03-27 | Goedecke Aktiengesellschaft | Pyrrolocarbazole derivatives, compositions containing them, and methods for using them |
WO1996011933A1 (en) | 1994-10-14 | 1996-04-25 | Cephalon, Inc. | Fused pyrrolocarbazoles |
EP0768311A1 (en) | 1995-03-09 | 1997-04-16 | Kyowa Hakko Kogyo Co., Ltd. | Pyrrolocarbazole derivatives |
US5728709A (en) | 1995-03-09 | 1998-03-17 | Kyowa Hakko Kogyo Co., Ltd. | Alkyl and aralkyl-substituted pyrrolocarbazole derivatives that stimulate platelet production |
WO1998009967A1 (en) | 1996-09-09 | 1998-03-12 | Kyowa Hakko Kogyo Co., Ltd. | Pyrrolocarbazole derivatives |
WO1999041276A1 (en) | 1998-02-12 | 1999-08-19 | Molecumetics Ltd. | β-SHEET MIMETICS AND METHODS RELATING TO THE USE THEREOF |
WO1999065911A1 (en) | 1998-06-16 | 1999-12-23 | Ortho-Mcneil Pharmaceutical, Inc. | OCTAHYDROPYRROLO-[3,4-c]CARBAZOLES USEFUL AS ANALGESIC AGENTS |
JP4230385B2 (en) | 2004-03-05 | 2009-02-25 | 本田技研工業株式会社 | Follow-up control device |
Non-Patent Citations (13)
Title |
---|
ABRASH ET AL., BIOCHEMISTRY, vol. 4, 1965, pages 99 |
BRAUNWALDER ET AL., ANAL. BIOCHEM., vol. 238, 1996, pages 159 |
HETEROCYCLES, vol. 2, 1974, pages 575 - 584 |
JONES ET AL., J. CHEM. SOC., PERKIN TRANS. I, 1984, pages 2541 |
JONES ET AL., J. ORG. CHEM., vol. 45, 1980, pages 4515 |
KRUTOSIKOVA ET AL., COLL. CZECH. CHEM. COMMUN., vol. 53, 1988, pages 1770 |
LEONARD ET AL., J. AM. CHEM. SOC., vol. 98, 1976, pages 3987 |
MUCHOWSKI ET AL., TETRAHEDRON LETT., vol. 28, 1987, pages 3453 |
NOLAND ET AL., J. ORG. CHEM., vol. 48, 1983, pages 2488 |
ORG. CHEM., vol. 55, 1990, pages 5368 |
PITT; LEE, J. BIOMOL. SCREENING, vol. 1, 1996, pages 47 |
PURNELL; WHISH, BIOCHEM. J., vol. 185, 1980, pages 775 |
RASHIDAN ET AL., ARM. KHIM. ZH., vol. 21, 1968, pages 793 |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010060968A1 (en) * | 2008-11-27 | 2010-06-03 | Cephalon France | Regioselective reduction of fused pyrrolocarbazoles-5,7-diones |
JP2012509926A (en) * | 2008-11-27 | 2012-04-26 | セファロン・フランス | Regioselective reduction of fused pyrrolocarbazole-5,7-diones |
WO2011141909A2 (en) | 2010-05-10 | 2011-11-17 | Radikal Therapeutics Inc. | Lipoic acid and nitroxide derivatives and uses thereof |
EP3594343A1 (en) | 2015-07-23 | 2020-01-15 | Institut Curie | Use of a combination of dbait molecule and parp inhibitors to treat cancer |
WO2018162439A1 (en) | 2017-03-08 | 2018-09-13 | Onxeo | New predictive biomarker for the sensitivity to a treatment of cancer with a dbait molecule |
WO2019175132A1 (en) | 2018-03-13 | 2019-09-19 | Onxeo | A dbait molecule against acquired resistance in the treatment of cancer |
WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
Also Published As
Publication number | Publication date |
---|---|
NZ573643A (en) | 2012-01-12 |
CN101500563B (en) | 2015-05-06 |
HK1131747A1 (en) | 2010-02-05 |
CA2655014C (en) | 2014-12-30 |
IL195821A (en) | 2016-05-31 |
CN101500563A (en) | 2009-08-05 |
AU2007261464B2 (en) | 2012-09-13 |
WO2007149451B1 (en) | 2008-04-10 |
PL2066324T3 (en) | 2013-10-31 |
US20110059959A1 (en) | 2011-03-10 |
MX2008016348A (en) | 2009-01-30 |
JP2009541322A (en) | 2009-11-26 |
WO2007149451A3 (en) | 2008-02-21 |
IL195821A0 (en) | 2009-09-01 |
DK2066324T3 (en) | 2013-08-26 |
ES2416309T3 (en) | 2013-07-31 |
AU2007261464A1 (en) | 2007-12-27 |
JP5385133B2 (en) | 2014-01-08 |
PT2066324E (en) | 2013-08-01 |
SI2066324T1 (en) | 2013-07-31 |
EP2066324B1 (en) | 2013-05-29 |
US8716493B2 (en) | 2014-05-06 |
CY1114153T1 (en) | 2016-08-31 |
CA2655014A1 (en) | 2007-12-27 |
EP2066324A2 (en) | 2009-06-10 |
US20060276497A1 (en) | 2006-12-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2066324B1 (en) | Cycloalkanopyrolocarbazole derivatives and the use thereof as parp, vegfr2 and mlk3 inhibitors | |
KR100832602B1 (en) | Novel Multicyclic Compounds and the Use Thereof | |
CA2477967C (en) | Purine derivatives as kinase inhibitors | |
AU2023501A (en) | Fused heterotricyclic compounds, process for preparing the compounds and drugs containing the same | |
AU2007261305A1 (en) | Fused (d)pyridazin-7-ones | |
AU2001261327B2 (en) | Multicyclic compounds and the use as inhibitors of PARP, VEGFR2 and MLK3 enzymes | |
AU2001261327A1 (en) | Multicyclic compounds and the use as inhibitors of PARP, VEGFR2 and MLK3 enzymes | |
ES2351268T3 (en) | MULTICYCLIC COMPOUNDS AND THEIR USE AS INHIBITORS OF ENZYMES PARP, VEGFR2 AND MLK3. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200780029096.2 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07809679 Country of ref document: EP Kind code of ref document: A2 |
|
DPE1 | Request for preliminary examination filed after expiration of 19th month from priority date (pct application filed from 20040101) | ||
ENP | Entry into the national phase |
Ref document number: 2655014 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 195821 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 573643 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: MX/A/2008/016348 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2009516545 Country of ref document: JP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007261464 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007809679 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 242/KOLNP/2009 Country of ref document: IN |
|
ENP | Entry into the national phase |
Ref document number: 2007261464 Country of ref document: AU Date of ref document: 20070619 Kind code of ref document: A |